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Respiratory infections represent an important and frequent cause of disease in cats and dogs 
worldwide. Many pathogens have been associated with feline (FIRD) and canine infectious respiratory 
disease (CIRD) including feline calicivirus (FCV) and herpesvirus (FeHV-1) in cats and canine distemper 
virus (CDV), parainfluenza virus (CPiV), adenovirus type 2 (CAV-2), herpesvirus (CHV) and Bordetella 
bronchiseptica in dogs. All these pathogens are currently included in either core or non-core vaccines, 
leading to a reduction in overall disease burden.  
 
Despite widespread use of vaccines, disease is still present at significant levels. In dogs, 
several new pathogens, potentially associated with respiratory disease, have recently emerged 
including canine respiratory coronavirus (CRCoV) and canine pneumovirus (CnPnV). In cats, it has been 
theorised that the high rates of evolution of viruses such as FCV may lead to a reduction of vaccine 
efficacy. Finally, even though respiratory disease of suspected infectious origin is frequent, the culprit 
often remains unidentified. This thesis aims to build understanding of canine and feline infectious 
respiratory disease epidemiology, re-evaluate the roles of known and suspected pathogens in this 
syndrome and to aid in informing the development of new disease prevention strategies. 
 
During a cross-sectional study across 6 European countries, samples were collected from 
1521 veterinary practice attending cats. The prevalence of FCV in this population was 9.2%. 
Phylogenetic analysis of these field isolates showed high viral variability with a radial phylogeny. In 
vitro viral neutralisation suggested that antibodies raised to the FCV-F9 vaccine strain (which has been 
widely in use for decades) are still broadly cross-reactive to contemporary field isolates.  
 
A retrospective serosurvey of 200 canine and 179 feline samples screened for influenza A and 
B viruses suggested that UK dogs and cats have been rarely exposed to influenza viruses in recent 
years with only 1.5% of canine samples being seropositive for equine H3N8 and 0.56% of feline 
samples being seropositive to human pandemic 2009 H1N1. 
 
Two case control studies were conducted in British veterinary practices in order to re-
appraise the role of known and potential upper respiratory pathogens in pet dogs and cats. In the 
feline study, FCV was detected in 21.1% of cases and 4.7% controls. FeHV-1 was detected in 10.5% 
cases and 1.6% controls. Bordetella bronchiseptica was identified in 5.3% cases and 9.4% controls. 
Finally, 65.8% cases and 48.8% controls were positive for M. felis. In the canine study, CRCoV was 
identified in 6.1% of cases, CnPnV in 4.4% cases and 1.2% controls, M.cynos in 4.4% cases and 2.3% 
controls, and B.bronchiseptica in 6.7% cases and 20.7% controls. No samples tested positive for CAV-
2, CPiV, CHV, CDV, influenza A, Streptococcus equi subsp. zooepidemicus or C.felis.  
 
 A cross-sectional sampling of dogs and cats was conducted in four British shelters with one 
of these also taking part in a 10-week longitudinal study. FCV, FeHV-1 and M. felis were detected in 
7.4%, 4.6% and 16.8% feline samples. Cross-sectional dog samples tested negative for all pathogens 
included in the study. In the longitudinal study, M. felis was the most frequently encountered 
microorganism followed by FCV in cats. In dogs, CnPnV was identified during two weeks that coincided 
with reports of canine respiratory disease by members of the shelter staff. 
 
 Together, findings confirm the importance of CIRD and FIRD as multifactorial syndromes in 
both pet and unowned shelter populations where pathogen shedding is often observed without 
clinical signs. In FIRD, FCV is reaffirmed as a majorly important disease causing pathogen. Finally, 
where CIRD is concerned, findings suggest that recently emerged pathogens such as CRCoV are of 
increasing importance in this syndrome whereas classic pathogens seem to be less and less present, 
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1 Introduction to infectious respiratory disease 




















1.1 Introduction to infectious respiratory disease in dogs and cats 
Infectious diseases of the respiratory tract are a major cause of morbidity in most 
animal species. Dogs and cats are no exception, and despite widespread vaccination, 
infectious respiratory disease is still a major reason for veterinary visits (Arsevska et 
al., 2018). In both species, it is recognized that these syndromes are multifactorial in 
nature. In the past and in many instances to this day, they are presumptively 
diagnosed and treated based mostly on clinical signs. However, the advent and 
widespread availability of molecular diagnostic testing (i.e. polymerase chain 
reaction - PCR) is making it possible to increasingly diagnose recognised infectious 
causes of these clinical signs (Mitchell et al., 2017; Mitchell and Brownlie, 2015; 
Priestnall et al., 2014).  
 
A wide range of viral and bacterial pathogens are recognised as causative agents of 
feline and canine infectious respiratory disease, with some degree of overlap 
between the two species (Afonso et al., 2017b; Priestnall, 2017). Despite this, in many 
instances, the aetiology remains unknown. In some cases, this is due to a clinical 
choice on the part of the attending veterinary surgeon that can be driven by financial 
restrictions or the lack of pathogen-specific treatment to justify the undertaking of 
expensive diagnostic tests, especially in the case of viral disease. In other cases, 
where diagnostic testing is undertaken, frequently no pathogen is identified. This 
could be due to a series of factors such as untimely sampling, sampling errors, 
inadequate sample storage or processing but possibly also the presence of only 
previously unidentified pathogens. Fortunately, the rapid evolution of metagenomics 
approaches such as next generation sequencing, signifies that this is an exciting time 
for new pathogen discovery (Radford et al., 2012). 
 
Below we will briefly review characteristics relating to canine and feline respiratory 
disease, respectively and summarize the most common pathogens potentially 




1.2 An overview of canine infectious respiratory disease (CIRD)  
Canine infectious respiratory disease (CIRD), also referred to as infectious 
tracheobronchitis or “kennel cough” is a common, acute and highly contagious 
syndrome of dogs with a worldwide distribution. CIRD is often seen in shelter and 
other multi-animal environements. It is typically characterized by paroxysmal cough 
and, in some cases, may be accompanied by other signs including serous or purulent 
nasal discharge, dyspnoea, pyrexia, conjunctivitis, anorexia and lethargy. On clinical 
exam, submandibular lymphadenopathy and congestion of mucous membranes may 
be present (Opperman and Brownlie, 2018). It can persist for weeks and may lead to 
severe disease such as bronchopneumonia and may even result in euthanasia or 
natural death (Mitchell et al., 2017).  
 
CIRD is a complex multifactorial clinical syndrome in which pathogen, host and 
environmental factors act together influencing disease susceptibility and severity 
(Mitchell et al., 2017). While occurring throughout the year, recent evidence shows 
seasonal prevalence fluctuations in CIRD (and, to a less extent, in FIRD), with peaks 
of disease occurring around Autumn in the UK and certain pathogens, such as CRCoV, 
being more common during cooler months (Erles and Brownlie, 2005, Arsevska et al,. 
2017, Maboni et al., 2019, Singleton et al., 2019). Despite widespread vaccination, 
CIRD remains an important threat to susceptible animals especially those that are 
housed in multi-animal environments such as shelters and boarding kennels where 
outbreaks are an important cause of morbidity (Chalker et al., 2003b). CIRD has often 
been considered a mild syndrome of relatively limited clinical importance especially 
in the pet dog. However, in the past two decades, due to the emergence and re-
emergence of several pathogens, this paradigm has begun to shift, and a surge of 
interest in this disease has occurred (Priestnall et al., 2014).  
 
In CIRD, infections of clinical significance include bacterial and/or viral pathogens that 
can act alone as primary pathogens, or synergistically in combination, to cause 
disease (Mitchell and Brownlie, 2015; Priestnall et al., 2014). Traditionally, canine 
herpesvirus type-1, canine parainfluenza virus, canine adenovirus type 2 and 
Bordetella bronchiseptica have been considered the main causes of CIRD (Appel, and 
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Percy, 1970; Bemis, 1992; Binn et al., 1967). Vaccination is the primary prevention 
and control strategy used for these pathogens but despite its widespread use, CIRD 
is still a major problem especially in more sensitive environments such as multi-
animal households, kennels and shelters (Erles et al., 2004). In recent years the 
emergence and re-emergence of other pathogens associated with upper respiratory 
tract disease has shed further light on the multifactorial nature of this syndrome and 
the possibility that unknown pathogens may be involved in disease pathogenesis. 
Viruses such as canine respiratory coronavirus, influenza viruses and others are now 
considered as potential aetiologies in suspected cases of CIRD (Decaro et al, 2016; 
Erles et al, 2003; Mitchell et al., 2017; Priestnall et al., 2014; Renshaw et al., 2010). 
Table 1.1 presents a summary of prevalences of these pathogens in dogs with CIRD-
like disease found in relevant studies published within the past 15 years.   
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Table 1.1 Summary of prevalences of pathogens involved in CIRD-like disease. Pet populations 
include privately owned animals and kennelled populations refer to multi-animal environments 
including shelters, and breeding and research kennels.  
 
Pathogen Prevalence % 
(n) 
Population Region References 






Pet + kennelled 








Erles et al 2004 
Schulz et al 2014 
Pecoraro et al 2014 
Maboni et al 2019 
Mochizuki et al 2008 








Pet + kennelled 
Pet 








Mochizuki et al 2008 
Erles et al 2004 
Pecoraro et al 2014 
Maboni et al 2019 
Schulz et al 2014 
Joffe et al 2016 
CHV-1 0% (0/61) 
1.6% (1/64) 
18.8% (20/110) 






Schulz et al 2014 
Joffe et al 2016 
Erles et al 2004 





Pet + kennelled 









Schulz et al 2014 
Pecoraro et al 2014 
Mochizuki et al 2008 
Joffe et al 2016 
Maboni et al 2019 






Pet + kennelled 
Pet + kennelled 
Pet 






Mochizuki et al 2008 
Mitchell et al 2017 
Pecoraro et al 2014 
Joffe et al 2016 
Schulz et al 2014 




Pet + kennelled 
Kennelled 




Pecoraro et al 2014 
Mitchell et al 2013 
Mitchell et al 2017 







Pet + kennelled 
Pet + kennelled 
Pet 








Mochizuki et al 2008 
Pecoraro et al 2014 
Schulz et al 2014 
Joffe et al 2016 
Mitchell et al 2017 
Maboni et al 2019 






Pet + kennelled 





Maboni et al 2019 
Mochizuki et al 2008 
Pecoraro et al 2014 
Schulz et al 2014 
S.equi 0% (0/78) 
0% (0/559) 




Pecoraro et al 2014 
Maboni et al 2019 





Pet + kennelled 









Mitchell et al 2017 
Pecoraro et al 2014 
Chalker et al 2004 
Maboni et al 2019 





1.2.1 Canine adenovirus type 2 (CAV-2) 
Canine adenovirus type 2, a member of the Adenoviridae, is a non-enveloped double 
stranded DNA virus. It was originally identified in 1961, in Canada in dogs with 
laryngotracheitis (Ditchfield et al., 1962).  
 
CAV-2 is considered as one of the classic causes of CIRD with acute onset cough being 
its dominant characteristic (Ditchfield et al., 1962). Infection usually leads to mild or 
inapparent disease when the virus is acting alone. However, when other viral or 
bacterial causes are present, it can be associated with more severe disease. Young 
puppies and immunosuppressed animals are also at higher risk of developing 
bronchopneumonia which, in some cases, can be fatal (Decaro et al., 2008). 
Transmission is via the oronasal route, with replication peaking at 3 to 6 days post-
infection and occurring mostly in the nasal, pharyngeal and non-ciliated bronchiolar 
epithelium (Buonavoglia and Martella, 2007). 
 
Vaccination against CAV-2 provides cross-protection against canine adenovirus type 
1 infection and is a part of the World Small Animal Veterinary Association (WSAVA) -
recommended core vaccination schedule using live-attenuated vaccines (Day et al., 
2016). Widespread vaccination has been associated with significantly reduced viral 
circulation, and isolation of the virus is now rare within Europe. In a longitudinal study 
conducted over a period of two years in a vaccinated British shelter population with 
endemic respiratory disease, CAV-2 was not isolated (Erles et al., 2004) and, more 
recently in another study conducted in Southern Germany, this virus was only 
isolated from 1.1% of healthy participants (n=90) with no diseased dogs testing 
positive for CAV-2  (Schulz et al., 2014). 
 
1.2.2 Canine parainfluenza virus (CPIV) 
Canine parainfluenza virus (CPIV) is classically considered one of the most common 
viruses involved in the CIRD complex. It is a member of the Paramyxoviridae and a 
single stranded negative sense RNA virus with a lipid envelope of host cell origin 




CPiV is present worldwide and is highly contagious (Buonavoglia and Martella, 2007; 
Priestnall, 2017). This pathogen is able to spread quickly especially in high-density 
populations, and is transmitted through contact with infectious aerosols. Dogs may 
start shedding viral particles before the onset of clinical signs and remain infectious 
up to 10 days post infection (Buonavoglia and Martella, 2007).  
 
Clinical signs typically start 2 to 8 days post infection, and are generally mild in the 
uncomplicated forms. A dry, hacking cough lasting for 3 to 6 days is the most common 
presentation of disease. Other clinical signs include modest pyrexia, mucous nasal 
discharge, pharyngitis and tonsillitis (Love, 1972). In most cases, dogs appear healthy 
and maintain normal activity levels. When coinfections with other viruses or bacteria 
are observed, the clinical presentation tends to be more severe; a complicated form 
which can occur in young unvaccinated puppies and immunocompromised animals 
leads to more severe signs such as lethargy, inappetence and pneumonia 
(Buonavoglia and Martella, 2007; Priestnall, 2017).  
 
Diagnosis can be made using viral isolation from nasopharyngeal and laryngeal swabs 
and CPiV is able to grow in cell lines from several mammal species. However, with 
the widespread use of molecular diagnostic techniques it is now more common to 
use reverse-transcription PCR (RT-PCR) for CPiV identification in respiratory 
secretions, swabs and tracheal or lung tissue samples (Erles and Brownlie, 2005; 
Mitchell et al., 2017). Vaccination is used worldwide, commonly combined with 
general core vaccines, as well as in CIRD specific vaccines, and is efficient in reducing 
severity of disease (Day et al, 2016). Although not considered core itself, vaccination 
is frequent with some 70% of vaccinated dogs being vaccinated against CPiV 
(Sánchez-Vizcaíno et al., 2018).  
 
1.2.3 Canine herpesvirus type 1 (CHV-1)  
Canine herpesvirus 1 is an enveloped, double stranded DNA virus belonging to the 
Alphaherpesvirus subfamily of the Herpesviridae. As typical of herpesviruses, CHV-1 
has a large genome of approximately 125kbp (Papageorgiou et al., 2016; Sarker et 
15 
 
al., 2018) and is thought to be a monotypic virus with a close relationship to feline 
herpesvirus type 1 (Buonavoglia and Martella, 2007; Poste et al., 1972).  
This virus is present worldwide in domestic and wild dogs and was originally 
described in the mid-1960s as the causative agent of fatal septicemia in young 
puppies (Carmichael et al., 1965).  
  
The involvement of CHV-1 in CIRD is still controversial. The virus leads to high 
mortality in newborn and very young puppies and is described as causing subclinical 
to mild respiratory and genital disease without systemic involvement in pups older 
than 2 weeks-of-age and adult dogs (Carmichael et al., 1965). In experimentally 
infected dogs, mild clinical signs of rhinitis, pharyngitis or tracheobronchitis have 
been observed (Appel et al., 1969). Transmission of CHV-1 occurs via direct oronasal 
contact with infected respiratory or genital secretions and transplacental 
transmission from bitch to pup in the uterus (Appel et al., 1969; Wright et al., 1974). 
The incubation period ranges from 6 to 10 days. After primary infection, and as is 
typical for other herpesviruses, recrudescence can occur after periods of stress and 
immunosuppressive disease or therapy. In between disease episodes the virus 
becomes latent in the trigeminal, lung and lumbosacral ganglia, retropharyngeal 
lymph nodes, tonsils and parotid salivary gland (Burr et al., 1996; Miyoshi et al., 
1999). 
 
Laboratory diagnosis has historically been achieved by using viral isolation in cell 
culture (in primary or secondary kidney or testicular cell lines, for example) and now 
more commonly, PCR of oronasal, ocular or genital swabs which significantly increase 
diagnostic sensitivity. Serology can be useful but does not confirm active infection. 
Vaccination against this virus is not done routinely but can be recommended in 
pregnant bitches to prevent infections of newborn pups and is currently licensed for 
use in Europe (Buonavoglia and Martella, 2007 Day et al., 2016). 
 
1.2.4 Canine distemper virus (CDV) 
CDV is an enveloped, single-stranded RNA virus belonging to the Paramyxoviridae. It 
is known to be able to infect a range of members of the order Carnivora including 
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canids, mustelids, procyonids, large felids, giant pandas and red pandas (Appel and 
Summers, 1995; Jin et al., 2017; Martella et al., 2008). The virus has also shown 
propensity for wider species transmission and has been described in members of the 
Rodentia, Artyodactila, Proboscidea and Primates orders (Martinez-Gutierrez and 
Ruiz-Saenz, 2016). The virus leads to systemic disease with neurologic manifestations 
and a high mortality rate in both dogs and other carnivores. For the purposes of this 
work we will focus mainly on respiratory disease caused by CDV.  
 
Transmission is via the oronasal route, through exposure to contaminated bodily 
fluids such as aerosols generated by coughing and sneezing. Viral incubation ranges 
from one to three weeks with shedding typically starting about 7 – 10 days post 
exposure.  Infection severity differs based on a variety of factors including, but not 
limited to, the animal’s age and immune status as well as the involved viral strain 
(Summers et al., 1984). While older dogs are more likely to develop subclinical or 
mild forms, puppies are more prone to severe courses of disease with serious sequels 
and high mortality (Blixenkrone-Møller et al., 1993; Summers and Appel, 1994).  
 
In addition to becoming lethargic and anorexic, many dogs develop respiratory and 
ocular signs, including cough and nasal and ocular discharge, which can range from 
serous to mucopurulent. In cases of mild respiratory signs without other systemic 
signs, it is impossible to clinically distinguish CDV infection from other causes of CIRD. 
Infection of the lower respiratory tract can also occur with associated pneumonia, 
predisposing the animal to secondary bacterial infections.  
 
Vaccination against this pathogen has been available for over five decades and is 
recommended as part of WSAVA’s “core” vaccination schedules (Day et al., 2016). 
However, due to the diverse wildlife reservoirs, CDV still poses a serious threat to 
canines in several countries.  
 
Diagnosis can be achieved by using molecular techniques such as RT-PCR and 
serology but most commercially available diagnostic tests do not distinguish between 
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vaccine and field strains in recently vaccinated dogs (up to 3 weeks post-vaccination) 
(Elia et al., 2006).  
 
1.2.5 Canine respiratory coronavirus (CRCoV) 
A large enveloped virus, CRCoV belongs in the Betacoronavirus genus of the 
Coronaviridae. It is a single-stranded RNA virus and is closely related to human 
coronavirus OC43 and bovine coronavirus (Erles et al., 2003; Erles and Brownlie, 
2008). In fact, it shares 97.3% sequence homology with the latter and it has been 
postulated that it may have originally been transmitted from cattle to canines (Erles 
et al., 2003). CRCoV is serogically and genetically distinct from canine coronavirus, 
which has a primarily gastrointestinal tropism (Erles et al., 2003; Stavisky et al., 
2012b). 
 
CRCoV was initially reported in 2003, in the UK, in a study of kennelled dogs 
vaccinated against the classical causes of CIRD that still exhibited upper respiratory 
disease signs. The original report showed a strong association between viral exposure 
and the development of CIRD signs (Erles et al., 2003).  
 
When present as a single pathogen, CRCoV primarily causes mild clinical disease with 
non-specific upper respiratory tract signs such as cough, sneezing and nasal 
discharge. However, as with human respiratory coronaviruses, CRCoV can lead to 
reversible and irreversible damage of the respiratory ciliated epithelia predisposing 
the animal to secondary infections and more severe clinical presentations (Erles and 
Brownlie, 2008). It is not uncommon to find CRCoV associated with other CIRD 
pathogens such as CPIV or CHV-1 (Mitchell et al., 2017; Schulz et al., 2014). 
 
Viral shedding has been observed up to 6 to 10 days after infection and viral particles 
are detected in a range of respiratory and lymphoid tissues. CRCoV is most commonly 
found in the trachea and nasal cavity, as well as other upper and lower respiratory 
tract tissues (Mitchell et al., 2013a). However, it has also been detected in the 
gastrointestinal tract which may indicate that this virus, as with some bovine 




Evidence of CIRD caused by CRCoV has been reported worldwide and the virus is now 
considered a cause of upper respiratory tract disease in dogs. There is currently no 
vaccine available against CRCoV and diagnosis, due to the non-specific nature of the 
clinical signs, cannot be based solely on clinical presentation. RT-PCR of 
oropharyngeal or nasal swabs is the most reliable diagnostic technique for this virus 
and serological assays are also becoming more readily available (Erles et al., 2003; 
Mitchell et al., 2009).  
 
1.2.6 Canine pneumovirus (CnPnV) 
Canine pneumovirus (CnPnV) is a single stranded, negative sense, enveloped RNA 
virus within the Pneumovirus genus and sub-family of the Paramyxoviridae (Decaro 
et al., 2014; Renshaw et al., 2010). It was first identified in a study of respiratory 
disease outbreaks in closely confined dogs in two related canine shelters in the USA. 
Nasal and oropharyngeal samples from 200 dogs collected between 2008 and 2009 
were analysed. After a series of passages in cell culture, a cytopathic effect with a 
pattern not similar to those seen with other viruses regularly isolated from dogs was 
observed. The virus was subsequently identified as closely related to murine 
pneumovirus, a common rodent pathogen observed in commercial and research 
colonies. CnPnV can replicate in mice lung tissue causing disease of varying severity 
(Glineur et al., 2013; Percopo et al., 2011; Renshaw et al., 2010). 
 
Since the publication of the original report of this novel pathogen, the virus was also 
identified in samples from eight further states in the USA (Priestnall et al., 2014), in 
the UK (Mitchell et al., 2013b), Italy (Decaro et al., 2014; Mitchell et al., 2017), 
Greece, Hungary, France, Spain and The Netherlands (Mitchell et al., 2017). 
Seropositive samples were also identified in Ireland (Mitchell et al., 2013b). 
 
While Koch’s postulates have not yet been fulfilled for this pathogen, very strong 
evidence suggests that it is an emerging cause of CIRD. CnPnV stands within a family 
of viruses side by side with various relevant pathogens causing severe respiratory 
disease in other mammal and avian species, and murine pneumovirus has been 
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proven to cause respiratory disease in mice. This is further strengthened by the fact 
that it is commonly present in dogs with CIRD signs and recently, in an 
epidemiological retrospective study by Mitchell et al (2017), it was found to be 
strongly associated with respiratory disease.  
 
1.2.7  Influenza viruses in dogs 
Influenza viruses belong to the Orthomyxoviridae and are single stranded RNA 
viruses. Until fairly recently there were only sporadic reports of influenza virus in 
dogs, and they were not considered important pathogens of this species. Canine 
influenza virus (CIV) H3N8 was originally detected in racing hounds with respiratory 
disease in the USA in 2004 (Crawford et al., 2005). It subsequently infected pet dogs, 
developed transmissibility between dogs, and became endemic in the USA. The virus 
is most closely related to equine influenza H3N8 suggesting a direct transmission 
event from horses and subsequent adaptation to the canine species (Crawford et al., 
2005; Payungporn et al., 2008). As with other pathogens causing upper respiratory 
tract disease, CIV was found to be more prevalent in multi-animal environments 
(Anderson et al., 2012; Dubovi, 2010). Outside of the USA, there is little evidence for 
H3N8 with only sporadic limited outbreaks of suspected equine to dog transmission 
being reported in the literature, with no evidence that these have established 
endemic infection in dogs (Daly et al., 2008; Kirkland et al., 2010). 
 
A second canine influenza virus, CIV H3N2, was identified in South Korean dogs 
exhibiting signs of respiratory disease (Song et al., 2008). This virus is thought to have 
been transmitted from avian reservoirs to dogs through ingestion of contaminated 
poultry. In 2015, CIV H3N2 emerged in the USA causing upper respiratory tract 
disease, similar to CIV H3N8. It has been postulated that the virus was introduced to 
the USA through rescue and rehoming networks of dogs from Asia (Voorhees et al., 
2017). 
 
Other influenza subtypes have also been identified in the canine population 
worldwide showing that dogs are susceptible to influenza viruses of equine, avian 
and human origin.  These include highly pathogenic avian H5N1, which has been 
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associated with generally subclinical infection in the canine species, although the 
virus has been reported as the cause of death in a dog in Thailand (after ingestion of 
duck carcasses infected with the virus) (Maas et al., 2007; Songserm et al., 2006). In 
another report, pandemic H1N1 was found in two dogs presenting with respiratory 
disease signs in China; samples were collected from both animals and researchers 
established that experimental infection with this subtype of influenza virus leads to 
mild disease signs and low transmissibility between dogs (Lin et al., 2012). In 2009 in 
China, a dog with signs of respiratory disease was identified as being infected by a 
novel influenza virus H5N2 generated by the reassortment of viral genome segments 
(Zhan et al., 2012). Dogs experimentally infected with this virus developed mild signs 
of influenza-like disease (Song et al., 2012). Canine influenza H3N1 is another 
example of a reassortant virus, in this case between human pandemic H1N1 and 
canine H3N2 that was detected in asymptomatic dogs in South Korea (Song et al., 
2012). The cases above, and others not mentioned in this brief summary, show that 
dogs can potentially play an important role in the evolution, spread and interspecies 
transmission of influenza viruses (Na et al., 2016; Pulit-Penaloza et al., 2017; Song et 
al., 2013). 
 
Vaccines against H3N8 and H3N2 CIV are available in the USA and considered 
“lifestyle” vaccines (i.e: not core) which are recommended to dogs at greater risk of 
exposure (Ford et al., 2017).  
 
1.2.8  Bordetella bronchiseptica (B. bronchiseptica) 
The aerobic coccobaccilus B. bronchiseptica is another pathogen frequently 
associated with the CIRD complex. Originally isolated in the early 20th century (in a 
study that wrongly implicated it in the pathogenesis of canine distemper) (Ellis, 2015; 
Ferry, 1910), it is known to be a commensal of the nasal mucosa of healthy animals 
(Bemis et al., 1977a, 1977b). This Gram-negative bacterium is both capable of acting 
as a primary agent of upper respiratory tract infection as well as an opportunistic 
pathogen associated with other causative agents of CIRD such as CPiV and CRCoV 
leading to more severe infections (Priestnall, 2017; Schulz et al., 2014). In the past it 
has been referred to as a “disease of puppyhood” similar to whooping cough in 
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children, but it is often isolated from adult animals with and without respiratory signs 
(Bemis et al., 1977a, 1977b; Chalker et al., 2003b).  
 
B. bronchiseptica is also known to infect and cause disease in other species such as 
cats, rabbits, pigs and birds (Binns et al., 1998; Dawson et al., 2000, Kadlec and 
Schwarz, 2017). While immunocompetent humans do not seem to usually develop 
clinical disease after exposure to B. bronchiseptica, it is a seemingly infrequent, 
zoonosis of immunocompromised people (Mani and Maguire, 2009, Register et al., 
2012). Mild to severe disease has been reported in children post lung 
transplantation, as well as in patients with HIV, cystic fibrosis and lymphoma (Mani 
and Maguire 2009, Szvalb et al 2019, Ackerman et al 2014 ). B.bronchiseptica has also 
been found to cause disease in cancer patients in contact with animals (dogs, horses 
and cattle) post haematopoietic stem cell transplantation (Szvalb et al 2019). In 
immunocompromised humans, it is recommended that contact with animals recently 
vaccinated with modified life attenuated vaccines is avoided (Mani and Maguire, 
2009) and B.bordetella associated disease has been reported post-kidney 
transplantation in a patient in close contact with recently vaccinated dogs (Gisel et 
al., 2010). Additionally, it has been hypothetised that B. bronchiseptica may have 
given origin to human pathogens Bordetella pertussis and parapertussis (Bjornstad 
and Harvill, 2005).   
 
The incubation period for B. bronchiseptica has been observed to range from 2 to 14 
days post infection (Thrusfield et al., 1991) and shedding can persist for over 6 
months in some cases (Bemis et al., 1977b, 1977b; Ellis, 2015). To improve its ability 
to infect and colonise the respiratory tract, it produces several toxins including 
cytotoxins which induce ciliostasis (Bemis, 1992). 
 
Similarly to other classic agents of CIRD, B. bronchiseptica leads to upper respiratory 
tract clinical signs such as coughing and nasal discharge as well as systemic signs, 
which are present in a lower number of animals, such as an elevated temperature 
and anorexia (Thrusfield et al., 1991). Isolation of B. bronchiseptica is the gold 
standard for diagnosis of infection. Specimens from nasal or oropharyngeal swabs 
22 
 
are often used due to their convenience but are not as sensitive as samples collected 
by bronchioalveolar lavage (BAL).  
 
Parenteral and, more commonly, intranasal vaccination against B. bronchiseptica has 
been used for decades. Intranasal live-modified B. bronchiseptica vaccines are 
available in Europe, often in combination with CPiV, and are recommended annually 
for all at risk dogs such as those being kennelled (Day et al., 2016; Ellis, 2015; Jacobs 
et al., 2007). They are not considered core vaccines and are only used in about one 
third of vaccinated animals (Sánchez-Vizcaíno et al, 2018). Due to the difficulty in 
administering intranasal vaccines to some animals, an oral vaccination is now 
available in the USA but is not presently commercialised in Europe (Ellis, 2015). There 
is some controversy relating to the efficiency of different routes of administration of 
B. bronchiseptica vaccines at the time of the writing of this thesis (Ellis, 2015).  
 
1.2.9 Streptococcus equi subs. zooepidemicus (S. zooepidemicus) 
Streptococcus equi subs. zooepidemicus (S. zooepidemicus) is a Lancefield group C, 
beta-haemolytic bacterium causing acute necrotising haemorrhagic pneumonia 
(Chalker et al., 2003a; Priestnall et al., 2014). As the name implies, it is a zoonotic 
pathogen and at least one instance of human disease has been directly linked to 
contact with a dog with pneumonia (Abbott et al., 2010; Arsevska et al., 2018).  
 
While sporadic disease in dogs has been described since the 1970s, in recent years 
this pathogen seems to have re-emerged and several outbreaks of pneumonia 
associated with S. zooepidemicus have been described. As with other respiratory 
pathogens, S. zooepidemicus is frequently associated with disease in multi-animal 
environments such as rescue shelters and racing kennels (Pesavento and Murphy, 
2014; Priestnall et al., 2014).  
 
The clinical course of S. zooepidemicus-associated disease often starts similarly to 
other CIRD pathogens including cough and serous to mucous nasal discharge. 
However, more severe signs often quickly develop which include pyrexia and 
epistaxis, with sudden death sometimes reported within 24 to 48 hours of disease 
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onset. The high morbidity and mortality associated with S. zooepidemicus infection 
is likely associated with the production of bacterial exotoxins that are thought to act 
as superantigens (Priestnall et al., 2014).  
 
Diagnosis can be confirmed via bacterial culture or molecular techniques such as real 
time PCR (Arsevska et al, 2018). At the time of writing there is no vaccine available 
against this bacterium and treatment in confirmed cases is largely supportive 
(intravenous broad spectrum antibiotics and fluid therapy). Prevention is therefore 
focused on good hygiene and quarantine of suspected cases (Arsevska et al, 2018). 
 
1.2.10 Mycoplasma cynos (M. cynos) 
Mycoplasmas, members of the class Mollicutes, are bacteria lacking a cell wall and 
are the smallest living organisms capable of existing independently (Priestnall et al., 
2014). Mycoplasma spp. are thought to be commensal inhabitants of the canine 
upper respiratory tract and a diverse range of these organisms are frequently isolated 
from healthy and diseased dogs (Bemis, 1992; Chalker et al., 2004).  
 
M. cynos was first isolated from the lungs of a dog with pneumonia in the early 1970s 
(Priestnall, 2017). In a study published in 2004, this Mycoplasma species was the only 
one found to be associated with respiratory disease (Chalker et al., 2004). However, 
its role in CIRD is still not fully understood (Priestnall et al., 2014). Furthermore, the 
role played by other Mycoplasma spp. in respiratory disease also remains to be 
clarified and experimental infection with other Mycoplasmas such as M. canis, M. 
gateae and M. spumans have not reproduced respiratory disease in the canine 
species (Chalker, 2005).  
 
The pathogenicity of canine mycoplasmas is still poorly understood. M. cynos persists 
in the lungs of infected animals for up to 3 weeks after infection and it can also be 
isolated from the tonsils and conjunctiva of infected dogs (Chalker, 2005; Chalker et 
al., 2004). Due to their unique structure, Mycoplasma spp. are resistant to beta-
lactam antibiotics, and if considered clinically necessary, doxycycline is often 




1.2.11 Other pathogens of possible clinical significance in CIRD 
A positive-sense RNA virus tentatively named canine hepacivirus (genus Hepacivirus, 
family Flaviviridae) was identified, using high-throughput sequencing, in respiratory 
tract samples of dogs with CIRD signs and in liver tissues of dogs with gastrointestinal 
disease in US shelters (Kapoor et al., 2011). This virus was found to be genetically 
very closely related to human hepatitis C virus (HCV). This discovery intrigued 
researchers since, up until then, all known hepaciviruses had, as their name perhaps 
suggests, a strict hepatic tropism. However, subsequent studies attempting 
identification of Canine hepacivirus RNA or seroconversion in additional dogs have 
been unsuccessful (Bexfield et al., 2014; Burbelo et al., 2012; Lyons et al., 2012). The 
virus has since been reclassified as a non-primate hepacivirus (NPHV) due to the 
finding of CHV-like viruses in horses (Burbelo et al., 2012). The newly named NPHV 
were subsequently also found in commercially available equine sera for cell culture 
which raises the question of whether the finding of NPHV in dogs may be the 
consequence of contamination rather than true infection, as can occur with 
pathogen discovery projects based on next-generation sequencing (Postel et al., 
2016).  
 
Canine enteric coronavirus (CECoV) usually leads to intestinal tract infections which 
are normally self-limiting and characterised by mild clinical signs. Infection is most 
common in kennelled dogs with a prevalence ranging from 5 - 13.5% in boarding 
kennels and 13.8% - 33.3% in rescue kennels (Stavisky et al., 2012b). The prevalence 
of CECoV in dogs attending veterinary practices was found to be much lower 
(approximately 3%) and around 8% in pet dogs with severe diarrhoea (Godsall et al., 
2010; Stavisky et al., 2010). In 2005, an outbreak of fatal disease in puppies in Italy 
was caused by a highly pathogenic variant of CECoV that was isolated from several 
organs including the lungs, where severe lesions were observed; these variants of 
CECoV with tropism outside the enteric tissue have been since termed pantropic 
coronaviruses (Buonavoglia et al., 2006). Whilst they remind us of the potential for 
coronaviruses to infect enteric and respiratory tissues, this particular virus is not 




Mammalian orthoreoviruses (MRV; genus Orthoreovirus, family Reoviridae) have 
occasionally been isolated from dogs with respiratory disease in association with 
other viruses (including CDV and canine parvovirus type-2) but their role in CIRD is 
unclear (Buonavoglia and Martella, 2007). 
 
A range of bacteria can also be isolated and may be involved in lower respiratory 
tract infections (often as a secondary or opportunistic pathogen). These include but 
are not limited to Escherichia, Pseudomonas, Pasteurella and Staphylococcus spp 
(Bemis, 1992). Due to this work’s focus being majorly on CIRD within the context of 
upper respiratory tract disease, these organisms are not further considered.  
 
1.3 An overview of feline infectious respiratory disease (FIRD) 
The following section is based on work published by the author:  Afonso, M.M., 
Radford, A., Gaskell, R.M., 2017. Chapter 229: Feline Upper Respiratory Infections in: 
Textbook of Veterinary Internal Medicine: Diseases of the Dog and Cat. Elsevier, 
Missouri, pp. 1013-1016.  
 
Similarly to CIRD, feline infectious respiratory disease (FIRD; often referred to as “cat 
flu”) is common and manageable in individual cats (Bannasch and Foley, 2005). 
However, it is more prevalent and challenging in environments where cats are 
housed together such as catteries and shelters. In these environments a number of 
factors including but not limited to host susceptibility, stress, concomitant disease, 
current and previous exposure to pathogens, shelter design and biosecurity 
protocols, endemic disease and shelter density act synergistically creating the perfect 
conditions for disease spread (Willby, Radford and Afonso, 2018). FIRD is 
characterized by sneezing, oculonasal discharge, conjunctivitis and, in some cases, 
hypersalivation and coughing. More severe presentations including pneumonia and 
systemic disease may occur, especially in young or immunocompromised animals 




Feline herpesvirus-1 (FeHV-1) and feline calicivirus (FCV) are the two main viral 
causes of FIRD. FCV seems to be more commonly isolated than FeHV-1 but the latter 
often leads to more severe disease (Radford et al., 2009; Thiry et al., 2009). 
Bordetella bronchiseptica, Chlamydophila (Chlamydia) felis and possibly Mycoplasma 
felis are also involved in the FIRD disease complex (Litster et al., 2015). Like dogs, cats 
are also increasingly recognised as being susceptible to Influenza A virus infection 
including highly pathogenic and zoonotic avian influenza H5N1 and canine H3N2 and 
some interesting reports have emerged in recent years (Jeoung et al., 2013; Thiry et 
al., 2009). Table 1.2 presents a summary of prevalences of the above mentioned 
pathogens in cats with CIRD-like disease found in relevant studies published within 
the past 15 years. 
 
Table 1.2 Summary of prevalences of pathogens involved in FIRD-like disease. Pet populations 
include privately owned animals and catteries refer to multi-animal environments including shelters, 
and breeding and research kennels. Number of animals reported alongside percentages where 
available in original research papers.  
Pathogen Prevalence % (n) Population Region References 
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1.3.1 Feline herpesvirus – 1 (FeHV-1) 
Feline herpesvirus type 1 is an enveloped, double-stranded DNA virus (alpha-
herpesvirus) of which only one serotype exists with all isolates being genetically 
similar (Gaskell and Willoughby, 1999; Willoughby et al., 1991). Cats and other 
members of the Felidae are susceptible to infection. Infection tends to be associated 
with relatively severe signs of FIRD. In addition, FeHV-1 is also associated with severe 




FeHV-1 is primarily transmitted by direct contact between cats, although indirect 
transmission may also occur in the short term through contact with infectious 
discharges. In addition to clinical signs previously mentioned for FIRD, FeHV-1 
replication can more rarely lead to osteolytic damage of nasal turbinate bones which 
is believed to predispose animals to more chronic and debilitating forms of rhinitis 
(Gaskell et al., 2007).  
 
Whilst acutely infected cats are a source of virus, transmission also commonly occurs 
from clinically recovered carrier and persistently infected cats. It is generally believed 
that all cats recovering from acute infection develop a lifelong latent infection. In 
such cats, the virus persists in a latent or quiescent form largely in trigeminal ganglia, 
though other tissues may also be involved (Gaskell et al., 2007; Townsend et al., 
2013). During this latent phase, infectious virus is generally not detectable from oro-
nasal secretions. Periodically, particularly after a stressful event, virus reactivates in 
such carriers and they can then infect other animals. Stresses that may induce virus 
shedding include a change of housing (including going into a cattery), kittening and 
lactation, and corticosteroid treatment (Gaskell and Povey, 1977). Some cats may 
show clinical signs during a reactivation episode, which can be a useful indicator that 
they are likely to be infectious (Gaskell et al., 2007; Thiry et al., 2009).  
 
FeHV-1 diagnosis (as well as FCV) has long been performed by virus isolation in cell 
culture from oropharyngeal and conjunctival swabs. Currently, PCR is the most 
commonly used technique for diagnostic purposes as it is more sensitive than 
traditional methods (Poste et al., 1972; Thiry et al., 2009).  
 
Although several topical and systemic antivirals and other putative treatments have 
been investigated for use against FeHV-1, none of these are licensed for FIRD, their 




1.3.2 Feline calicivirus (FCV) 
FCV (family Caliciviridae, genus Vesivirus) is a small non-enveloped RNA virus. 
Although it is quite variable, it is generally considered that there is only one genotype 
and one serotype of the virus (Geissler et al., 1997; Glenn et al., 1999; Radford et al., 
2009). There is some evidence of two genetic clusters/genotypes in Japan, although 
the wider significance of this remains uncertain (Ohe et al., 2007; Sato et al., 2002).  
 
Most strains of FCV are closely related enough antigenically to induce some degree 
of cross-protection and this has been utilized in developing vaccines. FCV affects both 
domestic cats, and some non-domestic Felidae. Interestingly, FCV-like viruses have 
also been isolated from dogs; however, their clinical significance in dogs, and their 
ability to transmit between these species is uncertain (Binns et al., 2000; Helps et al., 
2005). In addition, epidemiologic evidence of a possible association between dogs 
and FCV infection in cats is conflicting (Binns et al., 2000; Helps et al., 2005).  
 
FCV transmission mostly follows direct contact with infected cats through the oro-
nasal route. The virus may also be shed in urine (Larson et al., 2011) and faeces 
(Zhang et al., 2014) of cats, as well as being found in fleas (Mencke et al., 2009), 
although these are not thought to be of major relevance to transmission. 
 
Usually cats shed FCV for up to a month, and at this point an infected animal is 
considered to be a carrier. In a small number of cats, the FCV carrier state can be 
lifelong (Radford et al., 2009). However, most carriers appear to eliminate virus at 
some point, remaining susceptible to reinfection. During the carrier phase, and in 
contrast to FeHV-1, cats shed virus more or less continuously, and are therefore likely 
to be infectious to other cats. The virus persists in the tonsils and other 
oropharyngeal tissues. FCV carriers appear to be common, with approximately 10% 
of cats in the general population shedding FCV, rising to almost 100% in some more 
densely populated environments such as rescue shelters and larger colonies 
(Bannasch and Foley, 2005; Coyne et al., 2006a, 2007a; Helps et al., 2005). From 
studies of endemically infected colonies, it appears that only a minority of carrier cats 
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are true persistent shedders; the majority seemingly undergoing cycles of reinfection 
from other cats in the colony (Coyne et al., 2007a). 
 
Following FCV infection, considerable strain diversity may lead to some variation in 
clinical signs. The most characteristic sign is oral ulceration, typically on the tongue, 
but lesions may also occur elsewhere in the mouth or on the skin. Classic upper 
respiratory tract disease signs, such as sneezing, ocular and nasal discharges and 
conjunctivitis, also commonly occur, but these are generally milder than those seen 
with FeHV-1. With some strains of FCV, lameness and pyrexia may be a feature, with 
or without respiratory/oral disease (Dawson et al., 1994); other strains may induce 
an interstitial pneumonia with infection of alveolar macrophages (Monné Rodriguez 
et al., 2014), and some appear apathogenic (Rong et al., 2014). In addition, FCV 
infection is associated with chronic stomatitis, although its precise role in the 
condition is not clear and other factors are likely to be involved (Radford et al., 2009). 
 
More recently, hypervirulent strains (virulent systemic FCV; VS-FCV) have emerged 
across North America and in several European countries. In addition to URT disease, 
affected cats show, to varying degrees, pyrexia, cutaneous oedema, ulcerative 
dermatitis, anorexia, and jaundice, with a high mortality rate (Coyne et al., 2006b; 
Pesavento et al., 2004; Schulz et al., 2011). Adult cats are frequently affected more 
severely than kittens, and in the field, disease is seen in both vaccinated and 
unvaccinated individuals. Each outbreak appears to be caused by a distinct strain; so 
far none of these VS-FCVs appears to have become widely established in the 
population (Ossiboff et al., 2007). 
 
Currently, the most common diagnostic technique applied for FCV detection is RT-
PCR. In some cases this may be less sensitive than viral isolation in cell culture largely 
because of the variability between strains and the difficulty of finding suitably cross-
reactive primers. However, more recent RT-PCR assays appear to be highly sensitive 
(Litster et al., 2015). In addition to diagnosis, RT-PCR followed by sequencing is useful 
for differentiating between FCV strains in investigating the epidemiology of infection 
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and disease, and in particular, can help pinpoint where an individual cat became 
infected from (Coyne et al., 2007a, 2012; Radford et al., 1997).  
 
Both modified live and inactivated vaccines are available for FCV prevention and are 
reasonably effective at protecting against disease, but none are able to prevent 
infection or development of carrier status (Pedersen and Hawkins, 1995; Radford et 
al., 2009). Various strains of FCV are used in commercial vaccines, such as FCV-F9 or 
FCV-255 in isolation, or two strains such as FCV-431 and FCV-G1 (Poulet et al., 2005). 
These seem to be generally cross-reactive against most recent FCV isolates when 
assessed in vitro (Addie et al., 2008; Porter et al., 2008) and there are some 
publications that point to their continued ability to induce heterologous cross-
protection following challenge (Almeras et al., 2017; Lesbros et al., 2013; Poulet et 
al., 2008). Partial efficacy has also been reported with some vaccines against some 
VS-FCV strains (Pedersen et al., 2000; Poulet et al., 2008; Rong et al., 2014). Because 
FCV is highly variable and able to evolve rapidly, there is a consensus that field 
efficacy should be regularly monitored.  
 
1.3.3 Bordetella bronchiseptica 
In domestic cats, B. bronchiseptica is considered a primary as well as secondary 
pathogen. Experimentally, B. bronchiseptica infection induces mild clinical signs of 
FIRD and submandibular lymphadenopathy (Jacobs et al., 1993). On the other hand, 
field infection may lead to more severe disease, especially in younger animals, 
including pneumonia, dyspnoea, cyanosis and death (Egberink et al., 2009; 
Willoughby et al., 1991). As previously mentioned, B.bronchiseptica has the ability to 
cause disease in immunocompromised humans and it has been isolated from cystic 
fibrosis patients in contact with cats suffering from acute respiratory illness (Register 
at al 2012).  
 
Diagnosis of B. bronchiseptica is done by culture or PCR. Animals that have clinically 
recovered from infection can continue to shed the organism and thus test 
interpretation must be carefully done. As with dogs, vaccines are available, but are 




1.3.4 Chlamydophila felis 
Chlamydophila felis (C. felis) is an obligate intracellular Gram-negative rod-shaped 
coccoid bacterium (Gruffydd-Jones et al., 2009). Infection with C. felis is generally 
associated with both acute and chronic conjunctivitis, though upper and 
lower respiratory signs may sometimes also be seen. Cases that start in one eye can 
rapidly progress to become bilateral. Affected eyes can be markedly painful with 
profound conjunctival hyperemia, chemosis, blepharospasm, and watery followed by 
mucoid or mucopurulent ocular discharges. In some cases adhesions of the 
conjunctiva may develop. More severe signs such as keratitis and corneal ulcers, and 
other systemic illness, are not common, and this can help differentiate C. felis from 
FeHV-1. Whilst thought to be primarily an ocular pathogen, it is mentioned here as 
part of the differential diagnosis for FCV and FeHV-1, both of which can cause ocular 
as well as respiratory disease (Gruffydd-Jones et al., 2009; Sykes, 2012). 
 
1.3.5 Mycoplasma spp.  
As in dogs, the role of Mycoplasma species as primary pathogens in FIRD is still 
controversial as these have been isolated from both animals with respiratory disease 
and healthy cats, with studies suggesting that mycoplasmas are more common in 
cats with respiratory and/or ocular disease (conjunctivitis) than those without 
(Haesebrouck et al., 1991). Additionally, a recently published meta-analysis of field 
literature concluded that Mycoplasma felis is associated with upper respiratory tract 
disease (Le Boedec, 2017). Diagnosis can be achieved via culture, but PCR allows for 
faster results and speciation (Lee-Fowler, 2014). Antimicrobials are the main focus of 
treatment but any underlying or concurrent disease should also be addressed as 
Mycoplasmas are often associated with other pathogens (Bemis, 1992; Lee-Fowler, 
2014). 
 
1.3.6  Influenza viruses in cats 
In parts of Asia where H5N1 infection is endemic in poultry, localized outbreaks of 
H5N1 with high mortality have been described in various felids including domestic 
cats, tigers and leopards (Keawcharoen et al., 2004; Kuiken et al., 2004). Occasional 
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asymptomatic infections have also been seen in domestic cats in Europe, where there 
was close contact with infected aquatic birds (Leschnik et al., 2007). Experimental 
studies have shown that cats can become infected both through contact with 
infected cats and by consuming infected poultry. Infected cats develop severe 
respiratory disease with high mortality, and can transmit infection directly to in-
contact cats (Kuiken et al., 2004; Rimmelzwaan et al., 2006). Influenza H5N1 should 
be considered in cats in contact with birds where highly pathogenic H5N1 is currently 
circulating. Heterologous vaccination of cats has been shown to protect against lethal 
infection of cats with H5N1, and reduce shedding, leading some to suggest vaccines 
may have a role in reducing risk of onward transmission from cats (Vahlenkamp et 
al., 2008). 
 
Recently, CIV H3N2 has also been reported in shelter housed cats with coughing and 
dyspnoea and was associated with high mortality (Jeoung et al., 2013). Population 
and experimental studies have also shown that cats are susceptible to a wide range 
of influenza viruses including H1N1,  H3N8, H5N2 and H9N2 and in some cases 
developing clinical signs (Damiani et al., 2012; Hai-xia et al., 2014; Su et al., 2014; van 
den Brand et al., 2010; Zhao et al., 2014). 
 
Cats (and dogs) are only recently being considered as part of the influenza-
susceptible species and much more work needs to be done to clarify their role, both 
in transmission from aquatic birds, and for their potential to infect people.  
 
Other pathogens of possible clinical significance in FIRD 
Feline reovirus and cowpox virus have occasionally been reported in animals with 
respiratory and/or ocular disease (Muir et al., 1992; Schöniger et al., 2007). However, 





1.4 Conclusions and thesis aims  
It is clear that upper tract respiratory disease of infectious origin remains an 
important health issue of different cat and dog populations both in the UK and 
worldwide. Many questions still remain unanswered regarding the aetiologies and 
risk factors involved in the pathogenesis of these multifactorial syndromes.  Thus, the 
aims of this study were:  
 
● Assess the diversity and epidemiology of FCV in the UK and wider European 
cat population and assess the efficacy of anti-FCV-F9 vaccine antisera to 
neutralise a panel of recent field isolates of FCV.  
● Determine, through a retrospective sero-survey, whether there is evidence of 
exposure to Influenza A and B viruses in UK cats and dogs.  
● Re-evaluate, through a case-control study, the role of known and potential 
FIRD and CIRD pathogens as well as risk factors for clinical disease, in cats and 
dogs attending UK veterinary practices.  
● Re-evaluate, through a longitudinal and cross-sectional study, the presence 
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Feline calicivirus (FCV) is an important pathogen of cats for which vaccination is 
regularly practiced. Long-term use of established vaccine antigens raises the 
theoretical possibility that field viruses could become resistant. This study aimed to 
assess the current ability of the FCV-F9 vaccine strain to neutralise a randomly 
collected contemporary panel of FCV field strains collected prospectively in six 
European countries. 
Veterinary practices (64) were randomly selected from six countries (UK, Sweden, 
Netherlands, Germany, France and Italy). Oropharyngeal swabs were requested 
from 30 (UK) and 40 (other countries) cats attending each practice. Presence of FCV 
was determined by virus isolation, and risk factors for FCV shedding assessed by 
multivariable logistic regression. Phylogenetic analyses were used to describe the 
FCV population structure. In vitro virus neutralisation assays were performed to 
evaluate FCV-F9 cross-reactivity using plasma from four vaccinated cats. 
The overall prevalence of FCV was 9.2%. Risk factors positively associated with FCV 
shedding included multi-cat households, chronic gingivostomatitis, younger age, 
not being neutered, as well as residing in certain countries. Phylogenetic analysis 
showed extensive variability and no countrywide clusters. Despite being first 
isolated in the 1950s, FCV-F9 clustered with contemporary field isolates. Plasma 
raised to FCV-F9 neutralized 97% of tested isolates (titres 1:4 to 1:5792), with 
26.5%, 35.7% and 50% of isolates being neutralized by 5, 10 and 20 antibody units 
respectively. 
This study represents the largest prospective analysis of FCV diversity and antigenic 
cross-reactivity at a European level. The scale and random nature of sampling used 
gives confidence that the FCV isolates used are broadly representative of FCVs that 
cats are exposed to in these countries. The in vitro neutralisation results suggest 
that antibodies raised to FCV-F9 remain broadly cross-reactive to contemporary 





Feline calicivirus (FCV) is a common pathogen of cats causing oral and upper 
respiratory tract disease (URTD) (Radford et al 2009). It has a single-stranded, 
positive-sense RNA genome (Afonso et al., 2017), the plasticity of which is important 
for antigenic evolution, viral persistence (Coyne et al., 2007a; Radford et al., 2009), 
recombination (Coyne et al., 2006a; Symes et al., 2015), and the sporadic outbreaks 
of highly virulent FCV strains causing severe disease (Radford et al., 2009). Despite 
high levels of variability, FCV strains are generally considered to comprise one diverse 
genogroup with a radial phylogeny and little evidence for sub-species clustering 
(Coyne et al., 2007a, 2012; Glenn et al., 1999; Hou et al., 2016; Sato et al., 2002).  
This diverse genogroup is mirrored by a single diverse serotype; although individual 
strains are distinguishable antigenically, they generally show some cross-reactivity 
(Wardley et al., 1974) allowing the development of several FCV vaccines based on 
different antigens (Radford et al 2009). Whilst vaccines reduce clinical signs, none are 
licensed to reduce virus shedding post-challenge and FCV infection remains highly 
prevalent in both vaccinated and unvaccinated populations (Radford et al 2009). 
Most live vaccines include FCV-F9 (Pedersen and Hawkins, 1995) whereas inactivated 
vaccines commonly include strains FCV-255, or a combination of FCV-431 and FCV-
G1 (Poulet et al., 2008, 2005). These vaccine antigens are chosen based on their 
ability to induce broadly cross-reactive antisera against contemporary isolates 
circulating at the time of vaccine development (Pedersen and Hawkins, 1995; Poulet 
et al., 2005). The widespread use of such vaccines together with the high adaptability 
of FCV raises the theoretical possibility that vaccine resistant strains may evolve over 
time. Whilst some studies have supported this hypothesis (Addie et al., 2008; 
Lauritzen et al., 1997; Wensman et al., 2015), others have not (Porter et al., 2008). 
Here we describe the antigenic and genetic relationships between FCV-F9 and a 
representative panel of currently circulating FCV strains, obtained from randomly 
selected veterinary practices across six European countries.  
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2.3  Materials and methods 
 
Ethical statement 
Ethical approval was from the Veterinary Research Ethics Committee, University of 
Liverpool. Informed consent was obtained from participating owners. 
Recruitment 
Samples were collected between October 2013 and May 2014 from cats attending 
veterinary practices in the UK, France, Italy, Netherlands, Sweden and Germany. 
In the UK, three Unitary Authorities (UAs) were randomly chosen from each of the 
nine regions of England, as well as from Wales, Scotland and Northern Ireland. 
Geographically remote islands were also selected (Western Isles, Orkney, Shetland, 
Anglesey, Isle of Wight, Scilly Isles, Isle of Man, Channel Islands) based on 
convenience. From each of these 44 regions, a small animal practice was randomly 
selected from the Royal College of Veterinary Surgeons database. The remaining five 
countries were chosen based on convenience, divided into five regions based on 
official divisions and/or local geography, and a single practice randomly selected 
from each. If chosen practices declined to participate, a further practice was 
randomly selected. This process was repeated up to three times until a practice in 
each region agreed to take part. 
Field isolates 
There is much debate regarding the most appropriate FCV isolates to use for 
assessment of in vitro neutralisation. Several studies have used isolates obtained by 
convenience from diagnostic laboratories to represent pathogenic viruses (Lauritzen 
et al 1997, Addie et al 2008, Wensman et al 2015); lack of random sampling means 
such results may not be generalizable to the wider population (Addie et al, 2008). 
Here we sample sick and healthy cats randomly to ensure our results are 
representative of the sampled population. The occasional description of non-
pathogenic FCV strains (Povey and Hale, 1974) justifies the inclusion of isolates from 
healthy animals. In this regard, it should be noted that FCV isolates from healthy cats 
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can still be pathogenic: virulent FCV continues to be shed from cats recovered from 
acute disease (Povey and Hale 1974), and seropositive cats previously exposed to 
vaccine or field virus may shed virus in absence of clinical signs when subsequently 
challenged with virulent virus (Kahn and Hoover, 1976). Indeed, experimental 
challenge has confirmed that FCV from healthy cats can recreate typical disease 
(Povey and Hale 1974). 
In each practice, veterinary surgeons were asked to collect oropharyngeal swabs 
from the next 30 (UK) or 40 (other countries) cats presented at their surgery 
regardless of reason for presentation (diseased or healthy). Random recruitment of 
practices and random sampling of cats based on attendance at these practices were 
used to ensure results could be generalised to the sampled population, and is in 
contrast to an earlier study by the authors where sampling was by convenience (Hou 
et al., 2016). 
Swabs were collected into virus transport medium, stored at −20 °C before shipping 
to the laboratory. The veterinary surgeon and owner were asked to complete a short 
questionnaire capturing demographic data, vaccination history and information 
about current respiratory disease, mouth ulcers and chronic gingivostomatitis (CGS). 
Viral isolation (VI) 
Feline calicivirus was isolated using standard techniques (Jarrett et al., 1973) based 
on presence of typical cytopathic effect (CPE). Samples were only considered 
negative after two passages (Knowles et al., 1991).  
 
RNA extraction and reverse transcription-PCR 
Viral RNA was extracted from positive cell cultures (second passage or less) (Viral 
RNA mini-kit; Qiagen). One negative control (mock infected cells) was included for 
each three samples. Reverse transcription was performed using 200 ng random 
hexamers (Superscript III, Life Technologies). A 529-nucleotide region of 
the capsid gene, equivalent to residues 6406-6934 of FCV-F9 (GenBank M86379) and 
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incorporating immunodominant regions C and E (Radford et al., 1999; Seal et al., 
1993), was amplified according to manufacturer’s guidelines (Reddy-Mix; Thermo 
scientific) and published protocols using 25pmoles of each primer per 50 µl 
reaction (Hou et al., 2016). In addition, 486 nucleotides from the 3ʹ end of the 
FCV polymerase gene were also sequenced as previously described (Hou et al., 
2016). 
 
Nucleotide sequencing and phylogenetic analysis 
Amplicons were purified (QIAquick; Qiagen), quantified (Nanodrop; Genequant) and 
sequenced (Source Bioscience; Nottingham). Forward and reverse sequences were 
aligned (ChromasPro; Technelysium), and pairwise p-distances and neighbour-
joining trees (1000 bootstrap replicates) calculated using MEGA7. A threshold of 20% 
uncorrected nucleotide distance was used to define distinct strains (Prikhodko et al., 
2014; Radford et al., 1997). 
 
Epidemiological analysis 
Prevalence estimates with 95% confidence intervals were determined (Epitools; 
AusVet) based on results of VI. Data from questionnaires were used to examine risk 
factors and associations with FCV carriage. Univariable and multivariable 
multilevel logistic regression allowing for clustering within practice was conducted 
using MLwiN (v2.1, University of Bristol). Potential risk factors included country, cat’s 
age, gender, breed, lifestyle, vaccination status, vaccine strain, neutering status, 
presence of mouth ulcers, URTD signs, CGS and number of cats in the household. 
Variables with P–values <0.25 in initial univariable analysis were considered in the 
multivariable model retaining variables with Wald P-values <0.05. 
 
Isolates and plasma for viral neutralisation (VN) testing 
Isolates for VN testing were randomly selected with stratification, approximately half 
were from the UK, the remainder from other participating countries. There is no 
approved standard for producing immune reagents for FCV neutralisation studies. 
Conventional FCV vaccination induces insufficient neutralisation titres (Dawson et 
al., 1993b), such that previous studies have used infection with vaccine viruses to 
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produce test sera (Addie et al., 2008; Lauritzen et al., 1997; Porter et al., 2008; 
Wensman et al., 2015). This will likely impact on both the quantity and range of any 
measured immune response compared to vaccination, especially when the tested 
vaccines often contain inactivated antigens. The plasma used in this study was 
collected from animals used in a standard vaccine safety study conducted by the 
funders. Four specific pathogen free cats were vaccinated subcutaneously with 10 
commercial doses of Nobivac® TricatTrio (FCV-F9 live-attenuated vaccine) at 8–
9 weeks of age, and again four weeks later. Blood samples were taken three weeks 
after the second vaccination. Whilst such a challenge regime will induce a 
quantitatively higher response than routine vaccination, the antigenic targets for the 
response should be broadly similar to those of routine vaccination. The plasma from 
all four cats was used as a pool for all tested isolates, and also separately for 10 
randomly selected isolates. 
 
Viral neutralisation assays 
Virus neutralisation tests were performed using a constant virus, varying plasma 
method. Briefly, duplicate, serial twofold dilutions of plasma were incubated with 
32–320 TCID50 (Dawson et al., 1993a) of virus at 37 °C for 1 h before addition to FEA 
cells which had been plated 24hours previously at approximately 1 × 104 cells/well of 
a 96 well plate. Plates were observed for CPE at 48 h and 120 h. Antibody titres were 
expressed as 50% end points (Reed and Muench, 1938). An internal FCV-F9 
homologous control was included in each experiment. As homologous antibody titres 
can vary between experiments, between serum from different cats and depending 
on the method of challenge, antibody units (AU) for each isolate were calculated 
using the titre of this internal control. One antibody unit (AU) is the highest plasma 
dilution neutralizing 100TCID50 of homologous virus in 50% of cultures (Povey, 1974). 
AUs were also calculated using the mean FCV-F9 titre of all experiments (Porter et 
al., 2008), excluding those in which the internal homologous FCV-F9 titre was >2-fold 




Fifty (27 UK, 23 mainland Europe) of the 64 recruited practices (78.1%) returned 
samples (Figure 2.1). Of the 2140 samples requested, 1521 (71%) were received. 
 
 
Figure 2.1 Map showing the 64 recruited veterinary practices. Circles in red are the 50 practices that 
supplied samples during the study. Blue circles are the 14 recruited practices that did not send back 






A total of 140 of 1521 samples tested positive for FCV (9.2%, 95% confidence interval 
(CI) 7.8, 10.8), ranging from 5.4% in Italy to 16.2% in the Netherlands (Table 2.1). 
 
Table 2.1 Summary of samples, isolates and strains identified in each country. 
Country UK France Netherlands Germany Sweden Italy 
Samples (n) 686 187 99 175 205 149 























56 11 16 19 17 10 
Strains (n) 48 11 14 14 14 10 
 
Questionnaires were not received for 1.2% of samples and therefore analysis was 
performed using 1502 questionnaire-sample matches. Nine of twelve predictor 
variables were significantly associated with FCV isolation in univariable analysis (data 
not presented). Of these, five remained significant on multivariable analysis (Table 
2.2): Cats sampled in France, Italy and the UK were at a lower risk of shedding FCV 
than those from the Netherlands. Entire (non-neutered) cats were 1.7 times more 
likely to shed FCV than neutered cats, regardless of gender. Cats in multi-cat 
households were 1.7 (2–3 cats) and 2.8 (4–10 cats) times more likely to shed FCV 
than cats living alone. Cats with CGS were 8.3 times more likely to shed FCV than 
those without. Finally, each additional year of a cat’s age reduced FCV shedding 
likelihood by 12%. Vaccination was not significantly associated with risk of FCV 





Table 2.2 Multilevel multivariable logistic regression analysis (allowing for clustering within practice) 
of factors associated with FCV isolation in 1502 vet visiting cats from UK and mainland Europe. P-
values below 0.05 considered significant. 
Variable Odds ratio 95% CI lower 95% CI upper P-value 
Country  
France 0.29 0.11 0.75 0.01 
The Netherlands Ref. 
   
Italy 0.234 0.087 0.631 0.004 
Germany 0.72 0.31 1.65 0.44 
Sweden 0.599 0.253 1.419 0.24 
UK 0.434 0.213 0.88 0.02 
Neutered status  
Yes Ref. 
   
No 1.69 1.053 2.736 0.03 
 
 
Chronic gingivo-stomatitis  
Yes Ref. 
   
No 0.12 0.06 0.23 <0.001 
 
 
No. cats/household  
1 Ref. 
   
2–3 1.75 1.10 2.79 0.02 
4–10 2.82 1.49 5.31 0.001 
>11 0.74 0.08 6.97 0.79 
Age (month) 0.99 0.99 0.99 0.01 
Level 2 variance (standard error) 




A total of 128 partial capsid consensus sequences were obtained from the 140 FCV 
isolates (Figure 2.2; GenBank accession numbers KX257491–KX257617). The 
unamplified isolates typical of such experiments are presumed to be caused by 
primer mismatches (Coyne et al., 2012; Hou et al., 2016). In total, 110 strains 
(pairwise genetic distance>20%) were observed, ranging from 10 (Italy) to 48 (UK) 
(Table 2.1). Of these strains, only 10 were represented by more than one isolate 
(bootstrap values >80%; A to L on Figure 2.2). The largest cluster included FCV-F9-like 
isolates from the UK and Sweden (D in Figure 2.2). All other strains with more than 
one variant were restricted to individual practices, with no evidence for widespread 
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or international transmission. Similar phylogenetic results were obtained for 




Figure 2.2 Unrooted Neighbor-Joining tree of 128 FCV partial capsid consensus sequences obtained 
from the national study (including the sequence of FCV vaccine strain F9 [GenBank accession 
No. M86379]). The percentage of replicate trees in which the associated taxa clustered together in 
the bootstrap test (1000 replicates) are shown, only bootstrap values >80% are indicated. The tree is 
drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to 
infer the phylogenetic tree and relate to the distance bar. The evolutionary distances were computed 
using the Tamura-Nei method and represent the number of base substitutions per site. The rate 
variation among sites was modelled with a gamma distribution (shape 
parameter = 1). Codon positions included were 1st + 2nd + 3rd + Noncoding. All ambiguous positions 
were removed for each sequence pair. There were a total of 435 positions in the final dataset. The 
geographical origin of sequences is shown in different colours. Those strains represented by more 
than a single sequence (<20% capsid divergence) are boxed, additionally labelled A–L, and the intra-
strain capsid diversity indicated next to the box; isolates in each box originate from the same country 
and veterinary practice with the exception of cluster D, where all sequences were collected in different 
practices and two different countries. Circles at the tip of the branch indicate isolates used in viral 
neutralisation testing: empty circles represent isolates from animals with either chronic or 
acute upper respiratory tract disease (URTD) and full circles represent isolates from animals either 




Figure 2.3 Unrooted Neighbor-Joining tree of 128 FCV partial polymerase consensus sequences 
obtained from the national study (including the sequence of FCV vaccine strain F9 [GenBank accession 
no. M86379]). The percentage of replicate trees in which the associated taxa clustered together in the 
bootstrap test (1000 replicates) are shown, only bootstrap values >80% are indicated. The tree is 
drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to 
infer the phylogenetic tree and relate to the distance bar. The evolutionary distances were computed 
using the Tamura-Nei method and are in the units of the number of base substitutions per site. The 
geographical origin of sequences is shown in different colours. Circles at the tip of the branches 
indicate the isolates used in Viral Neutralisation testing: empty circles represent isolates from animals 
with either chronic or acute upper respiratory disease (URTD) and full circles represent isolates from 
animals either without URTD or no information in regards to clinical status.   
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The reproducibility of VN assays was assessed in two ways. Firstly, 10 field isolates 
were randomly repeated giving an average difference in neutralisation titres 
between repeats of 2.08, comparable to previous studies (Dawson et al., 1993a). In 
addition, the mean homologous titre for the internal FCV-F9 control across 19 
experiments was 1 in 1658 ± 345 standard error (data not presented). 
 
Viral neutralisation was attempted in 121 of the 140 FCV isolates. In total, 98 VN tests 
were successfully completed (48 UK, 6 Sweden, 9 France, 16 Germany, 10 the 
Netherlands and 9 Italy; Appendix 1A); the remaining 23 failed due to inability to 
regrow in cell culture, titration failure, or bacterial contamination. 
 
Of these 98 FCV isolates, 95 (97%) were neutralized at titres ranging from 1:4 to 
1:5792 (Figure 1.4a; Appendix 1A). Whilst group sizes precluded statistical analysis, 
the pattern of neutralisation appeared to be broadly similar when isolates from 
different clinical presentations were compared (Figure 1.5). The VN results based on 
different countries are shown in Figure 1.4b. When titres were standardised to 
homologous FCV-F9 titres derived within individual experiments, 26.5%, 35.7% and 
50% of isolates were neutralized by 5, 10 and 20 AUs respectively. When using the 
same method as described previously (Dawson et al., 1993b), using only those 
experiments where the titre for the internal FCV-F9 control was within 2-fold of mean 
FCV-F9 titre across all experiments, 0%, 20% and 32% of 25 isolates were neutralized 








Figure 2.4 Results of viral neutralisation testing. A: VN titre ranges (% of isolates) for the current study. 
B: Percentage of isolates neutralized by 20, 10 and 5AU per country. 
 
 
Figure 2.5 Scatterplot of log2 of VN titres (Y axis) for FCV isolates grouped based on the presence of 
respiratory and oral disease at time of sampling (X axis). Acute only:  animals with ulcers and/or upper 
respiratory tract disease. Chronic only: cats with chronic gingivostomatis. Both: cats with both chronic 
and acute disease. Healthy: animals with neither acute nor chronic disease. Unknown: cats where 
information regarding clinical disease was not provided by the assisting veterinary surgeon through 
questionnaire at the time of sampling.   
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Table 2.3 Percentage of isolates neutralized by 20, 10 and 5AU (antibody units) for each different cut-
off or analysis method used. 
Cut-off Number of VN 
results 
20AU 10AU 5AU 
AUs based on individual experiment FCV-F9 
homologous control 
 
98 50 36 27 
AUs for those isolates where the titre for the internal 
F9 control was within 2-fold of mean F9 titre across 
all experiments 
25 32 20 0 
 
In order to analyse the variability of plasma from the four cats, viral neutralizations 
with single cat plasma were undertaken for 10 random field isolates and FCV-F9 
(Table 1.4). The plasma from each cat had demonstrable neutralizing ability to each 
isolate. However, there was variation in the order of individual cat responses, with 
some cats’ plasma seemingly neutralising some viruses particularly well, and others 
less well. 
 
Table 2.4 Neutralizing titres for pooled plasma from four cats vs individual plasma. BT stands for back 
titration. Isolates were given a unique ID code using two letters to represent the country of origin 
(GB=United Kingdom, FR=France, DE=Germany, IT=Italy, NL=Netherlands, SE=Sweden) followed by 
two digits representing the practice where the sample was collected and the two next digits 
representing the individual animal.  
Isolate pool Cat 6071 Cat 6038 Cat 6480 Cat 6452 F9 titre F9 BT isolate BT 
NL0129 5.7 5.7 5.7 8 2 1448 31.6 215.4 
S0436 42.2 32 84.4 128 215.3 1448 31.6 31.6 
F9 4096 2048 4096 1024 2048 4096 46.4 46.4 
GB1818 2.8 5.7 5.7 8 4 4096 46.4 100 
SE0114 2 4 2.8 2.8 4 4096 46.4 215.4 
IT0421 26.9 26.9 13.5 22.6 22.6 2896 100 31.6 
GB0325 26.9 32 13.5 22.6 22.6 2896 100 316.2 
NL0342 256 512 512 181 181 2896 100 100 
GB1612 5.7 4 8 5.7 5.7 2896 31.6 215.4 




2.5 Discussion and conclusions 
Widespread use of individual vaccines is associated with a theoretical risk for the 
emergence of vaccine resistance strains, particularly for RNA viruses. Here we have 
undertaken the first multinational European study to assess the current in vitro cross 
reactivity of FCV-F9, first isolated over 40 years ago, and still one of the most 
frequently used vaccine antigens (Kalunda et al., 1975).  
 
In order to maximise the generalizability of our findings to the European cat 
population, a cross-sectional survey sampling cats from randomly recruited 
veterinary practices was undertaken. This approach also provided an opportunity to 
assess the epidemiology and molecular epidemiology of FCV infection. Whilst every 
effort was made to sample in a random manner, we are unable to rule out that some 
practitioners may have selected for diseased patients. In a previous study looking 
into tick prevalence in dogs in the UK where veterinary surgeons were recruited on a 
voluntary basis it was postulated that over-reporting may have happened due to 
participants being particularly interested in ticks and tick-borne diseases, resulting in 
selection bias (Abdullah et al, 2016). Since veterinary surgeons participating in the 
present study also agreed to take part voluntarily it is likely that a similar bias may be 
present. Additionally, this study only sampled veterinary visiting cats which would 
seem appropriate as the project aimed to look at vaccine efficacy. However, results 
should not be generalised to non-veterinary visiting cats. It is likely that viruses 
circulating in the latter population are similar to those present in veterinary visiting 
cats but we cannot formally comment on that. In future studies, it would be 
interesting to compare viruses from both populations.   
 
Consistent with previous studies, cats in multi-cat households, those with CGS, 
and younger cats, were more likely to shed FCV (Fernandez et al., 2017; Porter et al., 
2008). Chronic gingivostomatitis affects 0.7% of the population (Healey et al., 2007), 
with most affected cats testing FCV positive (Fernandez et al., 2017; Knowles et al., 
1991). Previous studies have shown that FCV prevalence increases from around 10% 
in single-cat households to over 50% in some larger colonies (Coyne et al., 2007b; 
Helps et al., 2005). These large colonies are believed to drive antigenic diversity as 
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strain variants evolve under positive selection within a variable population immunity 
(Coyne et al., 2007b; Radford et al., 2001). In addition, neutered cats were less likely 
to test positive for FCV regardless of age. This suggests behavioural changes 
associated with neutering, such as becoming less territorial, may lower FCV risk as 
has also been shown for feline immunodeficiency virus (Berger et al., 2015; Wardley 
et al., 1974). We also found that cats in some countries (the Netherlands) had a 
higher prevalence of FCV infection than those from others (France, Italy, UK). 
Whether this represents true population differences, or the relatively small sample 
sizes in some countries will need to be assessed further. 
 
The phylogenetic analysis is broadly in agreement with previous national and 
international studies (Coyne et al., 2012; Glenn et al., 1999; Henzel et al., 2012; Hou 
et al., 2016), highlighting a radial phylogeny with little evidence for sub-species 
clustering except viruses sharing immediate temporal or spatial links. As 
previously (Abd-Eldaim et al., 2005; Coyne et al., 2012, 2007b), FCV-F9 variants were 
found in this population, five from the UK and two from Sweden, of which four had 
been vaccinated with FCV-F9 attenuated vaccines <25 days prior to sampling, one 
was un-vaccinated for at least three years, and one a rescue cat that was presumed 
unvaccinated. The only time such vaccine-derived viruses are not observed is when 
recently vaccinated cats are excluded from the sampled population (Hou et al., 2016). 
Our findings are consistent with experimental studies showing occasional shedding 
of vaccine virus following live-FCV vaccination (Dawson et al., 1991; Pedersen and 
Hawkins, 1995). Looking at the diversity within this FCV-F9 clade, six of the seven 
strains were <3.6% distant from the FCV-F9 published sequence, suggesting they had 
not been replicating for long in the cat, consistent with recent vaccination history of 
most of these cats. In contrast, a Swedish isolate from a vaccinated cat (unknown 
strains), was 16.9% different to FCV-F9, possibly representing a rare persisting and 
evolving strain of FCV-F9 or an unrelated strain. Taken together, this confirms that 
whilst live vaccine viruses are occasionally shed following vaccination, they only seem 
to have a limited potential to persist in the general cat population. 
 
The balance between antibody- and cell-mediated immunity in FCV protection is 
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somewhat uncertain. Some cats exposed to previous FCV antigens show protection 
to heterologous challenge, even when there are no demonstrable in vitro antibodies 
to the new challenge (Knowles et al., 1991), suggesting that other factors including 
cellular immunity contribute to protection. That said, it is still believed that there is 
sufficient correlation between antibody levels and protection, for in vitro virus 
neutralisation tests to remain the accepted method of assessing cross-reactivity 
(Addie et al., 2008; Porter et al., 2008; Povey and Ingersoll, 1975; Wensman et al., 
2015). Therefore, we have used a pool of plasma raised to 10 doses of FCV F9 vaccine, 
and demonstrated neutralising activity to the majority of this cross-sectional 
European panel of contemporary FCV isolates. These results are broadly similar to 
those observed in a similar cross-sectional study of FCV-F9 strain diversity in the UK 
in 2001 (Porter et al., 2008). When results are expressed as antibody units to try and 
control for variations in sera production (infection vs vaccination overdose), and the 
between-cat variation, the percentage of isolates neutralized by 20, 10 and 5 AUs 
was similar to, or higher than, that from the earlier study in 2001 (Porter et al., 2008). 
When taken together, this suggests antisera against FCV-F9 remains broadly cross-
reactive against recently circulating FCV strain diversity. This is consistent with our 
observation that, despite its age, FCV-F9 remains an integral part of this 
contemporary phylogeny, and suggesting that FCV may not evolve in a linear (“clock-
like”) fashion, such as is typical for other rapidly evolving viruses (Gojobori et al., 
1990; Kimura, 1987). 
 
These conclusions are in contrast with other studies suggesting the levels of FCV-F9 
cross-reactivity have reduced over time (Addie et al., 2008; Lauritzen et al., 1997; 
Wensman et al., 2015). However, two important methodological differences 
between studies make direct comparisons impossible. Firstly, previous studies used 
isolates collected by convenience from diagnostic laboratories; these should not be 
considered representative of those in the general population (Addie et al., 2008). 
Secondly, previous studies have used infection rather than vaccination to produce 
antisera of sufficient titre for testing; differences in viral replication and 
antigen presentation between virus replicating locally in target tissues of the upper 
respiratory tract as opposed to the subcutaneous tissues at the site of vaccination, 
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are likely to impact in albeit unknown ways, on the nature of the ensuing immune 
response, and this impact is likely to be greatest for viral antigens from inactivated 
vaccines. Here for the first time we used subcutaneous vaccination (albeit at 10× 
release dose), of a live vaccine, using a cross-sectional sample of contemporary FCV 
isolates to maximise the generalizability of our results. Clearly these in vitro results 
cannot be used to suggest the rate of cross-protection in the field. To facilitate better 
comparison between these studies in the future, we recommend the development 
of an internationally agreed study protocol as exists for other viral vaccines.
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2.6 Appendix to Chapter 2 
 
Appendix 2A Viral neutralisation data alongside questionnaire data for each tested isolate. Country names in this table use ISO codes. DSH stands 


































































































































































Fr0135 316.2 8 100 512 Fr M N Dsh Both 5 Y 31 Fcv-f9 4 to 10 N N N N 
Fr0201 316.2 256 46.4 4096 Fr F Y Dsh Both 72 Y N/a N/a 4 to 10 N N N Y 
Fr0204 316.2 <2 31.6 256 Fr M N Dsh Indoors 5 Y N/a N/a 2 to 3 N Y Y N 
Fr0208 46.4 256 31.6 4096 Fr F Y Dsh Outdoors 8 N N/a N/a 2 to 3 N N N N 
Fr0236 100 128 215.4 512 Fr N/a N/a N/a N/a N/a N/a N/a N/a N/a N/a N/a N/a N/a 
Fr0321 46.4 181 31.6 512 Fr F Y Dsh Both 67 Y N/a Fcv-f9 1 N N N Y 
Fr0515 46.4 724 100 724 Fr M Y Dsh Both 9 N N/a N/a 2 to 3 N N N N 
Fr0538 46.4 362 100 512 Fr M Y Pedigree Unknown N/a N/a N/a N/a 2 to 3 N N N N 
Fr0637 46.4 362 31.6 512 Fr M N Dsh Both 5 Y N/a Fcv-431 + g1 2 to 3 N N N N 
De0104 170 5.7 31.6 512 Deu M Y Pedigree Outdoors N/a N N/a N/a 1 Y N Y Y 
De0130 316 11.3 316 512 Deu F Y Dsh Both 151 Y 362 Fcv-f9 2 to 3 N N N N 
De0209 316.2 8 215.4 512 Deu F Y Pedigree Both 110 Y 37 Fcv-f9 2 to 3 N Y Y Y 
De0214 31.6 168.9 100 724 Deu F Y Dsh Outdoors N/a N N/a N/a 11 to 30 Y N Y Y 




































































































































































De0232 316.2 22.6 100 512 Deu F Y Pedigree Both 115 Y 37 Fcv-f9 2 to 3 N N N Y 
De0234 316.2 107.6 46.4 2896 Deu N/a N/a N/a N/a N/a N/a N/a N/a N/a N/a N/a N/a N/a 
De0235 100 5.7 31.6 724 Deu F Y Pedigree Both 132 Y 34 Fcv-f9 2 to 3 N N N N 
De0237 100 11.3 31.6 256 Deu F N Dsh Outdoors N/a N N/a N/a 11 to 30 Y N Y Y 
De0242 100 256 31.6 256 Deu M Y Dsh Outdoors N/a N N/a N/a 4 to 10 N N N N 
De0321 316.2 90.5 31.6 256 Deu F Y Pedigree Both 137 Y 379 Fcv-431 + g1 1 N N N N 
De0322 46.4 256 316.2 512 Deu F N Dsh Indoors 2 N N/a N/a 2 to 3 N Y Y N 
De0426 316.2 90.5 316.2 512 Deu M N Dsh Both 7 Y N/a N/a 2 to 3 N N N N 
De0502 100 22.6 46.4 1448 Deu M N/a Pedigree Indoors 89 Y 1874 Fcv-f9 2 to 3 Y Y Y Y 
De0520 100 90.5 100 724 Deu M Y Dsh Both 24 Y 380 Fcv-431 + g1 2 to 3 Y N Y Y 
De0538 316.2 64 46.4 2896 Deu M Y Pedigree Indoors 20 Y 454 Fcv-f9 1 N N N N 
It0107 316 64 316 512 Ita M N Dsh Both 18 N N/a N/a 2 to 3 N Y Y N 
It0201 215.4 16 316.2 512 Ita M Y Dsh Both 75 N N/a N/a 1 N N N N 
It0208 215.4 11.3 46.4 1448 Ita M N Dsh Both 48 Y 1043 Fcv-431 + g1 2 to 3 Y Y Y Y 
It0341 46.4 128 31.6 512 Ita M N Dsh Indoors 5 Y 16 Fcv-f9 1 N Y Y Y 
It0418 100 512 46.4 1448 Ita M Y Dsh Outdoors 15 N N/a N/a 1 N N N N 
It0421 46.4 32 100 724 Ita F Y Dsh Outdoors 10 Y 108 Fcv-f9 1 N N N N 
It0427 316.2 107.6 46.4 4096 Ita M N Dsh Outdoors 9 N N/a N/a 2 to 3 N N N N 




































































































































































It0539 316.2 128 100 4096 Ita N/a N/a N/a N/a N/a N/a N/a N/a N/a N/a N/a N/a N/a 
Nl0129 100 8 31.6 1448 Nld M Y Dsh Both 6 Y 89 Fcv-f9 2 to 3 N N N N 
Nl0131 100 90.5 31.6 4096 Nld M Y Cross Indoors 12 Y 253 Fcv-f9 2 to 3 N N N N 
Nl0132 31.6 181 100 2896 Nld F Y Dsh Indoors 6 Y 127 Fcv-f9 1 N N N N 
Nl0135 316.2 512 46.4 4096 Nld F Y N/a Unknown 62 Y 13 Fcv-f9 1 N N N N 
Nl0342 31.6 181 100 724 Nld M Y Dsh Both 162 Y 779 Fcv-431 + g1 2 to 3 N Y Y N 
Nl0413 215.4 64 46.4 1448 Nld F N Dsh Both 7 Y 112 Fcv-f9 4 to 10 N N N N 
Nl0415 215.4 128 46.4 1448 Nld M N Dsh Both 86 Y 23 Fcv-f9 1 N N N N 
Nl0425 31.6 90.5 46.4 724 Nld F Y Dlh Both 122 Y 3002 Fcv-f9 2 to 3 N Y Y N 
Nl0426 316.2 362 46.4 4096 Nld M Y Dsh Both 20 Y 16 Fcv-f9 1 N N N Y 
Nl0434 316.2 8 46.4 1448 Nld F Y Dlh Both 83 Y 240 Fcv-f9 1 N N N Y 
Se0114 316 45.3 316 512 Swe F Y Dsh Indoors 36 Y N/a Fcv-f9 11 to 30 N N N N 
Se0216 31.6 1024 100 2896 Swe F Y Dsh Both 6 Y 78 Fcv-f9 2 to 3 N N N N 
Se0315 316.2 2896 100 4096 Swe F N/a Dlh Indoors N/a Y N/a Fcv-f9 1 N N/a N/a N/a 
Se0329 68.1 11.3 31.6 724 Swe M Y Pedigree Indoors 156 Y 1334 Fcv-f9 1 Y N Y N 
Se0404 46.4 16 31.6 512 Swe F Y Pedigree Indoors 63 Y 304 Fcv-f9 2 to 3 N N N N 
Se0436 100 64 215.4 512 Swe M Y Dlh Outdoors N/a N/a N/a N/a 2 to 3 N N N N 
Gb0110 46.4 168.9 31.6 256 Gbr F Y Dsh Both 5 Y 62 Fcv-431 + g1 1 N N N N 




































































































































































Gb0116 215 11.3 31.6 512 Gbr F Y Dsh Both 135 N N/a N/a 2 to 3 N N N Y 
Gb0203 100 5792 46.4 2896 Gbr M Y Dsh Both 69 N N/a N/a 4 to 10 N N N N 
Gb0311 100 64 215.4 4096 Gbr F N Pedigree Indoors 2 N N/a N/a 4 to 10 N N N N 
Gb0325 316 22.6 316 512 Gbr M Y Dsh Outdoors 105 Y 296 Fcv-f9 1 Y N Y N 
Gb0331 170.1 512 316.2 512 Gbr M N Dsh Indoors 3 Y 21 Fcv-f9 1 N N N N 
Gb0424 316.2 48 31.6 724 Gbr M Y Dsh Both 166 Y 2190 N/a 1 Y N Y Y 
Gb0528 46 128 316 512 Gbr F Y Dsh Both 183 N/a N/a N/a 2 to 3 N N N N 
Gb0805 31.6 22.6 100 724 Gbr F Y Dlh Outdoors 79 Y 2562 Fcv-255 N/a N/a N/a N/a N/a 
Gb0810 316 256 316 512 Gbr F Y Dsh Outdoors 12 N N/a N/a N/a N N N N 
Gb0814 46.4 181 46.4 2896 Gbr M N Dsh Both 180 N N/a N/a 2 to 3 N N N N 
Gb1504 316.2 2048 215.4 4096 Gbr F Y Dsh Indoors N/a Y 21 Fcv-f9 2 to 3 N N N N 
Gb1508 31.6 22.6 31.6 1448 Gbr M Y Dsh Both 144 N N/a N/a 1 Y N Y Y 
Gb1521 46.4 32 46.4 1448 Gbr M Y Pedigree Indoors 8 N/a N/a N/a 4 to 10 N N N N 
Gb1524 316 <2 31.6 512 Gbr M Y Dlh Both 28 Y 682 Fcv-f9 4 to 10 N N N N 
Gb1612 215.4 4 215.4 362 Gbr M Y Dsh Both 12 N/a N/a N/a 2 to 3 N N N N 
Gb1628 170.1 181 100 512 Gbr F N/a Pedigree Indoors N/a N/a N/a N/a N/a N N N N/a 
Gb1630 215.4 181 215.4 4096 Gbr M N Dsh Outdoors 96 N/a N/a N/a N/a N N N N/a 
Gb1811 100 45.3 100 724 Gbr M Y Dsh Both 43 Y 13 Fcv-431 + g1 2 to 3 N N/a N/a N/a 




































































































































































Gb1823 31.6 22.6 31.6 724 Gbr M Y Dsh Indoors 162 Y 8 Fcv-431 + g1 1 N N N N 
Gb1925 316.2 11.3 215.4 4096 Gbr F Y Dsh Both 6 Y N/a N/a 2 to 3 N N N N 
Gb2128 170 11.3 31.6 724 Gbr F N Dsh Outdoors 12 N/a N/a N/a N/a N N N N 
Gb2207 316.2 181 215.4 362 Gbr M Y Dsh Both 132 N N/a N/a 2 to 3 N N N N 
Gb2210 146.7 256 215.4 512 Gbr F N Dsh Indoors 32 N N/a N/a 1 N N N N 
Gb2324 215.4 16 31.6 256 Gbr F Y Dsh N/a N/a Y 58 Fcv-f9 2 to 3 N N N N 
Gb2515 46.4 8 100 2896 Gbr F Y Dsh Both 60 Y 383 Fcv-f9 4 to 10 N N N N 
Gb2726 100 53.8 46.4 2896 Gbr F Y Pedigree Indoors 7 N/a 121 Unknown 2 to 3 N N/a N/a N 
Gb2803 316.2 181 31.6 1448 Gbr F Y Dsh Both 5 N N/a N/a 2 to 3 N N N N 
Gb2825 170 64 31.6 512 Gbr M Y Dsh Indoors 7 N N/a N/a 2 to 3 N N N N 
Gb2907 316.2 724 100 4096 Gbr F Y Dsh Indoors N/a N N/a N/a 4 to 10 N N N N 
Gb2926 215.4 11.3 316.2 512 Gbr M Y Dsh Both 84 N N/a N/a 4 to 10 N N N N 
Gb2927 46.4 5.7 46.4 4096 Gbr F Y Dsh Both 6 Y 179 Fcv-f9 2 to 3 N N N N 
Gb2929 316.2 362 46.4 4096 Gbr F Y Dsh Outdoors 5 Y 8 Fcv-f9 2 to 3 N N N N 
Gb3020 316.2 90.5 46.4 2896 Gbr F N Dsh Indoors 6 N/a N/a N/a 2 to 3 N N N N 
Gb3029 46.4 181 100 2896 Gbr F Y Dsh Both 36 Y 22 Fcv-f9 2 to 3 N N N N 
Gb3114 316.2 11.3 215.4 362 Gbr F Y Pedigree Both 79 Y N/a Fcv-f9 4 to 10 Y N Y N 
Gb3115 215.4 5.3 100 4096 Gbr F N N/a Indoors 3 Y 14 Fcv-f9 2 to 3 Y N Y N/a 




































































































































































Gb3123 316.2 362 316.2 512 Gbr F Y Dsh Both 22 Y 229 Fcv-f9 2 to 3 N N N N 
Gb3130 316.2 90.5 100 4096 Gbr M Y Dsh Both 87 Y 243 Fcv-f9 4 to 10 N N N N 
Gb3132 68.1 11.3 31.6 724 Gbr F Y Dlh Both 15 Y 84 Fcv-f9 2 to 3 N N N N 
Gb3804 100 11.3 215.4 362 Gbr M Y Dsh Both 54 Y 266 Fcv-431 + g1 4 to 10 Y N Y Y 
Gb3807 316.2 <2 100 2896 Gbr M Y Dsh Both 73 N/a N/a N/a 1 N N N N 
Gb3812 316.2 8 215.4 4096 Gbr M Y Pedigree Both 16 Y 412 Fcv-431 + g1 4 to 10 N Y Y N 
Gb4211 31.6 107.6 31.6 4096 Gbr F Y Dsh Both 28 Y N/a Fcv-f9 2 to 3 N N N N 









3 A retrospective serosurvey of influenza A and B 





There is historic evidence of sporadic infection of dogs and cats with influenza A and 
B viruses and, more recently, two influenza A subtypes (equine-origin H3N8 and 
avian-origin H3N2) have become established in dogs in the USA. In order to 
investigate the potential transmission and circulation of influenza viruses in dogs and 
cats in the UK, a retrospective serosurvey was carried out using archival serum 
samples collected from 2012 to 2014.  
 
A total of 200 canine and 179 feline serum samples were screened for influenza A 
(human seasonal H3N2, human pandemic H1N1, equine H3N8) and influenza B 
(Yamagata and Victoria lineages), using haemagglutination inhibition (HI). Single 
radial haemolysis (SRH) was used to confirm any HI positive results. 
 
 Of the dogs, 1.5% (3 samples) tested positive for antibodies to an equine H3N8 
subtype strain in both HI and SRH tests. One of the cat samples (0.56%) was positive 
for H1N1 antibodies, representing the first evidence of seroreactivity of cats to the 
human 2009 H1N1 pandemic virus in the UK.  
 
These data suggest that dogs and cats in the UK sporadically come into contact with 
influenza A viruses. The risk of infection appears low, but we recommend that 
veterinary practitioners consider influenza virus as a differential diagnosis in pets 
with acute clinical signs of respiratory disease, especially if these coincide with 
influenza-like illness in owners or other in-contact species.  
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3.2 Introduction  
Influenza A viruses are sporadically transmitted from aquatic birds to various 
mammalian species and, occasionally, certain subtypes (e.g. human H1N1 and H3N2 
and equine H3N8) become established in the new host (Lipatov et al., 2004; Short et 
al., 2015; Webster et al., 1992). Influenza A viruses, including human seasonal H3N2, 
2009 pandemic H1N1 and H5N1 strains, have occasionally been reported to infect 
cats and dogs (Harder and Vahlenkamp, 2010; Horimoto et al., 2015; Löhr et al., 2010; 
Short et al., 2015; Songserm et al., 2006; Yin et al., 2014). However, influenza A 
viruses were not reported to circulate endemically in dogs or cats until an H3N8 
subtype virus of equine origin was isolated from racing greyhounds with respiratory 
disease in the USA in 2004 (Crawford et al., 2005). This virus became established in 
shelter and pet dog populations in the USA.  In the UK, transmission of equine H3N8 
influenza to foxhounds has been described (Daly et al., 2008), which is believed to 
occur sporadically (Newton et al., 2007). A similar occurrence took place in dogs in 
close proximity with horses during an outbreak of equine influenza in Australia in 
2007 (Kirkland et al., 2010).  
 
In Asia, an avian-derived H3N2 influenza virus has also been a source of acute 
respiratory disease in dogs (Li et al., 2010) and since 2015, this virus has been 
circulating in dogs in the USA (Abente et al., 2016; Jang et al., 2017; Voorhees et al., 
2017). There are also reports of transmission of the avian-origin canine H3N2 
influenza virus to cats in Asia (Jeoung et al., 2013; Song et al., 2011).  
 
Evidence of influenza B virus infection in animal species other than humans and seals 
is very limited (Osterhaus et al., 2000). However, it has been suggested that dogs may 
be susceptible to these viruses (Todd and Cohen, 1968).  
 
The aim of this study was to determine whether there is serological evidence of 




3.3 Materials and methods 
 
Ethics 
Ethical approval for the use of archived serum samples was obtained from the 
Veterinary Research Ethics Committee, University of Liverpool.  
 
Viruses 
Viruses used in this study were the human pandemic influenza A H1N1 strain 
A/California/7/2009 (A/H1N1), human seasonal influenza A H3N2 strain 
A/Texas/50/2012 (A/H3N2), A/equine/Newmarket/5/2003 (A/eq/H3N8), and human 
influenza B strains from the Yamagata lineage, B/Massachusetts/1/2012 (B/Mas), 
and the Victoria lineage, B/Brisbane/60/2008 (B/Bris). All human influenza viruses 
were obtained from the National Institute for Biological Standards and Control 
(NIBSC). Equine influenza virus was kindly provided by Dr. Debra Elton (Animal Health 
Trust). Virus stocks were cultivated in embryonated hens’ eggs and stored at -80ºC. 
 
Serum samples 
Archived serum samples were available from 200 dogs and 179 cats, and represented 
leftover diagnostic samples collected from patients attending the University of 
Liverpool’s Small Animal Teaching Hospital for various reasons between 2012 and 
2014. All serum samples had been stored at -20ºC. The relevant positive control 
serum samples for the human influenza virus isolates were obtained from NIBSC. The 
equine influenza virus control serum was collected from a hyper-immune 
experimental pony that had been subjected to multiple viral exposures. 
 
Serological testing  
Haemagglutination inhibition (HI) testing was performed using an adapted protocol 
from the World Health Organization (World Health Organization, 2002). Briefly, test 
and positive and negative control serum samples were heat-inactivated at 56ºC for 
30 minutes and pre-treated with receptor destroying enzyme (RDE, Sigma-Aldrich) 
resulting in a final dilution of 1:10. Serial two-fold dilutions of each sample were 
incubated for 30 minutes at room temperature (RT) with four haemagglutination 
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(HA) units of test virus. Subsequently, an equal volume of 0.5% chicken red blood 
cells (RBCs, TCS Biosciences Ltd.) in PBS was added, and HI titres determined as the 
highest serum dilution giving at least 50% inhibition of agglutination after incubation 
for 30 minutes at RT.  
 
Single radial haemolysis (SRH) testing as described in the OIE Terrestrial Manual (OIE, 
2015) was used as a confirmatory test in all samples that exhibited HI titres ≥1:10. 
Briefly, the different viral strains were coupled with 8% sheep RBCs with chromium 
chloride. Immunoplates containing 1% agarose were prepared using the sensitised 
sheep RBCs and guinea pig complement. Then, 10 µl test and control sera treated as 
previously described were pipetted into pre-punched 3 mm wells on the 
immunoplates and incubated at 34ºC in a humidified box for 20 hours. Haemolytic 
zones were measured with digital callipers and areas of haemolysis were calculated. 
 
Confidence intervals for the proportion of positive samples (expressed as a 




3.4 Results  
Of 200 canine serum samples tested by HI, seven had HI titres ≥1:10 against A/H1N1 
(Figure 3.1) and four samples tested positive for antibodies against A/eq/H3N8. 
Twenty-two samples tested positive for antibodies against both B/Mas and B/Bris, 
two of which were also positive for A/H1N1 as above. A further five samples tested 
positive for B/Mas alone and five more for B/Bris alone. No samples tested positive 
for A/H3N2. Single radial haemolysis was performed with all 41 samples exhibiting HI 
titres ≥1:10. Anti-influenza A/eq/H3N8 antibodies were confirmed in three samples 
(1.5%, 95% CI 0.5%, 4.3%); all remaining samples were negative by SRH to both 
influenza B strains and A/H1N1 (Table 3.1). 
 
Of 179 feline serum samples tested by HI, three tested positive for antibodies against 
A/H1N1 with titres of 1:40 (n=2) to 1:320 (n=1). No samples tested positive for 
A/H3N2, B/Mas, B/Bris or A/eq/H3N8. The feline sample with an HI titre of 1:320 was 
confirmed positive by SRH testing (0.56%, 95% CI 0.1%, 3.1%; Table 3.1).  
 
 
Figure 3.1 Numbers of canine serum samples (indicated in brackets) for which titres ≥1:10 were 
obtained in haemagglutination inhibition tests with influenza A/H1N1 = A/California/7/2009 (H1N1), 
A/H3N2 = A/Texas/50/2012 (H3N2), A/eq/H3N8 = A/equine/Newmarket/5/2003 (H3N8), B/Mas = 
B/Massachusetts/1/2012, and B/Bris = B/Brisbane/60/2008. 
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Table 3.1 Samples testing positive by both haemagglutination inhibition and single radial haemolysis. 
 
Sample ID 
A/equine/Newmarket/5/03 (H3N8) A/California/7/2009 (H1N1) 
HI titre SRH area (mm2) HI titre SRH area (mm2) 
Canine 1 1:640 62.3 - - 
Canine 2 1:640 82.8 - - 
Canine 3 1:40 60.1 - - 




3.5 Discussion and conclusions 
The results of this study suggest a very low canine and feline level of seroreactivity 
of to influenza A viruses in the UK. 
 
Initial screening of the serum samples by HI suggested that 41 canine and three feline 
sera were influenza antibody positive. However, the high number of samples that 
tested positive for both influenza B strains, with two of these samples also testing 
positive for A/H1N1 in HI, suggested non-specific inhibition of agglutination. This was 
confirmed by SRH testing, with only the feline sample with an HI titre of 1:320 against 
A/H1N1 and three canine samples with HI titres of 1:40 or 1:640 against A/eq/H3N8 
also testing positive against the respective viruses.  
 
The HI assays were performed using 0.5% chicken red blood cells and the sera heat-
inactivated and treated with RDE to remove non-specific inhibitors of agglutination. 
The HI assay was shown to have high sensitivity (99.6%) and specificity (94.6%) for 
diagnosis of canine H3N8 influenza with a positive titre cut-off of 1:32 providing 
serum was pre-treated with RDE or periodate and 0.5% turkey or chicken RBCs and 
an antigenically-matched H3N8 virus strain was used (Anderson et al., 2012).  
 
The results of the current study suggested that a positive titre cut-off of 1:40 was 
appropriate for the feline sera with all of the viruses tested, but that titres of up to 
1:80 should be treated with caution for influenza A viruses with canine sera and all 
samples testing positive with influenza B viruses required confirmatory testing. An 
earlier study (Todd and Cohen, 1968) suggested that dogs could be experimentally 
infected with an influenza B virus. However, a more recent study showed that 
although dogs were susceptible to experimental infection with human influenza A 
2009 pandemic H1N1 and H3N2 viruses, they were not infected with the same 
Victoria lineage influenza B strain (B/Brisbane/60/2008) used in this study (Song et 
al., 2015). Furthermore, there is only limited serological evidence of seroreactivity of 
dogs or cats to influenza B viruses with no reports of influenza B virus isolated from 




The low A/eq/H3N8 seroprevalence in canine samples obtained in this study 
contrasts with the generally higher seroprevalence reported in the US during a similar 
period that the samples in this study were taken (Anderson et al., 2013) but is in line 
with studies conducted in several other European countries. In an extensive study of 
canine infectious respiratory disease in Europe, Mitchell et al. (2017) found that 2.7% 
of dogs (6/220) were seropositive using two ELISA methods including one using 
A/equine/Miami/63 (H3N8) as antigen. In a serosurvey conducted in Italy, 0.03% (2 
of 6,858) of samples of canine sera tested positive for H3N8 antibodies (De Benedictis 
et al., 2010). Interestingly, one of these two dogs had lived in Florida for three years 
and another was raised in close contact with horses, each of which are risk factors 
for exposure to H3N8 virus (De Benedictis et al., 2010). More recently, 0.36% (2 of 
562) of canine serum samples from southern Italy tested positive for virus antibodies 
(Pratelli and Colao, 2014). The clinical records for the three dogs testing positive for 
antibodies against A/eq/H3N8 in this study did not show any indication of travel, 
vaccination against canine influenza virus, contact with horses or past acute 
infectious respiratory disease (data not shown). However, none of these factors can 
be excluded given the retrospective nature of the study and potential for such 
information not to be recorded in their clinical records.   
 
In the present study, no samples of canine sera tested positive for human A/H1N1 or 
A/H3N2 viruses although other recent studies have demonstrated low 
seroprevalence levels in dogs in China, Germany and the USA (Damiani et al., 2012; 
Jang et al., 2017; Sun et al., 2014). However, the isolation of an H3N1 virus from a 
dog in South Korea that was evidently a reassortant with seven gene segments from 
human A/H1N1 and the haemagglutinin gene from canine A/H3N2 confirms that 
dogs can be infected with the human A/H1N1 virus (Song et al., 2012). 
 
The finding of a very low seroprevalence of A/H1N1 in cats is in contrast to studies 
conducted with samples collected in the US during and shortly after the 2009 
pandemic. In feline serum samples collected between 2009 and 2010, seropositivity 
of 22.5% for A/H1N1 was observed (Ali et al., 2011) and, in another study of samples 
dated from 2011 to 2012, seroprevalence was 33.6% (Ibrahim et al., 2016). However, 
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in these studies, heat-inactivation was the only method used to remove non-specific 
inhibitors after previously finding that treatment with RDE appeared to make no 
difference, which could potentially have had an impact on the results. The results of 
this present study are more in line with the low seroprevalence of 1.93% (8/414) 
found in Germany by testing feline serum samples collected from 2010 to 2011 by 
ELISA and confirming positive results using a virus neutralisation test (Damiani et al., 
2012). Such sporadic infections of cats with H1N1 are consistent with occasional 
pathological demonstration of infection in naturally infected cats (Ozawa and 
Kawaoka, 2013). No antibodies to A/eq/H3N8, A/H3N2 or influenza B were detected 
in the feline sera in this study, although human seasonal H3N2 antibodies were 
detected in cats in a recent US study (Ibrahim et al., 2016). 
 
The results from this study and the apparently increasing incidence of influenza A 
viruses in dogs in particular in some parts of the world support the need for 
continued surveillance of influenza in pet populations. In the future, the avian-origin 
H3N2 strain of canine influenza should be included in the panel of viruses against 
which canine (and to a lesser extent feline) sera are screened. It is important to take 
into account that retrospective studies such as the present one using convenience 
samples from a population of pets that were sampled as part of a diagnostic workup 
may have an inherent bias. Additionally, the population sampled here is a referral 
one attending a busy specialist veterinary hospital and possibly geographically 
limited to the surrounding areas of North West England and North Wales. The 
sampling bias present in this study design is quite clear due to the convenience 
nature of used samples and, therefore, a prospective study design would potentially 
hold different results. Signalment data as well as history was also not available prior 
to sample testing and therefore, conclusions are limited and cannot be generalised. 
Therefore, it would be useful to further evaluate this in the form of prospective 
studies alongside careful data collection. Although current evidence suggests cats 
and dogs are rarely affected by human influenza strain, it would be prudent not to 
exclude these species from the surveillance of these viruses (Ozawa and Kawaoka, 
2013). Finally, veterinary practitioners should consider influenza as a potential 
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differential in animals showing acute signs of respiratory disease, particularly if these 
coincide with influenza-like illness in owners / in-contact animals   
71 
 
4 Pathogens associated with signs of respiratory 
disease in cats attending veterinary practices in 
















Feline infectious respiratory disease (FIRD) is a common syndrome in cats attending 
veterinary practices worldwide with many recognised potential viral and bacterial 
causes. This case-control study aimed to reappraise the role of feline calicivirus (FCV), 
feline herpesvires (FeHV-1), influenza A, Mycoplasma felis (M.felis), Chlamydophila 
felis (C.felis), Bordetella bronchiseptica (B.bronchiseptica) in FIRD-like disease as well 
as identify potential cat-level risk factors for infection in animals attending UK 
veterinary practices.  
 
Veterinary practices (12) were recruited into the study and samples from a total of 
38 cases and 64 controls were collected. Presence of pathogens was determined 
using bacterial culture and polymerase chain reaction (PCR). Telephone 
questionnaires were administered to participating pet owners to collect data relating 
to signalment, lifestyle and characteristics of respiratory disease and risk factors for 
case status were assessed using multivariable logistic regression.  
 
FCV was detected in 10.8% of study samples (21.1% in cases and 4.7% in controls) 
and FeHV-1 was detected in 4.9% of samples (10.5% in cases and 1.6% in controls). 
In regards to bacterial pathogens, 7.8% of samples tested positive for B. 
bronchiseptica (5.3% in cases and 9.4% in controls) and 30.6% tested positive for 
M.felis (65.8% in cases and 48.4% in controls). No samples tested positive for 
influenza A or C. felis. Previous history of respiratory disease was found to be 
positively associated with case status.  
 
Although recruitment rates were disappointing, this study reaffirms the importance 
of FCV as one of the major pathogens of FIRD in veterinary practice attending cats. 
Over a quarter of cases tested negative for all tested pathogens, suggesting other 





Infectious respiratory disease remains a common and important reason for clinical 
presentation in cats attending veterinary practices around the world despite 
widespread vaccination being common place for over three decades (Binns et al., 
2000). While FIRD is a bigger issue in animal shelters, cats living in outdoor colonies 
and multi-animal households, it remains as an important reason for veterinary 
consultation. In a report by SAVSNET (Small Animal Veterinary Surveillance Network), 
2.3 % of cats attending veterinary practices in the UK between January 2014 to 
December 2015 were presented for respiratory disease (Sánchez-Vizcaíno et al., 
2016). More recently, SAVSNET reported that presentation due to respiratory disease 
had decreased to 1.3% of the feline veterinary practice attending population which 
still comprises an important number of animals (Arsevska et al., 2018).  
 
Clinical signs associated with FIRD include sneezing, coughing, nasal and ocular 
discharges, conjunctivitis, keratitis, lethargy, pyrexia and difficulty breathing (Binns 
et al., 2000; Gerriets et al., 2012). In most cases, a presumptive diagnosis is made 
based on clinical examination and history alone, without resorting to further testing 
(Afonso et al., 2017b). This leads to a still poor understanding of the true prevalence 
of different pathogens and associated risk factors for infection especially in privately 
owned pet cat populations, since most studies have focused in high throughput, 
multi-cat environments.  
 
Previous studies indicate that FIRD causes are commonly of viral nature with FCV and 
FeHV-1 being the two most commonly isolated pathogens (Afonso et al., 2017a; 
Binns et al., 2000; Litster et al., 2015; Wardley et al., 1974). FCV is typically associated 
with oral ulceration and relatively mild ocular and nasal discharges, although strain 
variants may also be associated with inapparent infection, lameness and even severe, 
life threatening systemic disease. FeHV-1 generally causes a more severe but 
consistent disease with purulent ocular and nasal discharges; some cats can also 
develop ocular complications including ulcerative keratitis (Gaskell et al., 2007; Thiry 
et al., 2009). Both pathogens can be found in healthy and diseased animals as they 
are capable of inducing carrier states (Afonso et al., 2017b; Radford et al., 2009; Thiry 
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et al., 2009; Wardley et al., 1974). Subclinically infected animals therefore present an 
extra challenge in the etiological diagnosis of FIRD since pathogen identification 
cannot be considered synonymous with clinical disease (Veir and Lappin, 2010). 
Bacterial pathogens such as B. bronchiseptica, C. felis and M. felis are also part of the 
infectious respiratory disease complex in cats (Afonso et al., 2017b; Dawson et al., 
2000; Gruffydd-Jones et al., 2009; Le Boedec, 2017). Despite the importance of FIRD 
in clinical practice, there has been no recent systematic investigation of its aetiology 
and risk factors for its development.  
 
The aim of this chapter was to use recent assays to reappraise FIRD. In particular, we 
performed a case-control study in cats attending veterinary practices in the UK to 
identify significant cat-level risk factors associated with the presence of FIRD, as well 
as the role of infection with known and/or potential respiratory pathogens (such as 





4.4 Materials and methods 
 
Ethics and informed consent  
Ethical approval was obtained from the Veterinary Research Ethics Committee, 
University of Liverpool (VREC233). Informed consent was obtained from participating 
cat owners (Appendix 4A).  
 
Study design 
In order to identify and quantify risk factors for cats with clinically suspected FIRD, a 
case-control study design was used. As one of the main causes of FIRD is FCV which 
has an expected prevalence of 10% (Chapter 2) and the frequency of exposure to 
other pathogens and risk factors was uncertain the sample size estimate was based 
on an exposure of 10% (Epi Info 7). For a study with 2 controls per case , to detect 
odds ratio of 3 or greater, with a confidence level of 95% and a power of 80%, the 
required sample size was 71 cases and 142 matched controls.  
 
Recruitment  
Samples were collected from July 2014 to December 2016 from cats attending UK 
veterinary practices. Practices were recruited based on convenience using a 
combination of phone calling and sharing on social media platforms (blogs, Twitter 
and Facebook; Appendix 4A). A total of 165 British veterinary practices were 
contacted to participate in this study. Several had participated in a previous study 
conducted as part of this PhD project while others were approached by using the 
RCVS veterinary practice register (Chapter 2).  A total of 36 veterinary practices 
spread throughout the United Kingdom agreed to participate in the study. The period 
of participation of each practice ranged from approximately 3 months to 10 months, 
depending on time of recruitment. No incentives were offered to participating 
practices.  
 
Case and control definitions 
A case was defined as any cat presenting at a veterinary surgery which, to the best 
of the clinical judgement of the attending veterinary surgeon, was suffering from 
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infectious respiratory disease at the time of consultation and presented with two or 
more of the following clinical signs: oral ulcers, ocular discharge, facial ulceration, 
cough, sneezing, altered lung sounds, altered respiratory patterns, pyrexia. Animals 
were to be excluded if they suffered from any of the previously mentioned clinical 
signs due to a cause different than respiratory disease (for example: cough in animals 
with cardiac disease, epistaxis in animals with hypertension, sneezing in animals with 
nasal foreign bodies, etc). 
 
Control cats were defined as the next two cats to be presented to each veterinary 
surgeon following a case, with the exclusion of any cats which suffered from 
respiratory disease within the previous fortnight or were showing any of the 
previously mentioned clinical signs of disease.  
 
Sample collection  
Veterinary staff at participating practices were asked to recruit up to 10 cases and 20 
controls per practice (a mixture of cats and dogs). All practices had confirmed, upon 
recruitment, that they believed their caseload would allow for the sampling of these 
animal numbers in a period of 3 to 6 months. A pack containing 32 dry cotton swabs, 
32 collection tubes containing viral transport media (VTM), 32 charcoal Amies swabs, 
32 owner consent forms (Appendix 4B), a laminated owner information sheet 
(Appendix 4B), a sampling protocol (Appendix 4C), 10 plastic containers (with space 
for 3 samples in VTM; 1 case and 2 matching controls) and 10 pre-paid envelopes for 
returning samples to the University of Liverpool team at the Leahurst Campus was 
sent to practices. Practice staff were informed that VTM vials should be frozen (-
20ºC) on arrival and again after sample collection until posting the samples back to 
the author. Veterinary staff were asked to simultaneously collect two oropharyngeal 
swabs (dry cotton swab placed into VTM and charcoal Amies swab) as explained in 
the sampling protocol (Appendix 4C).  
 
On arrival at the University of Liverpool, samples were recorded and assigned an 
alphanumeric code to allow for all testing to be performed blinded to control or case 
categorization. Samples in VTM were aliquoted into two tubes labelled OPA and OPB 
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and frozen at -80ºC until testing. Charcoal Amies swabs were either immediately 
tested or refrigerated at 4ºC until test performance.   
 
Staff at each of the veterinary practices explained the study to the owners of 
recruited cats using the previously mentioned owner information sheet. Owner 
contact details, preferred contact times and contact details (Appendix 4D) were 
collected alongside consent to participate.  
 
Questionnaire design 
The questionnaire for cases and control contained a core of identical questions, with 
additional details being collected for cases including questions regarding the nature 
of the respiratory signs (Appendix 4D). Data collected included signalment, 
vaccination and worming status, contact with other animals (including other cats, 
dogs and birds), exposure to potential risk factors, previous respiratory disease, 
current or past illnesses and medication. All data was owner reported.  
 
Once the samples were returned to the author alongside owner contact details, 
telephone contact was attempted in order to administer the questionnaire.  
Participating owners were telephoned as soon as possible after receiving the samples 
and contact was attempted at least three times per participant. Questionnaires were 
administered either by the author or by Dr. Shirley Bonner, after briefing by the 
author. No incentives were offered to participating veterinary practices or owners.  
 
Viral isolation 
FCV and FeHV-1 were isolated using standard techniques as described in Chapter 2, 
using confluent monolayers of feline embryo A (FEA) cells and by observing typical 
CPE (Povey and Johnson, 1971). Samples were reported negative after two negative 
passages and positive isolates were stored at -80ºC for further analyses (Knowles et 
al., 1991).  
 
Nucleic acid extraction 
Viral nucleic acid (RNA and DNA) was extracted from oropharyngeal swabs or tissue 
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culture fluid using the same method as described in Chapter 2 (Viral RNA mini-kit; 
Qiagen).  
 
Reverse transcription and PCR 
Reverse transcription was performed using 200 ng random hexamers (Superscript III, 
Life Technologies). Table 4.1 shows details of diagnostic tests using PCR for detection 
of nucleic acids from oropharyngeal swabs. Conventional PCRs were performed for 
FCV, Influenza A (using cDNA obtained from reverse transcription), M felis, C felis and 
FeHV-1. Real-time PCRs were performed for B. bronchiseptica (in addition to bacterial 
culture). Positive controls for each pathogen were included in each PCR run. 
 
Where viral isolation for FCV or FeHV-1 was positive but PCR from OP swab was 
negative, PCR was repeated using nucleic acid extracted from the second sample 
passage in cell culture (p2). 
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Table 4.1 Details of PCR diagnostics used for detection of pathogens. AT stands for annealing temperature. 
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Isolation and identification of Bordetella bronchiseptica 
Charcoal swabs were streaked onto charcoal selective media. Any small grey/white 
colonies growing within 24-48 hours were sub-cultured onto blood agar. Suspected 
colonies were gram stained and underwent an oxidase test (ProLab). Gram negative, 
oxidase positive colonies were subjected to the API 20 NE biochemical test to identify 
B. bronchiseptica.  
 
Epidemiological analysis 
All sample, diagnostic results and questionnaire data were entered onto a 
spreadsheet programme (Microsoft Excel for Mac). Visual verification of correct data 
input was verified for 5% of entries.  
 
The outcome variable used was case or control status and the associations with 
predictor variable were assessed using univariable logistic regression using R Studio 
(version R 3.4.1 GUI 1.70 El Capitan build).  
 
Sixteen predictor variables were assessed including gender (female or male), 
neutered status (entire or neutered), breed (re-classified from questionnaire 
responses as pedigree or crossbreed), number of cats in household (classified into 
three groups: 1 cat/household, 2 to 3 cats/household, 4 or more cats/household), 
contact with other animals (yes or no), lifestyle (classified as living indoors, outdoors 
or both), recent stay/visit to multi-animal household (eg.: shelter, cattery, veterinary 
surgery, etc. Re-classified from questionnaire data to yes or no), where cat goes to 
the toilet (uses litter tray, goes outdoors or both), vaccination history (classified into 
three groups: vaccinated within last year, over one year ago, never), vaccine antigen 
used (FCV-F9; FCV-431 + FCV-G1), worming and flea and tick control status (both 
classified into: within last three months, more than three months ago or never), 
reason for veterinary visit (classified into routine appointment, ill health – respiratory 
or ill health – not respiratory), previous history of respiratory disease (yes or no) and 




To build a multivariable analysis model, univariable analysis results were taken into 
account in combination with a causal web built specificically for FIRD (figure 4.1). 
Number of cats in household, vaccine status, previous respiratory disease and age 
were taken into account as variables for testing. All these, with the exception of age, 
had p-values < 0.1 on univariable analysis. Age has been previously found as a risk 
factor for respiratory disease in cats (chapter 2) and therefore was also considered. 
Roughly, one explanatory variable per 10 cases was considered. Variables were then 
eliminated from testing until only those with likelihood ratio p-value < 0.05 remained 





Figure 4.1 Causal web showing relationships between several independent variables (information 
collected through questionnaires) and dependent variable (i.e. case status, in this context, cases of 





Out of the 36 practices recruited into the study, only 12 submitted samples from 
feline patients. Figure 4.2 shows the approximate geographical location of these 
practices.  
 
Figure 4.2 Map of the United Kingdom showing the approximate location of practices that returned 
samples to the study 
 
The number of samples submitted by each practice was variable, ranging from 1 to 
15 (median 7.5). A total of 38 cats meeting the case definition and 64 controls 
presenting to participating veterinary practices were recruited into the study. 
Despite the long period allowed for sample collection, the low number of samples, 
and the failure to collect matched case control sets in some practices meant that a 
matched analysis using conditional logistic regression was not possible Therefore, 
83 
 
further analysis was done using an unmatched analysis. Table 4.2 summarises study 
population signalment and pathogen detection rates.  
 
Table 4.2 Study population signalment and pathogen detection rates. Age: kitten (1 – 12 
















































































      










     
 
Telephone contact of owners for questionnaire administration was always 
attempted within the first week post sample reception (and up to three months after 
in cases where there was no answer) during a time selected by the participating 
owners when study participation was agreed to (morning, afternoon or evening). 
Despite each pet owner being contacted at least three times via phone, out of the 
total number of animals recruited into the study (n=102), questionnaire data were 
obtained for only 66.3% (n=65, 26 cases and 39 controls) of participating cats.  
 
The association between reason for presentation to the veterinary practice with the 
outcome (case or control) were assessed in univariable models only as this is a 
consequence (rather than the cause of) FIRD. 
 
Out of the 26 cases for which questionnaire data was obtained, 22 (57.9%) owners 
reported their cat had been sneezing, followed by 16 (42.1%) owners reported 
coughing and 13 (34.2%) reported nasal discharge in their animals. Ocular discharge 
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and breathing difficulties were each reported five times (13.2%), nose bleed was 
reported three times (7.9%) and mouth ulcers, conjunctivitis (“red eye”) and pyrexia 
were each reported once (2.6%). All except one owner, reported two or more 
concomitant clinical signs. Two owners also added clinical signs not included in the 
questionnaire and reported their animal as having “difficulty swallowing” in one 
instance and a “crusty nose” in the second case.  
 
Within the case group, 21 of the animals were brought into the veterinary practice 
for consultation due to respiratory illness. Of the remaining cases, four animals were 
presented for routine appointments and one animal had suffered from fighting 
wounds. These five animals were all deemed to be suffering from respiratory disease 
by the attending veterinary surgeon and also had signs of respiratory disease 
included in the case definition.   
 
Regarding onset of clinical disease, 12 (46.2%) owners reported respiratory signs had 
been ongoing for 15 or more days, three (11.5%) cases between 8 - 14 days, four 
(15.4%) cases between 3 - 7 days, and four (15.4%) owners reported signs had started 
in the previous 48 hours. Three (11.5%) owners were unsure when clinical signs had 
first manifested.  
 
Owners of cats belonging to the cases group were asked about any potential reasons 
why they thought their animal may be showing signs of respiratory nature. Some of 
the reasons mentioned were “a rough life” (mentioned once), contact with other 
infected cats (eg.: feral or in multi-cat households/breeder; mentioned twelve times), 
allergies (e.g.: to air freshener; mentioned three times) and a reaction to vaccination 
(mentioned once).  
 
Univariable analysis of signalment and clinical data collected from questionnaires are 
shown in Appendix 4E and are briefly summarised here. No significant associations 
were shown between case status and gender, neutered status, breed, contact with 




Cases were 3.3 times more likely than controls to come from households with four 
or more animals (p-value 0.1). Compared to cats living indoors only, cases were less 
likely (OR = 0.4, p-value = 0.08) to have a mixed indoor and outdoor lifestyle and 
more likely to be fed a mixture of commercial and homemade food, than commercial 
food alone (OR = 2.4, p-value = 0.15). Additionally, cases were 4.2 times more likely 
to have been vaccinated over one year ago animals vaccinated over one year ago 
were 4.2 more likely to be cases (p-value = 0.1) and cats that were never wormed 
(OR = 9.3, p-value = 0.05) or treated for fleas and ticks (OR = 5.2, p-value = 0.16) were 
also more likely to be cases. Cases were more likely to have had a history of previous 
respiratory disease (OR = 5, p-value = 0.02) and were less likely to have concurrent 
disease (OR = 0.4, p-value = 0.16). Finally, animals undergoing treatment with 
antibiotics were more likely to be cases of FIRD (OR = 3.10, p-value = 0.1). 
 
Variables with P<0.25 were carried forward to the multivariable model and included 
number of cats per household, lifestyle, food, vaccination, worming and flea/tick 
treatment statuses, concurrent medical conditions.  
 
The final multivariable model is shown in Table 4.3. Animals with no history of 
previous respiratory disease were found to be less likely to belong in the cases group 
(OR = 0.19, p-value = 0.014). Additionally, animals not undergoing courses of 












Table 4.3 Multivariable logistic regression of factors associated with respiratory cases in cats attending 
veterinary practices in the UK (n=65 questionnaires, 26 cases, 39 controls). P-values below 0.05 
considered significant. 
 
The results of laboratory testing are shown in Table 4.3. Eleven samples (10.8%) 
tested positive for FCV, five (4.9%) tested positive for FeHV-1, eight (7.8%) tested 
positive for B. bronchiseptica by PCR and 56 (30.6%) tested positive for M felis. No 
samples tested positive for either Influenza A or C felis. All the samples positive for 
Bb by PCR were negative by bacterial culture. Mixed infections were present with 
FCV and M. felis being the most common (six occurrences, only cases), followed by 
FeHV-1 with M. felis (three cases) and M. felis with B.bronchiseptica (two controls). 
A significant proportion of cases tested negative for all tested pathogens (26.3%; 
n=10). Table 4.4 shows the results of univariable logistic regression of PCR testing 
results. FCV was the only pathogen significantly associated with case status (p-value 
< 0.05) with cats with FIRD being 5.4 times more likely to test positive for FCV. Cases 
were also more likely to be FeHV and M. felis positive but these associations were 













Previous respiratory disease           
Yes   Ref.       
No -2.3 (0.8) 0.098 0.02 0.46 0.006 
Age           
0 – 12m (kitten) ) Ref. 
   
13-60m (young adult) -2.6 (0.9) 0.07 0.009 0.4 0.005 
61-96m (adult) --3.3 (1.4) 0.04 0.001 0.4 0.02 
>96m (senior) -1.5(0.8) 0.23 0.05 1.2 0.06 
87 
 
Table 4.4 Univariable logistic regression results of PCR testing for pathogens associated with 
respiratory cases (n = 102 samples, 38 cases and 64 controls from 12 veterinary practices). P-values 
below 0.05 considered significant.  
 








 n % n %     
FCV  
Positive 8 21.1% 3 4.7% 5.4 0.02 1.5 26.13 
Negative 30 78.9% 61 95.3% Ref.    
FeHV  
Positive 4 10.5% 1 1.6% 7.4 0.08 1.04 148.1 
Negative 34 89.5% 63 98.5% Ref.    
B. bronchiseptica   
Positive 2 5.3% 6 9.4% 0.54 0.5 0.08 2.48 
Negative 36 94.7% 58 90.6% Ref.    
M.felis         
Positive 25 65.8% 31 48.4% 2.05 0.09 0.9 4.8 
Negative 13 34.2% 33 51.6% Ref.    
Influenza         
Positive 0 0% 0 0%     
Negative 38 100% 64 100%     
C.felis         
Positive 0 0% 0 0%     




4.6 Discussion and conclusions 
Feline infectious respiratory disease is recognised as an important syndrome in 
clinical practice with many recognised potential viral and bacterial causes. 
Vaccination against FeHV-1 and FCV, which is widespread in practice, is generally 
considered to reduce clinical signs, but may not entirely prevent them, nor does it 
prevent infection. Vaccination for B.bronchiseptica and C. felis is available but not 
commonly practiced in cats (Sanchez-Vizcaíno et al., 2018). Here we used a case 
control study, to reappraise the role of cat-level risk factors and infections in FIRD.   
 
In previous studies, severity scoring was used to assign animals into disease groups 
ranging from mild to moderate or severe (Bannasch and Foley, 2005). It was an 
overlook in our part not to include severity scoring as part of case definitions 
distributed to participating vets and should a similar study be performed in the 
future, we would consider doing this as it allows for more detailed risk factor analysis 
(especially where it relates to pathogens isolated and their potential to cause serious 
disease). However, given the small number of cases submitted to the study the 
simpler analysis of animals suffering with respiratory disease of suspected infectious 
origin of any severity (cases) versus controls seems more appropriate.  
 
No previous history of respiratory disease was found to be correlated with control 
status. This is consistent with the fact that the two most common viruses involved in 
FIRD are both capable of inducing a life-long carrier status. FeHV-1, can recrudesce 
in periods of stress causing new episodes of clinical disease thereby making animals 
previously affected by FIRD more likely to suffer from the syndrome again in the 
future (Gaskell et al., 2007; Helps et al., 2005; Thiry et al., 2009). Previous respiratory 
infections with viruses such as FeHV-1, that in their acute phase can damage 
turbinates and reduce localised respiratory innate immunity, can also lead to chronic 
lesions therefore predisposing the animal to subsequent infections (Gaskell et al., 
2007; Thiry et al., 2009). Other chronic respiratory diseases (such as feline chronic 




Age group was found to be significantly associated with case status in this sample 
with young adult, adult and senior cats being less likely to be cases. Previous studies, 
as well as our own findings in chapter 2, have  also shown that as animals grow older 
they are less likely to be shedding FIRD pathogens as well as less likely to exhibit 
severe signs of disease (Porter et al, 2008, Afonso et al 2016, Fernandez et al 2017). 
This may be an age-driven immune-mediated mechanism (Coyne et al 2006). As 
animals grow older, they are more exposed to both field and vaccine strains of FIRD 
pathogens which can boost immunity. Additionally, even though vaccination is 
widespread (specifically for FCV and FeHV-1), it does not prevent the carrier state 
which in turn leads to a relatively boosted immunity as these infected animals grow 
older.  
 
On multivariable analysis, the number of cats per household was not found to be 
associated with case or control status. In prior studies as well as in chapter 2, the 
opposite has been reported (Afonso et al., 2017a; Bannasch and Foley, 2005; Coutts 
et al., 1994; Helps et al., 2005; Wardley et al., 1974). Whether this observation 
represents the smaller than planned sample size of the current study, or some other 
difference in the study population is unknown.  
 
Vaccination status was also not found to be significantly associated with case status 
which is in contrast with other studies where vaccination was found, perhaps not 
surprisingly, to have a protective effect against respiratory disease (Binns et al., 2000; 
Fernandez et al., 2017). Again, this could be due to the size of the sample in the 
present study and the fact that only 10 animals in total had reportedly never been 
vaccinated.  
 
It is worth mentioning that for 12 cases (31.6%), no pathogen was identified. This is 
not uncommon in similar studies in cats (Binns et al., 2000). Failing to identify a 
causative known pathogen in diseased animals may be due to several factors 
including poor sample collection, timing of sampling (a lot of the animals had been 
suffering with respiratory signs for over two weeks before being taken to the 
veterinary surgery which decreases the likelihood of viral shedding being present 
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upon sampling), misdiagnosis due to broad case definitions (i.e: respiratory disease 
due to non-infectious causes or non-viral/bacterial causes such as parasites), poor 
sample handling, etc. Another possibility is that the actual aetiological agent was not 
among the panel of pathogens tested and may still be unknown to the veterinary 
community. Next generation sequencing offers an unbiased approach to identifying 
potential new pathogens in these cases (Radford et al., 2012). 
 
On the other hand, out of the 64 controls, 26 (40.6%) were found to be positive to 
one or more tested pathogens. Of these 4.7% (n=3) tested positive for FCV and 1.6% 
(n=1) for FeHV-1. Given the ability of both viruses to induce subclinical carrier 
infection these numbers are not surprising (Coutts et al., 1994; Harbour et al., 1991; 
Wardley et al., 1974). Cats recovered from acute FCV disease shed virus more or less 
continuously for 30 days; thereafter an approximate 75-day half-life has been 
proposed with only a minority of cats shedding virus possibly for life (Povey, 1986; 
Radford et al., 2009). In contrast, FeHV-1 develops a classic herpesvirus latent 
infection, only shedding virus intermittently following stressors such as kittening, 
lactation and rehoming (Gaskell and Povey, 1977). As a result, in most studies the 
carriage rate of FCV is higher than that of FeHV-1, as shown here (Binns et al., 2000; 
Helps et al., 2005; Holst et al., 2005; Zicola et al., 2009). Of note is the fact that FCV 
was found in 10.8% of the total samples which is similar to the prevalence reported 
in similar populations (Chapter 2) of animals with and without respiratory signs.  
 
Perhaps surprisingly, a higher percentage of controls than cases tested positive for 
B. bronchiseptica than cases. This is an interesting finding which contrasts with 
results from Binns et al., 1999, who showed B. bronchiseptica to be widespread in 
multi-animal environments but found no evidence of B. bronchiseptica infection in 
household pet cats. These contrasting results likely reflect differences in the sampled 
populations; clinical disease associated with B. bronchiseptica in cats is generally 
considered by most to be associated with stress and overcrowding, both likely to be 
less of an issue in pet cats than in rescue centre and catteries (Binns et al., 1999; 
Egberink et al., 2009; McArdle et al., 1994). Although vaccines are available for B. 
bronchiseptica, they are generally rarely used in the cat (Sánchez-Vizcaíno et al., 
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2018). It is also interesting to note that PCR proved to be more sensitive than 
bacterial culture in detecting B.bronchiseptica (see also Chapter 6) which, again, 
could explain the contrasting results to those obtained by Binns et al., 1999.  
 
M. felis was detected in high numbers in both cases and controls; although the 
percentage positive was higher in cases the differences between groups were not 
found to be statistically significant (p-value > 0.05) although this may be due to small 
sample size. Previous studies indicate that its presence is higher in animals with 
respiratory and/or ocular disease (Afonso et al., 2017b; Fernandez et al., 2017; Sykes, 
2012). M. felis was also found in all of the cases that tested positive in this study for 
more than one potential pathogen, hinting at a potential role in mixed infections. It 
would be interesting to further study this and understand if M. felis perhaps is mostly 
an opportunistic pathogen of the upper respiratory tract.  
 
Neither C. felis nor Influenza A viruses were detected by PCR in any of the collected 
samples. Influenza A is, to the author’s knowledge, an uncommon finding in cats and 
reports of feline influenza are scarce (Chapter 3). C. felis is mostly associated with 
ocular disease especially conjunctivitis so it is somewhat surprising that no samples 
tested positive for this pathogen since ocular signs of disease were mentioned at 
least six times in questionnaire responses and the prevalence in other studies were 
found to be high (Fernandez et al., 2017). As well as the small sample size, this could 
possibly be explained by the fact that only oropharyngeal swabs were collected from 
cats in this study. Ocular swabs would be more appropriate for C. felis detection given 
the pathogen’s tissue tropism (Fernandez et al., 2017; Gruffydd-Jones et al., 2009). 
 
This study’s conclusions are limited by the low sample numbers and therefore results 
should be interpreted with caution. It would be interesting to repeat this study in a 
larger sample population. Originally, the author decided to administer 
questionnaires to owners via the phone as feedback from previous studies (including 
the study conducted by the author in Chapter 2) as well as anecdotal evidence and 
discussion with veterinary researchers lead to the postulation that the time burden 
for questionnaire completion by veterinary surgeons would lead to low response 
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rate. However, telephone administration of questionnaires came with other 
challenges such as owners not answering the phone despite several contact attempts 
and possibly not recollecting information accurately. Despite efforts being made to 
reduce to time from sample collection to phone questionnaire administration as 
much as possible (with owner contact being attempted within 7 days of sample 
collection), recall bias is still likely. If another study was to be conducted, the author 
suggests that questionnaires are filled out directly by the attending veterinary 
surgeon during clinical history intake.   
 
It is also worth mentioning that originally, this study was meant to be conducted as 
a matched case-control study with results analysed with clustering by participating 
practice. However, due to the fact that some practices only submitted cases and no 
controls and vice versa as well as the fact that in a lot of instances there were no 
matched controls for each case, the data was analysed using an unmatched case-
control design.  
 
This study was designed in an attempt to allow the investigation of risk factors for 
infectious disease affecting the upper airways. However, the broad case selection 
criteria could represent a range of aetiologies of non-infectious origin. This was partly 
mitigated by asking participating veterinary surgeons to exclude any cases where an 
obvious non-respiratory origin (such as cardiac disease) was suspected but the 
possibility still remains that other, non-infectious, causes of respiratory symptoms 
were present. It is also worth noting that, as is known with FCV and FeHV-1 ability to 
cause carrier statuses, an absence of clinically apparent signs does not rule out 
respiratory tract infections and the inclusion of controls with subclinical disease was 
not possible. Other potential limitations, which would be hard to circumvent in a 
study like this, is the reliance on multiple veterinary surgeons to classify recruited 
animals as cases or controls and the possibility of observer selection.  
 
In conclusion, despite challenges around recruitment, this study was able to reaffirm 
the importance of FIRD in animals with prior history of respiratory disease and the 
importance of major vaccine preventable pathogens notably FCV. The high 
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proportion of cases that lacked a recognised pathogen despite using PCR tests 
general considered to be highly sensitive reiterates the need to look for new 
potential pathogens using more unbiased molecular techniques like next generation 




4.7 Appendix to Chapter 4 
Appendix 4A Figure shared through social media platforms (Twitter, Facebook and 











Pet Health Study - understanding infectious causes of respiratory disease in dogs 
and cats 
 
Dear pet owner,  
 
This document aims to invite you to participate in a research study. Please take time 
to read the following information carefully and feel free to ask if you would like more 
information or if there is anything that you do not understand. We would like to stress 
that you do not have to accept this invitation and you should only agree to take part 
if you want to.  
 
What is the purpose of this study?  
Respiratory infection represents an important cause of disease in cats and dogs, 
sometimes leading to outbreaks of respiratory disease in sensitive environments like 
rescue shelters, kennels and veterinary hospitals. It can have severe and even fatal 
consequences for our pets and can be caused by many viruses and bacteria. The 
purpose of this project, which is funded by one of the main manufacturer’s of pet 
vaccines (MSD Animal Health) is to understand the role of known and yet-to-be 
identified pathogens in respiratory disease in dogs and cats and to study which 
lifestyle and medical risks may be associated with disease in these cases.  
 
Why have I been chosen to take part?  
This study was designed as a case-control study. Therefore, there will be two types 
of participants: If your pet was selected as a case, it means that your dog or cat is 
currently suffering from respiratory disease according to strict criteria identified by 
your veterinary surgeon. On the other hand, if your pet was selected as a control, it 
means that your dog or cat is not currently suffering from respiratory disease but was 
one of two non-respiratory cases seen by your vet following a pet with respiratory 
disease.  
 
Do I have to take part?  
Participation is voluntary and you may withdraw from this project at anytime without 




What will happen if I take part?  
Your veterinary surgeon will collect a saliva sample from your pet (a double-mouth 
swab). This process is very straightforward, not painful and should take no more than 
a minute to complete. The veterinary surgeon will place a cotton-wool swab inside 
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your pet’s mouth, until the swab is coated in saliva (the swab is a bit like a long cotton 
bud). Your contact details will then be collected by your veterinary surgeon, so that 
we can contact you afterwards in order to ask you a few questions regarding your 
pet (this will be done in the form of a phone-administered questionnaire). The swabs 
and your contact details will be sent to the University of Liverpool and used to look 
for respiratory germs.  
 
Are there any risks in taking part? 
The sample collection is a very simple, harmless procedure that is routinely 
performed on many dogs and cats for diagnostic purposes. Some animals might chew 
on the swab as it is put in their mouth and very rarely, some have chewed off and 
swallowed the tip of the swab. In the very rare cases where this happens the involved 
animals never too our knowledge suffered any health problems. If, at any time, you 
are concerned about your pet’s safety please contact your veterinary surgeon 
immediately.  
 
Are there any benefits in taking part?  
By taking part in this study, you will be helping us ensure we better understand 
respiratory disease in dogs and cats. Also, if you were selected as a case, you can 
receive the results of the tests, in order to find out what may be causing your pet’s 
signs. In this case, results would be sent back to your veterinary surgeon (please note 
that we cannot provide results for control animals). 
 
What if I am unhappy or if there is a problem? 
Your veterinary surgeon will be happy to discuss the project with you. If you are 
unhappy, or if there is a problem, please feel free to let us know by contacting Dr 
Alan Radford the project lead (Telephone: 0151 794 6121; alanrad@liv.ac.uk) and we 
will try to help. If you remain unhappy or have a complaint which you feel you cannot 
come to us with then you should contact the Research Governance Officer on 0151 
794 8290 (ethics@liv.ac.uk). When contacting the Research Governance Officer, 
please provide details of the name or description of the study (so that it can be 
identified), the researcher involved, and the details of the complaint you wish to 
make. 
 
Will my participation be kept confidential?  
Samples and the information obtained may be retained to up to seven years and 
possibly used in future projects. All data will be kept confidential and will be stored 
in a secure database accessible only by people working on the project. You may 
withdraw from the project at any time, without explanation and any information 
provided by you can be destroyed. 
What will happen to the results of the study?  
The anonymised results of this study will be sent for publication in veterinary journals 
and non-veterinary press. No participant will be identifiable from any published 
work. Any germs we isolate will be frozen, and may be used for ongoing research and 






If you are happy to allow your pet to become involved, please read, initial the boxes 
and sign the consent form. The veterinary surgeon will then collect the required 





Dr Alan Radford 
Department of Infection Biology 
University of Liverpool 
Leahurst Campus 
CH64 7TE 














          
Owner’s Name                                               Date                   Signature 
 
 
Principal Investigator:  
Dr Alan Radford, Department of Infection Biology, University of Liverpool, Leahurst 
Campus, CH64 7TE; Tel: 0151 794 6121; email: alanrad@liv.ac.uk 
 
Student Researcher:  
Maria Afonso, Department of Infection Biology, University of Liverpool, Leahurst 
Campus, CH64 7TE; email: maria.afonso@liv.ac.uk  
 
Title of Research Project:  Pet Health Study - understanding 







Researcher(s): Alan Radford/G Pinchbeck/Maria Afonso/S Bonner 
 
 
1. I confirm that I have read and have understood the information 
sheet dated 11/06/2014 for the above study. I have had the 
opportunity to consider the information, ask questions and have 
had these answered satisfactorily.   
 
 Please 
initial box  
2. I understand that my participation is voluntary and that I am free 
to withdraw at any time without giving any reason, without my 
rights being affected.  If I do not participate this will not affect 
the care and treatment of my animal.  
 Please 
initial box  
3. I understand that, under the Data Protection Act,  I can at any 
time ask for access to the information I provide and I can also 
request the destruction of that information if I wish. 
 Please 
initial box  
4. I allow participation of my animal in the above study. 
 
 Please 
initial box  
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A matched case-control study to evaluate the role of pathogens and other risk 
factors in respiratory disease in vet-visiting cats and dogs in the UK  
 
 
Dear                               ,  
 
Thanks for agreeing to take part in our study. Here we provide instructions for the 
project including 
 
• What to find in the 3 parcels you receive 
• What to do for the project 
• Definitions of cases and controls 
• Protocol for “double” oropharyngeal swabbing 
• How to send the samples back to us 
 
If you have any questions then please do not hesitate to contact us, using the 
details provided below.  
 
Once again, many thanks for taking part in our study. We hope the findings will be 
published and expect that as a result of this study, some of the questions associated 









Reader in Infection 
Biology 
 







Contact:  Maria Afonso – Email: mmanuel@liverpool.ac.uk, Tel: 0151-794-
6005 
Dr Shirley Bonner – Email: shirley@liverpool.ac.uk, Tel: 0151-794-9 
 
 
• 30 vials of virus transport medium (VTM) – please store at -20°C. 
• 10 x Speci-safe packs for the return of 3 x VTM vials each  
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• 30 dry cotton swabs  
• 30 Amie’s charcoal swabs (please store at room temperature) 
• 30 Sheets with owner details form and owner consent form, one to be filled out 
for each animal  
• 2 Copies of the Owner Information Sheet 




What to do for the project 
 
We would like you to collect samples from 5 cat cases with 2 control animals per 
case and 5 dog cases with 2 control animals per case. More or less is fine too! 
 
For each animal please: 
• Obtain informed consent (by asking the owner to read the Owner Information 
Sheet and then sign the owner consent form) 
• Fill out the owners details on the reverse of the consent form 
• Collect 2 swabs (see below) 
• Send all forms and the swabs to us at the University via the postage paid 
padded envelopes 
 
Definitions of cases and controls 
 
Cases and controls should be recruited according to the following criteria: 
 
Cats - A case is defined as any cat presenting at a veterinary surgery which, to the 
best of the clinical judgement of the attending veterinary surgeon, is suffering from 
infectious respiratory disease at the time of consultation AND presents with two or 
more of the following clinical signs: pyrexia, sneezing, nasal discharge, ocular 
discharge, conjunctivitis, mouth ulcers, facial ulceration, cough, altered lung 
sounds, altered respiratory patterns. Control cats are defined as the next two cats 
to be presented to the same veterinary surgeon following a case, with the exclusion 
of any cats which have suffered from respiratory disease within the previous two 
weeks or are showing any of the above clinical signs of disease. 
 
NB – cats showing any of the previously mentioned clinical signs as a result of 
something other than infectious respiratory disease (e.g. cough in animals with 
cardiac disease, epistaxis in animals with hypertension, sneezing in animals with 
nasal foreign bodies), should also be excluded as controls. 
 
Dogs - A case is defined as any dog presenting at a veterinary surgery which, to the 
best of the clinical judgement of the attending veterinary surgeon, is suffering from 
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infectious respiratory disease at the time of consultation AND presents with two or 
more of the following clinical signs: pyrexia, cough, sneezing, nasal discharge, ocular 
discharge, inflamed tonsils, epistaxis, altered lung sounds, altered respiratory 
patterns. 
 
Control dogs are defined as the next two dogs to be presented to the same 
veterinary surgeon following a case, with the exclusion of any dogs which have 
suffered from respiratory disease within the previous two weeks or are showing 
any of the above clinical signs of disease. 
 
NB – dogs showing any of the previously mentioned clinical signs as a result of 
something other than infectious respiratory disease (e.g. cough in animals with 
cardiac disease, epistaxis in animals with hypertension, sneezing in animals with 
nasal foreign bodies), should also be excluded as controls. 
 
Protocol for “double” oropharyngeal swabbing 
 
Store all virus transport medium (VTM) in a freezer (-20oC). Thaw samples to be used 
as needed. Store Amies charcoal swabs in a dry cupboard.  
 
Each case and each control should be swabbed after consent was given by the rightful 
person (owner in privately owned animals and a member of staff in case of stray 
animals).  
 
You may exclude dogs or cats: 
• that in your clinical judgement, it would not be appropriate to swab.  
• that it may be dangerous to swab. 
 
Two kinds of swab are provided for each case and each control animal - a dry swab 
and an Amies charcoal swab in its own container. The animals should be swabbed 
simultaneously with each type: Place both swabs in the animal’s mouth. The animal 
is likely to chew on them. If possible, rub the swabs against the side and back of the 
pet’s mouth. If taken correctly, the swabs should be moist with saliva. Place the swab 
from the Amies charcoal back into its container, and the other (previously dry) swab, 
into a vial of VTM (you will need to break off most of the shaft). If the VTM is still not 
thawed, that is acceptable. Place the VTM vial into the Speci-safe container provided 
and the Amies Charcoal Swab in its container, into a plastic bag. Please ensure the 
pet’s name, and owner’s surname, are written on both the Amies Charcoal Swab 
tube and on the vial of VTM containing the other swab. Many vets are finding the 







How to send the samples to us 
 
Three sample vials of VTM will fit in the Speci-Safe packs - a case and 2 control VTM 
samples should be sent at the same time. Place the vials in the slots in the container 
and click the pouch shut. Do not peel the white material away. These containers 
mean that the samples meet requirements for proper mailing of biological samples. 
 
Fill in the owner details on the forms provided (on the reverse of the consent form) 
and place it, together with the corresponding samples inside one of the pre-paid 
addressed envelopes we have sent you. The samples should be sent as soon as 
possible after being collected, preferably within the same day. If you are not able to 
collect two controls in the same day as the corresponding case please place the VTM 
samples in the freezer until you are ready to send them. The pre-paid envelope can 
go in a normal Royal Mail postbox. 
 
Send back to us:  
• 1 x Specisafe containing 3 x swabs in VTM vials (1 case, 2 controls) 
• 3 charcoal swabs (1 case, 2 controls) 
• 3 consent/owner detail forms 





If the animal is a stray, the vet may consent for the study and could you please 
provide your contact details on the owner contact form. 
 
We will process the samples for the presence of respiratory pathogens. We will also 
contact the owners for further information about their animal. The project has 
Ethical Approval and any details provided by the owners/vets will remain completely 












A matched case-control study to evaluate the role of pathogens and other risk 
factors in respiratory disease in vet-visiting cats and dogs in the UK  
 
Summary of project for veterinary surgeons 
 
Infectious respiratory disease represents an important and frequent cause of 
disease in both cats and dogs. Over the years, research interest on the topic has 
been intermittent and respiratory disease has often been subvalued frequently 
leading to outbreaks in sensitive environments like rescue shelters, kennels and 
veterinary hospitals. Further understanding of the panoplia of pathogens associated 
with respiratory disease in dogs and cats is therefore critical to ensure the usage of 
the best techniques for the prevention and treatment of these diseases.  
 
This study aims to reassess the role of known and yet-to-be identified pathogens in 
respiratory disease in dogs and cats. In order to do so, two parallel matched case-
control studies will be undertaken to explore risk factors including pathogens in 
respiratory disease. Cases presenting for respiratory disease (71 cases for each 
species) will be recruited from general practices which will be  recruited based on 
convenience. Controls (142 controls for each species) will consist of two animals 
(two controls per case) seen for reasons other than respiratory disease.  Each 
practice will be asked to submit samples from cases and controls they see over a 
period of 6 months, in this way we expect to get the desired number of samples 
(see above), as obtained by sample size calculation based on a pathogen exposure 
of 10% (e.g.: FCV prevalance). 
A phone questionnaire will be administered by the University of Liverpool team to 
the participating pet owners in order to study risk factors associated with pathogen 
carriage.   
 
In the lab, respiratory pathogens will be looked for by virus isolation, PCR/RT-PCR, 
bacterial culture and API. Results for each case will be sent to you at a later date. 
The pathogens isolated will help us understand the current panorama of respiratory 
pathogens circulating in the UK and the risk factors involved in infection of dogs and 










Pet Health Study 
Understanding infectious causes of respiratory disease in dogs and cats 
 
PHONE ADMINISTERED OWNER QUESTIONNAIRE - CATS 
 
1. General information: 
 
Pet name  
Owner surname  
Owner postcode  
(to AA00 level eg.: CH60) 
 
Veterinary surgery  
 
2. Pet details:  
 
 
a) Age:        years        months (known / estimated – circle correct) 
                                 
                      Don’t know 
 
b) Gender: Male          Female         Don’t know  
 
c) Is your pet neutered (castrated/spayed)? Yes        No        Don’t know  
 
d) Is your pet a: Purebreed         Crossbreed          Don’t know  
 
e) If you answered purebreed, which breed is it?  
 
3. Lifestyle questions: 
 
a) How many cats are there in the house including this cat?  
 
b) Does your pet have contact with other animals? Yes        No        Don’t know 
 
c) If your answer to 3.b) was yes, which species does your pet have contact with?  
 
       Other cats  
       Dogs 
       Cattle/sheep  




+       Poultry  
       Horses 
       Pet birds 
       Wild animals (eg. If cat hunts, please specify) 
       Others (please specify 
 
d) Does your cat live? 
 
       Indoors 
       Outdoors 
       Both 
 
f) During the last month has your cat stayed at or attended any of the following? 
 
       Boarding cattery 
               Vet surgery (excluding the one during which he/she was recruited for this 
study) 
       Rescue shelter 
       Kitten parties 
       Groomers 
       Other. Please specify:  
 
g) Your cat eats (choose all that apply): 
 
       Commercial food (e.g: biscuits) 
       Raw meat 
       Home cooked meals  
       Solely vegetarian  
       Other. Please specify:  
 
h) Where does your cat alleviate him/herself? 
  
      Litter tray 
      Goes outside 
      Both 
      Other. Please specify:  
 
i) If you answered littered tray, what do you line the tray with?  
     
       Clay litter 
       Clumping litter 
       Deodorant litter 
       Crystal litter  
       Pine/Wheat/Corn litter 
       Recycled paper 




j) How long have you had your cat for?  
 
4. Medical information:  
        
a) Is your cat vaccinated? When was he/she last vaccinated?  
   
       Yes, within the last year.  
       Yes, within the last three years. 
       Yes, more than three years ago. 
       Yes, he has had his first vaccination but hasn’t received his booster yet.  
       No, he is not old enough to receive vaccination. 
       No, he was never vaccinated.  
       Don’t know.  
 
b) Do you know the name of the last vaccine used?  
 
c) When was your cat last de-wormed?  
       
      In the last 3 months. 
      In the last year. 
      Over a year ago. 
      Don’t know. 
      Never. 
 
d) When was your cat last treated for fleas and ticks? 
 
      In the last 3 months. 
      In the last year. 
      Over a year ago. 
      Don’t know. 
      Never. 
 




f) Before the vet visit you have just described, has your pet suffered from 
respiratory disease (example: coughing, sneezing, runny nose or eyes)? If yes, 










h) Is your cat currently on antibiotics?  
 
       Yes. Please specify:  
       No 
 
i) Is your cat currently receiving any medical treatment?  
 
       Yes 
       No 
 










Questions below are FOR CASES ONLY 
 
l) Has your cat showed any of the following signs within the past 14 days?  
 
      Coughing 
      Sneezing 
      Runny nose 
      Runny eyes 
      Nose bleed 
      Red eye 
      Trouble breathing 
      Mouth ulcers 
      Face/lip ulcers 
      Fever 
 
m) Has your cat had any other respiratory disease signs within the past 14 days?  
 
      Yes. Please specify:  
      No 
      Don’t know 
 
n) If you answered yes for any of these signs, when did they start?  
 
      Last 48 hours 
      Last 3 – 7 days 
      Last 8 – 14 days 
      15 or more days ago 
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      Don’t know 
 





p) Have you suffered from any signs of respiratory disease or conjunctivitis (red 





Thank you for taking part in this study!  
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Appendix 4E Univariable logistic regression results of questionnaire data associated 
with respiratory disease in cats attending veterinary practices in the UK. All variables 
with p-values < 0.25 are highlighted with an *.  
 








 n  n      
Gender  
Female 11  19  Ref.    
Male 15  20  1.29 0.6 0.5 3.6 
Neutered status  
Yes 22  35  Ref.    
No 4  3  2.12 0.35 0.42 11.6 
Breed  
Pedigree 3  3  Ref.    
Crossbreed 23  35  0.7 0.62 0.11 3.81 
Number cats/household         
1 9  15  Ref.    
2 to 3 9  20  0.8 0.6 0.2 2.4 
4 or more 8  4  3.3 0.1* 0.8 15.7 
Contact with other 
animals 
        
Yes 20  32  Ref.    
No 5  7  1.1 0.83 0.3 4.1 
Lifestyle         
Indoors 13  11  Ref.    
Indoors+Outdoors 13  28  0.4 0.08* 0.13 1.1 
Stay in multianimal 
environment 
        
Yes 5  4  Ref.    
No 21  35  0.5 0.3 0.1 1.98 
Food         
Commercial 18  33  Ref.    
Commercial + Home 
cooked 
6  6  2.4 0.15* 0.7 8.5 
Where cat alleviates         
Litter 14  17  Ref.    
Outdoors 6  13  0.6 0.34 0.17 1.86 
Litter + Outdoors 6  9  0.8 0.74 0.2 2.8 
Vaccinated         
 Within last year 17  29  Ref.    
>1 year ago 5  2  4.2 0.1* 0.8 32.1 
Never 3  7  0.7 0.7 0.1 3.02 
Vaccine antigen         
FCV-F9 10  16  Ref.    
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 n  n      
Worming         
Within last 3m 15  29  Ref.    
>3m ago 6  9  1.3 0.7 0.4 4.3 
Never 5  1  9.7 0.05* 1 194 
Flea/tick 
treatment 
        
Within last 3m 19  33  Ref.    
>3m ago 2  4  1.7 0.47 0.4 8.1 
Never 3  3  5.2 0.16* 0.6 109.5 
Reason for vet 
visit 
        
Routine 3  22  Ref.    
Ill (respiratory) 21  1  153 <0.001* 21 3357.6 
Ill (not-
respiratory) 




        
Yes 10  4  Ref.    




        
Yes 5  14  Ref.    
No 20  24  2.3 0.16* 0.7 8.2 
Current 
antibiotics 
        
Yes 7  4  Ref.    
No 19  34  0.32 0.1* 0.08 1.19 
Other current 
medication  
        
Yes 2  1  Ref.    
No 24  36  0.33 0.381 0.01 3.7 
Age         
0 – 12m 6  11  Ref.    
13-60m 3  12  0.14 0.015* 0.02 0.62 
61-96m 1  5  0.11 0.067* 0.005 0.88 





5 Pathogens and risk factors associated with 
signs of respiratory disease in dogs attending 



























Canine infectious respiratory disease (CIRD) is a major syndrome affecting dogs on a 
global scale. This case-control study aimed to reappraise the role of classic and 
emerging CIRD pathogens such as canine distemper virus (CDV), canine adenovirus 
type 2 (CAV-2), canine parainfluenza virus (CPiV), canine herpesvirus (CHV-1) and 
Bordetella bronchiseptica (B. bronchiseptica), canine respiratory coronavirus 
(CRCoV), canine pneumovirus (CnPnV), influenza A viruses, Mycoplasma cynos 
(M.cynos) and Streptococcus equi subsp. zooepidemicus (S .equi subsp. 
zooepidemicus). This study also aimed to identify potential dog-level risk factors for 
infection in animals attending UK veterinary practices.  
 
Veterinary practices (11) were recruited into the study and samples from a total of 
45 cases and 87 controls collected. Presence of pathogens was determined using 
bacterial culture and polymerase chain reaction (PCR). Telephone questionnaires 
were administered to participating pet owners to collect data relating to signalment, 
lifestyle and characteristics of respiratory disease. Risk factors for case status were 
assessed using multivariable logistic regression.  
 
No samples tested positive for CAV-2, CPiV, CDV, Influenza A or S.equi subsp. 
zooepidemicus. However, CRCoV was detected in 6.1% of samples (all of which were 
cases) and this virus was found to be positively associated with case status. M. cynos 
was detected in 3.1% of samples (4.4% cases and 2.3% controls), 2.3% of samples 
tested positive for CnPnV (4.4% cases and 1.2% controls) and 15.9% tested positive 
for B.bronchiseptica (6.7% cases and 20.7% controls). Entire (not neutered) and older 
animals were found to be more likely to suffer from CIRD.  
 
This study highlights the importance of newly emerged pathogens in CIRD as well as 
the need to re-evaluate the relevance of currently available CIRD vaccine antigens. 
CRCoV was identified as an important pathogen in CIRD in the UK for which 




5.2 Introduction  
Canine infectious respiratory disease (CIRD), classically referred to as “kennel cough”, 
is an important multifactorial syndrome affecting dogs, especially those which are 
housed in groups, such as breeding and rescue kennels, as well as working dogs. In a 
recent report by SAVSNET, 1.1% of canine patients are brought into consults at UK 
veterinary practices due to respiratory disease (Arsevska et al., 2018). This number 
shows a slight decrease in more recent years in comparison to a similar study by the 
same group which reported 1.7% of consults with dogs were due to respiratory signs 
(Sánchez-Vizcaíno et al., 2016). Additionally, it has also been suggested that dogs 
present for this reason slightly less frequently than cats (1.3%; Arsevska et al., 2018).  
 
While a range of clinical signs are associated with CIRD, the most commonly reported 
is coughing, often described as a dry honking cough. Other frequently associated 
signs include dyspnea, sneezing and nasal discharge (Arsevska et al., 2018; 
Buonavoglia and Martella, 2007; Mochizuki et al., 2008). 
 
CIRD is an endemic respiratory syndrome of worldwide distribution. Although 
historically it has been perceived as a disease complex of relatively limited 
significance (especially in pet dog populations), it has received growing attention 
more recently due to the emergence of new pathogens. Classical pathogens 
associated with CIRD include canine parainfluenza virus (CPiV), canine distemper 
virus (CDV), canine adenovirus type 2 (CAV-2), canine herpesvirus 1 (CHV-1) and B. 
bronchiseptica. More recently, canine respiratory coronavirus (CRCoV) was identified 
as a causative agent of kennel cough-like disease. It is commonly identified in samples 
of dogs with respiratory disease, seeming to be one of the most prevalent viruses in 
association with the complex (Erles et al., 2003; Priestnall et al., 2007, 2006). In 2010, 
canine pneumovirus (CnPnV) was isolated in the USA from kenneled dogs with CIRD-
like disease and has since been identified in several other countries (Decaro et al., 
2014; Mitchell et al., 2017, 2013b; Renshaw et al., 2010). Canine influenza was first 
detected in 2004 in racing greyhounds in Florida. The first circulating subtype 
identified in association with CIRD was H3N8 which seemingly underwent a species 
jump from horses to dogs (Crawford et al., 2005). This virus has subsequently become 
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adapted for transmission between dogs, and has become a major issue in several 
states of the USA. Other influenza subtypes causing disease in dogs have also 
emerged including canine influenza H3N2, which circulates in several Asian countries 
and continues to be an issue in the USA, where it was imported with rescue dogs 
(Song et al., 2008, Voorhees et al., 2017). Interestingly, canine influenza does not 
seem to have been able to establish itself outside of North America and very little 
evidence of its presence in the UK exists (chapter 3; Mitchell et al., 2017). Finally, in 
recent years, Streptococcus equi subsp. zooepidemicus has re-emerged as a relevant 
pathogen causing occasional outbreaks of severe and fatal lower respiratory tract 
disease and Mycoplasma cynos (M.cynos) has also been frequently found in animals 
with CIRD. The role of these two last microorganisms in the pathogenesis of CIRD is 
still not fully understood (Priestnall, 2017).  
 
While a myriad of studies looking into CIRD have focused on disease of animals 
housed in groups, few studies exist focusing solely on CIRD in pet dog populations 
(Mochizuki et al 2008, Joffe et al 2015) and, to the knowledge of the author, none 
focusing on CIRD in UK household dogs. The aim of this study was, therefore, to use 
recent assays to reappraise the role of CIRD where it relates to the UK veterinary-
visiting pet dog population. Taking a similar approach to this dissertation’s previous 
chapter, a case-control study was performed in dogs attending UK-based veterinary 
practices to identify risk-factors associated with the presence of CIRD and further 
understand the role of infection with classical and emerging/potential respiratory 
pathogens including CPiV, CDV, CAV-2, CHV-1, B. bronchiseptica, CRCoV, CnPnV, 




5.3 Materials and methods 
 
Ethics and informed consent  
Ethical approval was obtained from the Veterinary Research Ethics Committee, 
University of Liverpool (VREC233; same as previous chapter). Informed consent was 
obtained from participating dog owners (Appendix 5A).  
 
Study design 
This study was done in conjunction with the previous chapter. Thus, in order to 
enable comparison between dogs with and without clinically suspected canine 
infectious respiratory disease (CIRD), a case-control study design was used. An 
expected prevalence of 10% (see chapter 4) was used to construct a sample size 
calculation (Epi Info 7) for a 1:2 matched case-control study. 
 
Recruitment and sample collection 
Samples were collected from July 2014 to December 2016 from dogs attending UK 
veterinary practices. Recruitment and sample collection methods used were similar 
as for the feline patients in chapter 4. 
 
Case and control definitions 
A case was defined as any dog presenting at a veterinary surgery which, to the best 
of the clinical judgement of the attending veterinary surgeon, was suffering from 
respiratory disease at the time of consultation and presented with two or more of 
the following clinical signs: cough, sneezing, altered lung sounds, pyrexia, nasal 
discharge, ocular discharge, inflamed tonsils, epistaxis, altered respiratory patterns. 
As with cats in Chapter 4, animals were to be excluded if any of the previously 
mentioned signs were likely to be caused by a reason other than respiratory disease 
(e.g. cardiac disease).  
 
Control dogs were defined as the next two dogs to be presented to each veterinary 
surgeon following a case, with the exclusion of any dogs which suffered from 
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respiratory disease within the previous fortnight or were showing any of the above 
clinical signs of disease. 
 
Sample collection and processing 
The same methods were applied as previously described for feline samples in 
Chapter 4.  
 
Questionnaire design  
The questionnaires used for canine participants are shown in Appendix 5A. A core of 
identical questions was used for both cases and controls with additional questions 
for cases only. Questionnaire administration was performed in the same way as with 
feline patients (Chapter 4).  
 
Nucleic acid extraction, reverse transcription and PCR 
Viral nucleic acid (RNA and DNA) was extracted from oropharyngeal swabs using the 
same method as described in Chapter 2 (Viral RNA mini-kit; Qiagen). Reverse 
transcription was performed using 200 ng random hexamers (Superscript III, Life 
Technologies). Table 5.1 shows details of diagnostic tests using PCR for detection of 
nucleic acids from oropharyngeal swabs. Conventional PCRs were performed using 
cDNA from reverse transcription for Influenza A, CDV, CPiV, CRCoV and CnPnV; and 
using the nucleic acids extracted from oropharyngeal swabs for M. cynos, B. 
bronchiseptica, CAV-2 and CHV. Real-time PCRs were performed for B.bronchiseptica 






























































(Frisk et al., 1999) 58 40 OP swab  287 






























(Erles et al., 2003) 55 35 OP swab 621, 442 
(nested 
PCR) 








(Mitchell et al., 2013b) 60 45 OP swab 104 






(Hu et al., 2001) 60 40 OP swab 1030 





















(Helps et al., 2005) 60 45 OP swab 80 











Isolation and identification of Bordetella bronchiseptica and S. equi subsp. 
zooepidemicus 
For B.bronchiseptica, the methods used were described in Chapter 4. For S. equi 
subsp. zooepidemicus, charcoal swabs were streaked onto blood agar plates. Any β-
haemolytic colonies were sub-cultured on to a further blood agar plate to ensure 
single colonies and gram stained. Any gram-positive colonies were tested using an 
APIstrep kit to identify S. equi subsp. zooepidemicus. 
 
Data analysis 
All sample, diagnostic results and questionnaire data were entered onto a 
spreadsheet programme (Microsoft Excel for Mac). Visual verification of correct data 
input was verified for 5% of entries.  
 
The outcome variable used was case or control status and the associations with 
predictor variable were assessed using univariable logistic regression using R Studio 
(version R 3.4.1 GUI 1.70 El Capitan build).   
 
Twenty-two predictor variables were assessed including gender (female or male), 
neutered status (entire or neutered), breed (re-classified from questionnaire 
responses as pedigree or crossbreed), number of dogs in household (classified into 
three groups: 1 dog per household, 2 dogs per household, 3 or more dogs per 
household), contact with other animals (yes or no), contact with other dogs excepting 
those in the household (yes or no), contact with cats (yes or no), access to a private 
garden (yes or no), access to public spaces (yes or no), access to woods (yes or no), 
access to water streams (yes or no), recent stay or visit to a multi-animal household  
(e.g. shelter, boarding kennel, veterinary surgery, etc., re-classified from 
questionnaire data to yes or no), food (re-classified into two categories commercial 
or home-cooked/mixture), vaccination history (re-classified into two groups due to 
small sample size: within the last year and over one year ago/never), kennel cough 
vaccinated (yes or no, reclassified from questionnaire data based on vaccine brand 
and type information given by owner), worming (categorised into within last 3 
months, within last year or never) and flea and tick control status (classified into 
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within last three months and more than three months ago/never), reason for 
veterinary visit (classified into routine appointment, ill health – respiratory or ill 
health – not respiratory), previous history of respiratory disease (yes or no), antibiotic 
usage (yes or no), other current medication (yes or no) and history of concurrent 
medical conditions (yes or no).  
 
Univariable logistic regression was also used to analyse the relationship between 
pathogen presence and case or control status.  
 
To build a multivariable analysis model, univariable analysis results were taken into 
account in combination with knowledge of the CIRD clinical syndrome. Roughly, one 
explanatory variable per 10 cases was considered. The model was then built using 





Out of the 36 practices recruited into the study, only 11 submitted samples from 
canine patients. Figure 5.1 shows the approximate geographical location of these 
practices. 
 
The number of samples submitted by each practice was variable ranging from 3 to 
32 samples (median 9). A total of 45 dogs meeting the case definition and 87 controls 
presenting to participating veterinary practices were recruited into the study. 
Similarly to chapter 4, due to low number of samples, and the failure to always collect 
matched case control sets and questionnaire responses in some practices (with 
instances where no controls or no cases were collected in a participating practice) 
data were analysed using an unmatched case-control design. Table 5.2 summarises 
study sample signalment and pathogen detection.  
 























































































































         










Figure 5.1 Map of United Kingdom showing the approximate location of practices that returned 
samples to the study. 
Contact of participants was attempted at least three times via phone. Out of the total 
number of dogs recruited into the study (n=132), questionnaire data were obtained 
for only 50% (n=65) of participants.  
 
Out of the 22 cases for which questionnaire data were obtained, 19 (86.4%) owners 
reported their dog had been coughing, followed by six (27.3%) owners reporting 
sneezing and the same number reporting a runny nose. Trouble breathing was 
reported four times (18.2%), fever was reported in three instances (13.6%). Eye 
discharge and conjunctivitis were each reported twice (9.1%).  Eleven owners (50%) 
reported a single clinical respiratory sign during questionnaire administration (with 
the majority of these, n=9, reporting coughing as the only noticed clinical sign).   
 
Within the case group, 18 animals were taken for a veterinary consultation due to 
exhibiting respiratory disease signs The four remaining dogs presented for routine 
consultations and were identified as suffering from respiratory disease and recruited 
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as cases by the veterinary surgeon at the time of consult; in these animals the signs 
of respiratory disease were reported by their owners during questionnaire 
administration.  
 
Seven of the cases had started exhibiting respiratory signs within 48 hours of 
presenting to the veterinary surgery for consultation. Four animals had been 
suffering from respiratory disease for 3 to 7 days before their consultation, two 
animals for 8 to 14 days and seven animals for over 14 days. Two owners didn’t know 
when their dog’s respiratory signs had started. All dogs for which questionnaire data 
were obtained were pet dogs (no working or service dogs in the sample) and no 
animals were on antibiotics at the time of sampling.  
 
When asked if they could identify any factors that could have led to their animals 
contracting respiratory disease, five owners mentioned their animal had recently 
attended “doggy day-care”, four owners thought it had been contracted during walks 
out, two owners mentioned being aware of ongoing CIRD outbreaks in the area and 
two owners had taken their animals to dog shows. Five owners also mentioned 
having mild respiratory disease at the same time as their dogs.  
Univariable analysis of signalment and clinical data collected from questionnaires are 
shown in Appendix 5B.  The only variable with a p-value<0.05 on univariable analysis 
was neutered status with cases being 5.14 times more likely to be entire than 
controls. Age as a continuous variable was assessed for linearity using a generalised 
additive model (GAM) (figure 5.2) and was found not to have any significant non-
linear relationship with case or control status.   
 
To build the multivariable logistic regression model the following variables with p- 
values<0.2 in the univariable analysis were initially used: prior respiratory disease, 
vaccination status, worming status, flea and tick treatment status, currently 
medicated, access to water streams, neutered status and age. Table 5.3 shows the 




In the final model, cases were almost 8 times more likely than controls to be entire 
and dogs were more likely to suffer from respiratory disease as they got older 
(OR=1.02, per month). 




Table 5.3. Multivariable logistic regression of factors associated with respiratory cases in dogs 
attending 11 veterinary practices in the UK (n=132; 45 cases and 87 controls).  
Ref.= reference category 
 
The results of laboratory testing and univariable logistic regression of PCR testing 
results of 132 animals (questionnaire data was only available for 65 of these animals) 
are shown in Table 5.4. No samples tested positive for CAV-2, CPiV, CDV, Influenza A 
or S.equi subsp. zooepidemicus. Eight samples (6.1%, all cases) tested positive for 
CRCoV (these belonged to four different practices: one practice had four positives 
and another had two positives, none of these animals being co-habitants; the 
remaining two practices had one positive each). Four samples (2 cases , 2 controls)  
(3%) tested positive for M.cynos (three positive samples belonged to the same 
practice – one case and two controls, with the two controls animals living together). 
Three samples (2.3%) tested positive for CnPnV with two of these having been 
collected in the same practice (1 case and 1 control, not co-habitants). Twenty one 
samples (15.9%) tested positive by PCR to B.bronchiseptica (only three of these were 
cases and none belonged to the same household). By bacterial culture, only five 
samples tested positive for B.bronchiseptica (one case and four controls). Only three 
(2.3%) mixed infections were identified, all of which were cases: one sample was 
positive for CnPnv and B.bronchiseptica, one was positive for CRCoV, 
B.bronchiseptica and M.cynos and the last one was positive for both CRCoV and 












Neutered status           
Yes   Ref.       
No 2.07 (0.69) 7.95 2.19 33.85 0.003 
Age (in months)   0.02 (0.006) 1.02  1.003  1.029  0.02 
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Cases were found to be 18.8 times more likely to test positive for CRCoV. Cases were 
also found to be less likely to test positive for B.bronchiseptica than controls in this  
sample. The differences between cases and controls for CnPnV testing results were 




Table 5.4 Univariable logistic regression results of PCR testing for pathogens associated with 
respiratory cases (n=132, 45 cases and 87 controls). Due to complete data separation, one extra data 




n       % 
Control 
n       % 
Odds Ratio Wald 
P-value 
Lower 95%CI Upper 
95%CI 
CAV-2  
Positive 0 0% 0 0%     
Negative 45 100% 87 100%     
CDV  
Positive 0 0% 0 0%     
Negative 45 100% 87 100%     
CPiV  
Positive 0 0% 0 0%     
Negative 45 100% 87 100%     
CHV         
Positive 0 0% 0 0%     
Negative 45 100% 87 100%     
CRCoV*         
Positive 8 17.8% 0 0% 18.80 0.006 3.29 355.35 
Negative 37 82.2% 87 100% Ref.    
Influenza A         
Positive 0 0% 0 0%     
Negative 45 100% 87 100%     
CnPnV         
Positive 2 4.4% 1 1.2% 4.00 0.26 0.37 87.49 
Negative 43 95.6% 86 98.9% Ref.    
B. bronchiseptica (PCR)         
Positive 3 6.7% 18 20.7% 0.26 0.04 0.06 0.81 
Negative 42 93.3% 69 79.3% Ref.    
M. cynos         
Positive 2 4.4% 2 2.3% 1.98 0.5 0.23 16.9 
Negative 43 95.6% 85 97.7% Ref.     
127 
 
5.5 Discussion and conclusions 
CIRD is an important clinical syndrome in dogs, especially those housed in multi-
animal environments. While in UK pet dog populations it may be perceived as less 
impactful, it is not uncommon to see regional, small-scale outbreaks of CIRD from 
time to time in these populations (authors unpublished observations). CIRD has 
historically been considered as a self-limiting condition leading largely to mild clinical 
signs. However, in recent years, this paradigm has slowly shifted with the emergence 
of pathogens for which vaccination is not available and which can lead to more severe 
disease such as canine influenza (CIV) in the USA, CnPnV and CRCoV (Priestnall et al., 
2014). Despite its significance, few studies looking at vet visiting dogs have been 
conducted with most research focusing on multi-animal households (see Chapter 6). 
The author is not aware of any recent case-control studies focusing solely on CIRD in 
pet populations within the UK. Therefore, in this study, we sought to reappraise the 
role of known and potentially newer pathogens and dog-level risk factors in CIRD in 
a random population of UK veterinary visiting pet dogs.  
 
As with FIRD, scoring has been used in prior studies to assign animals into disease 
groups based on observed clinical signs (Erles et al., 2003, Mitchell et al., 2017, 
Maboni et al., 2019). A recent study found that disease severity was associated with 
vaccination status for classic viral pathogens CPiV, CDV and CAV-2 and presence of 
CRCoV and CnPnV was associated with more severe disease presentations (Mitchell 
et al., 2017). Another recent study showed that co-infections lead to more severe 
disease and that animal age is an important predictor of disease severity (Maboni et 
al., 2019). As previously discussed, it would have been useful to take a similar 
approach of using clinical scoring for a more in-depth analysis of risk factors. 
However, grouping animals into cases or controls, without any further grouping, 
seems more appropriate given the small sample sizes.  
 
In this case control study, entire dogs were found to be more likely to suffer from 
CIRD. This is an interesting finding similar to that of chapter two where entire cats 
were more likely to shed FCV, a FIRD pathogen. In cats, it is possible this increased 
risk is associated with the impact of neutering on behaviour, with entire cats tending 
128 
 
to roam more, which could lead to an increased likelihood of contact with other 
infected animals. For dogs, it is unclear why this would happen since, in most 
circumstances, their contact with other animals is likely controlled by their owners, 
with decisions to walk often revolving around owner needs not dog needs (Westgarth 
et al., 2017). Indeed, several studies have failed to find any association between 
neutering and dog walking (Westgarth et al., 2015, 2014). It is perhaps more likely 
that neutering itself is a marker for other factors not covered in the questionnaire. 
For example, it has been shown that owners of neutered animals may be more 
invested in the health care of their pets, and neutered dogs are more likely to be 
insured and vaccinated (Sánchez-Vizcaíno et al., 2018). Also, it is becoming 
increasingly clear that sex hormones have the ability to impact on immune reposes 
(Brown and Su, 2019). In dogs, hormonal changes associated with oestrus have been 
associated with reduced immune function, although in a bacterial infection (Sugiura 
et al., 2004). Understanding the basis of this apparent neutering effect on CIRD risk 
could provide new opportunities to enhance disease control. It is worth noting that 
these findings may be due to sampling bias. Similar biases have been identified in 
past studies where, for example, neutered cats were more likely to be registered with 
a veterinary practice in comparison with entire animals (Murray and Gruffydd-Jones, 
2012). 
 
Age was also found to be significantly associated with case status, with older animals 
tending to be more likely to have CIRD-like disease. This is also a curious finding since 
animals tend to have higher levels of immunity through both field exposure and 
vaccination as they grow older. These results could be down to the small sample size 
and a control selection bias as the controls were selected from the next veterinary 
visiting dogs following recruitment of a case. As with the previous chapter on feline 
infectious respiratory disease, the fact that recruited dogs were from a pool of 
animals registered and attending veterinary practices is known to introduce a 




Vaccination status was not found to be significantly associated with case or control 
status whereas in prior studies occurrence and severity of CIRD was found to be 
lower in vaccinated animals (Mitchell et al., 2017).  
 
In this study, 17.8% of all cases tested were positive for CRCoV. This virus was firstly 
described in 2003 and is now considered a pathogen of great importance in CIRD 
(Priestnall et al., 2014). The virus seemingly shows a strong association with disease 
and was not found in any control animals. In previous studies, CRCoV was also mostly 
found associated with disease. Joffe et al. (2016) looked at CIRD in pet populations 
attending Canadian clinics and found that 9.4% of cases were positive for CRCoV and 
no healthy animals tested positive for the virus. Schulz et al. (2014) reported a similar 
finding with 9.8% of diseased animals testing positive for the virus but with no 
positive results in healthy groups. Together these studies suggest that these 
respiratory coronaviruses may play a major role in CIRD and could represent a target 
for future vaccine development. Members of the Coronaviridae include both 
established and recently emerged respiratory pathogens in humans (Yin and 
Wunderink, 2018) and other animal species (Cavanagh, 2007; Saif, 2010), so it is not 
surprising that CRCoV has been found to be associated with CIRD (Erles and Brownlie, 
2008).  
 
CnPnV was found in three samples (2.27% of all samples) with two of these being 
cases (4.4% of cases). These numbers are significantly lower than findings previously 
reported in European mixed-origin samples (pet and kennelled), where this pathogen 
was detected in 23.4% of animals tested (Mitchell et al., 2017). It would be interesting 
to further explore these differences and understand whether they are related to the 
population being tested, in particular, pet dogs compared to kennelled animals.  
 
Bordetella bronchiseptica, similarly to what was found in cats in the previous chapter, 
was found more often in controls than in cases, findings seemingly counter to the 
known role of B. bronchiseptica as a primary CIRD pathogen. These findings highlight 
the potential carrier role of healthy animals in the pet population (Bemis et al., 
1977a) as well as the frequent role of B. bronchiseptica as an opportunistic pathogen 
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often acting synergistically after a virus firstly infects the host. As before, PCR was 
able to identify significantly more positives than bacterial culture. It is possible that 
the increased sensitivity of PCR meant we were able to detect lower levels of bacteria 
associated with a carrier state, below a threshold associated with disease. Being 
mostly live vaccines, B. bordetella can also be shed for some time after vaccination 
at high levels 3-10 days post vaccination, and at lower levels up to 28 days post-
vaccination (Ruch-Gallie et al., 2016). Although previous studies have not found 
shedding of vaccine bordetella to be a common occurrence in the field (Binns et al., 
1998), it would be interesting to genotype some of the isolates obtained in this study 
to see to what extent vaccine antigens as opposed to field isolates were responsible 
for the high rates of carriage in cases.  
 
M. cynos was detected in two cases and two controls and pathogen detection was 
not found to be significantly associated with case status. The degree of importance 
of the role of M. cynos in the CIRD complex is still controversial mostly due to a 
paucity of studies focusing on this pathogen. However, some studies do indicate that 
M. cynos is associated with CIRD, its presence correlated with increased severity of 
disease (Chalker et al., 2004).  
 
Several of the organisms tested for in this study were not detected. This is in part 
likely to reflect the underpowered nature of this study due to low number of dogs 
recruited. However, the absence of these pathogens still warrants some discussion. 
The absence of influenza A is in line with previous studies that suggest CIV has not 
been able to establish itself outside of the USA and Asia to become a major cause of 
CIRD. Similar findings have been previously recorded in Europe, Canada and Japan 
(Decaro et al., 2016; Joffe et al., 2016; Mitchell et al., 2017; Mochizuki et al., 2008). 
It will be important to continue to survey for canine influenza viruses in the UK, since 
it seems only a matter of time before human and canine movement will import this 
virus into what is likely to be a completely immunologically naïve population. If that 
does happen, it is likely that vaccines licensed for the control of these viruses would 




The absence of classical CIRD pathogens CAV-2, CDV or CHV mirrors that seen in pet 
and kennelled populations in a recent study by Decaro, et al. (2016). Given the fact 
vaccination against these pathogens is part of the widely recognised core vaccination 
schedule and that recent studies indicate that around 91.5% of UK vet-visiting dogs 
are vaccinated against these, these findings are not surprising and, if anything, are 
reassuring in regards to UK vaccination practices (Day et al., 2016; Sánchez-Vizcaíno 
et al., 2018). Similarly, CPiV was not found in this study’s population. Most recent 
studies have reported CPiV as a major pathogen in CIRD with detection rates of 7.4 – 
42% and a strong association with clinical signs (Decaro et al., 2016; Joffe et al., 2016; 
Mochizuki et al., 2008; Schulz et al., 2014). This is a curious finding and perhaps 
mirrors the fact that over 70% of the UK canine population seems to be vaccinated 
against CPiV (Sánchez-Vizcaíno et al., 2018).  
 
S. equi subs. zooepidemicus was also not cultured from any of the samples submitted 
through this study. This pathogen is generally responsible for extremely severe and 
sporadic disease, with high mortality generally in larger groups of dogs with 
haemorrhage and pneumonia (Byun et al., 2009; Chalker et al., 2003a; Priestnall et 
al., 2014, 2010). This contrasts the generally mild nature of the disease seen in the 
cases recruited here. 
 
As with the previous chapter, the broad case selection criteria applied in this study 
could lead to the inclusion of aetiologies of non-infectious origin. Other previously 
mentioned limitation (chapter 4) also apply here.   
 
In conclusion, this chapter highlights the importance of newly emerged pathogens in 
CIRD, particularly CRCoV, as well as the importance of vaccination. More so, it 
highlights the need to re- evaluate the relevance of current CIRD vaccine antigens 
available with CRCoV seeming to be an important pathogen in which prevention 
through vaccination would be an interesting area to explore. Finally, with over 75% 
of cases not testing positive for any of the pathogens in this panel, it is important to 
question whether this is due to sampling collection, handling and testing issues, 
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whether there are still unidentified significant pathogens in circulation leading to 




5.6 Appendix to Chapter 5 







Pet Health Study 
Understanding infectious causes of respiratory disease in dogs and 
cats 
 
PHONE ADMINISTERED OWNER QUESTIONNAIRE - DOG 
 
1. General information: 
 
Pet name  
Owner surname  
Owner postcode  
(to AA00 level eg.: 
CH60) 
 
Veterinary surgery  
 
2. Dog details:  
 
a) Age:        years        months (known / estimated – circle correct) 
                                 
                      Don’t know 
 
b) Gender: Male          Female         Don’t know  
 
c) Is your dog neutered (castrated/spayed)? Yes        No        Don’t know  
 
d) Is your dog a: Purebreed         Crossbreed          Don’t know  
 
e) If you answered purebreed, which breed is it?  
 
3. Lifestyle questions: 
 
a) How many dogs are there in the house including this dog?  
b) Does your dog have contact with other animals?  
Yes        No        Don’t know 
 
c) If your answer to 3.b) was yes, which species does your dog have 
contact with?  
 
       Other dogs  
       Cats 
       Cattle/sheep  
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       Pigs  
       Poultry  
       Horses 
       Pet birds 
       Wild animals (please specify) 
       Others (please specify) 
 
 
d) Does your dog have access to any of the following?  
 
      Garden 
      Woods 
      Water streams 
      Public spaces 
 
e) During the last month has your dog stayed at or attended any of the 
following? 
 
       Boarding kennel 
       Vet surgery (excluding the one during which he/she was recruited for 
this study) 
       Rescue shelter 
       Training/puppy classes  
       Competitions/dog shows 
       Groomers 
       Other. Please specify:  
 
g) Your dog eats (choose all that apply): 
 
       Commercial food (e.g: biscuits) 
       Raw meat 
       Home cooked meals  
       Solely vegetarian  
       Other. Please specify:  
 
h) Is your dog any of the following?  
 
      Herding dog 
       Hunting dog 
       Assistance/service dog. Please specify: 
       None.  
 
g) How long have you had your dog for?  
 
4. Medical information:  
        
a) Is your dog vaccinated? When was he/she last vaccinated?  
   
       Yes, within the last year.  
       Yes, within the last three years. 
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       Yes, more than three years ago. 
       Yes, he has had his first vaccination but hasn’t received his booster yet.  
       No, he is not old enough to receive vaccination. 
       No, he was never vaccinated.  
       Don’t know.  
 
b) Do you know the name of the last vaccine used?  
 
c) When was your dog last de-wormed?  
       
      In the last 3 months. 
      In the last year. 
      Over a year ago. 
      Don’t know. 
      Never. 
 
d) When was your dog last treated for fleas and ticks? 
 
      In the last 3 months. 
      In the last year. 
      Over a year ago. 
      Don’t know. 
      Never. 
 







f) Before the vet visit you have just described, has your dog suffered 
from respiratory disease (example: coughing, sneezing, runny nose or 



















h) Is your dog currently on antibiotics?  
 
       Yes. Please specify:  
       No 
 
i) Is your dog currently receiving any medical treatment?  
 
       Yes 
       No 
 








k) Is there any other information about your dog’s health that you feel 
might be relevant?  
 
 
Questions below FOR CASES ONLY 
 
 
l) Has your pet showed any of the following signs within the past 14 
days?  
 
      Coughing 
      Sneezing 
      Runny nose 
      Runny eyes 
      Nose bleed 
      Red eye 
      Trouble breathing 
      Mouth ulcers 
      Face/lip ulcers 
      Fever 
 
 
m) If you answered yes for any of these signs, when did they start?   
 
      Last 48 hours 
      Last 3 – 7 days 
      Last 8 – 14 days 
15 or more days ago 





n) Has your dog had any other signs of respiratory disease within the 
past 14 days?  
 
      Yes. Please specify:  
      No 
      Don’t know 
 
 







p) Have you suffered from any signs of respiratory disease or 










Appendix 5B Univariable logistic regression analysis of factors associated with case 
or control status in CIRD (questionnaires from 11 UK based veterinary practices; 
n=65, 22 cases and 43 controls) 
Variable Case 
n      % 
Control 








Male 9 40.9% 21 48.8% 0.73 0.54 0.25 2.04 
Female 13 59.1% 22 51.2% Ref.    
Neutered status  
Yes 12 54.5% 37 86.1% Ref.    
No 10 45.5% 6 13.9% 5.14 0.008 1.58 18.10 
Breed  
Pedigree 17 13.9% 30 69.8% Ref.    
Crossbreed 5 22.7% 13 30.2% 0.67 0.52 0.19 2.15 
#dogs/household         
1 11 50% 22 51.2% Ref.    
2 7 31.8% 13 30.2% 1.08 0.9 0.33 3.46 
3 or more 4 18.2% 8 18.6% 1 1 0.23 3.96 
Contact with other 
animals 
        
Yes 21 95.5% 42 97.7% Ref.    
No 1 4.5% 1 2.3% 2 0.63 0.08 52.28 
Contact with dogs         
Yes 21 95.5% 40 93.1% Ref.    
No 1 4.5% 3 6.99% 0.63 0.70 0.03 5.31 
Contact with cats         
Yes 7 31.8% 18 41.9% 0.65 0.42 0.21 1.88 



















Stay in  
multi-animal 
environment 
        
Yes 12 54.5% 21 48.8% Ref.    
No 10 45.5% 22 51.2% 0.79 0.66 0.27 2.23 
Access to private 
garden 
        
Yes 21 95.5% 39 90.7% Ref.    
No 1 4.5% 4 9.3% 0.44 0.48 0.02 3.23 
Access to public spaces         
Yes 21 95.5% 39 90.7% Ref.    
No 1 4.5% 4 9.3% 0.46 0.50 0.02 3.39 
Access to woods         
Yes 15 68.2% 35 81.4% Ref.    
No 7 31.8% 8 18.6% 2.04 0.24 0.62 6.73 
Access to water 
streams 
        
Yes 9 40.9% 26 60.5% Ref.    
No 13 59.1% 17 39.5% 2.21 0.14 0.78 6.47 
Food         
Commercial 16 72.7% 22 51.2% Ref.    
Home cooked/raw 1 4.5% 2 4.7% 0.69 0.77 0.03 7.79 
Both 6 27.3% 19 44.2% 0.43 0.15 0.13 1.29 
Concurrent disease         
Yes 5 22.7% 13 30.2% 0.68 0.52 0.19 2.15 









 n  n      
Worming         
Within last 3m 14 63.6% 39 90.7% Ref.    
Within last year 5 22.7% 2 4.7% 6.96 0.03 1.34 52.67 
Over 1y ago/never 1 4.5% 2 4.7% 1.39 0.79 0.06 15.67 
Flea/tick treatment         
Within last 3m 15 68.1% 38 88.4% Ref.    
>3m ago 4 18.2% 2 4.7% 5.07 0.08 0.89 39.41 
Never 1 4.5% 3 6.9% 0.84 0.89 0.04 7.21 
Vaccination status         
Within last year 17 77.3% 40 93.0% Ref.    
Over 1y/never 4 18.2% 2 4.7% 4.70 0.09 0.84 36.33 
CIRD vaccination         
Yes 2 9.1% 8 18.6% 0.50 0.46 0.06 2.84 
No 6 27.3% 12 27.9% Ref.    
Prior respiratory 
disease 
        
Yes 6 27.3% 6 13.9% 2.25 0.21 0.62 8.27 
No 16 72.7% 36 83.7% Ref.    
Currently medicated         
Yes 8 36.4% 9 20.9% 2.16 0.18 0.68 6.8 
No 14 63.6% 34 79.1% Ref.    
Age (month)     1.01 0.07 0.99 1.02 
Ref.= reference category  
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6 Cross-sectional and longitudinal surveys of 
canine and feline infectious respiratory 
disease-associated pathogens in four British 





Infectious respiratory disease in both dogs and cats is an important issue in rescue 
shelters, leading to increased running costs and decreased animal welfare, and is a 
frequent cause of failure to rehome animals. In this study, cats and dogs from four 
rescue shelters were sampled cross-sectionally in order to assess carriage status of 
FIRD- and CIRD-associated and potentially associated pathogens. One the 
participating shelters was also sampled longitudinally for a total period of 10 weeks.  
 
During the cross-sectional sampling visits, oropharyngeal (OP) swabs were collected 
from 42 dogs and 108 cats. Using polymerase chain reaction (PCR), feline calicivirus 
feline herpesvirus and Mycoplasma felis were detected in 7.4%, 4.6% and 16.8% of 
feline samples. No feline samples were positive for Chlamydophila felis, influenza A 
or Bordetella bronchiseptica. Canine samples tested negative for all pathogens 
screened for including canine adenovirus type 2, canine parainfluenza virus, canine 
distemper virus, canine herpesvirus, canine respiratory coronavirus, canine 
pneumovirus, influenza A, Bordetella bronchiseptica, Mycoplasma cynos and 
Streptococcus equi subps. zooepidemicus (all tested for using PCR with the exception 
of the latter for which bacterial culture was used).  
 
During the longitudinal study, OP swabs were collected from 10 dogs and 10 cats 
each week. M. felis was the microorganism identified the most from feline samples 
and through most of the sampling period. FCV was also detected in 6 of the 10 weeks 
of sampling. For both pathogens, most positive animals did not present any clinical 
signs at the time of sampling. In dogs, CnPnV was identified during weeks 9 and 10, 
which coincided with shelter staff reporting CIRD like clinical signs (especially cough); 
however, CnPnV-positive dogs did not present any clinical signs when sampled.  
 
This study highlights the importance of clinically silent carriers of infection acting as 
disease reservoirs; such animals pose an infection risk for naïve animals entering 
rescue shelters. Further work is also needed to understand the potential for CnPnV 
to cause disease in these shelters.  
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6.2 Introduction  
Rescue centres, often referred to interchangeably as animal shelters, rehoming 
centres or rescue kennels/catteries, have been estimated to handle approximately 
90,000 dogs and 160,000 cats per year in the UK (Stavisky et al., 2012a). These 
institutions have multiple important roles, which can include not only providing 
shelter, rehoming animals, and controlling stray and unwanted animal populations, 
but also preventing animal cruelty, educating members of the public and improving 
animal welfare standards (Pesavento and Murphy, 2014).  
 
Despite the positive role played by animal shelters in combatting overpopulation and 
improving animal welfare, these environments prove to be very challenging. The risk 
of exposure, susceptibility and transmission of infectious diseases in the shelter 
environment, where high numbers of animals are housed, is considered to be 
amplified due to several factors such as increased fomite contact, high levels of 
animal stress, high animal turnover and constant introduction of new, often 
immunologically naïve, animals (Pesavento and Murphy, 2014).  
 
While upper respiratory tract infections in household pets are common and usually 
relatively easy to manage, in the shelter context of “herd health management” where 
disease is quickly transmitted between animals, this becomes a major issue 
(Bannasch and Foley, 2005; Pedersen, 1991; Pesavento and Murphy, 2014). 
Additionally, shelters have often been found to provide the perfect context for the 
emergence of new pathogens (Pesavento and Murphy, 2014; Priestnall et al., 2014). 
 
In dogs, CIRD is a disease complex of multifactorial origin and a major issue in animals 
housed in shelters (Erles et al., 2004; Erles and Brownlie, 2005; Mitchell et al., 2017; 
Priestnall et al., 2014). The disease complex can become enzootic in these 
environments due to the constant introduction of new infectious agents to the 
canine population (Mochizuki et al., 2008). The disease is usually characterised by a 
dry hacking cough from which most animals recover in a short timeframe. However, 
in certain cases, more severe disease may develop leading to bronchopneumonia and 
can be a reason for euthanasia or result in fatalities (Priestnall, 2017). In addition to 
144 
 
causing discomfort to the affected animals, CIRD can also lead to increased costs to 
the shelter (i.e. treatment) as well as delays to training and rehoming of dogs. 
Additionally, sometimes it can result in the temporary closure of shelters (Erles et al., 
2003; Erles and Brownlie, 2005). 
 
While classic pathogens such as B. bronchiseptica, CAV-2, CDV, CPiV and CHV-1 are 
still considered important CIRD pathogens, the routine use of vaccination as well as 
antibiotics is thought to have exerted selective pressure on pathogens in the UK 
leading to a decrease in prevalence of these (Priestnall et al., 2014). Recently 
emerged pathogens have often been originally detected in the shelter environment 
and are commonly encountered in these settings. Examples are CRCoV, first isolated 
during an investigation into outbreaks of CIRD-like disease in a UK shelter (Erles et 
al., 2003), and CnPnV, described following a retrospective study of respiratory 
disease in USA shelters (Renshaw et al., 2010). M. cynos was also found to be 
associated with respiratory disease during a study undertaken at a large rehoming 
shelter (Chalker et al., 2004) and S. equi subsp. zooepidemicus has been often 
described in association with outbreaks of severe disease with high mortality in 
kennels (Britton and Davies, 2010; Byun et al., 2009; Priestnall et al., 2010). In respect 
to CIV, the pathogen is also most prevalent in multi-animal environments such as 
kennels, where it has been observed to rapidly spread especially among 
immunologically naïve dogs of all ages (Dubovi, 2010).  
 
In the feline sheltered population, FIRD also comprises a major issue. Cats are 
characterised as solitary territorial predators and thus, the shelter environment leads 
to a significant loss of life quality and decreased wellbeing in this species. This occurs 
not only due to the high levels of stress cats are subject to, but also due to the 
constant introduction of new pathogens (Möstl et al., 2013). FIRD pathogens 
including FCV, FeHV-1, M.felis, C.felis and B.bronchiseptica are frequently introduced 
to shelters due to high animal turnover, with the shelter environment amplifying the 
spread of disease and leading to more severe clinical presentations (Pedersen et al., 
2004). Molecular studies with FCV have shown high numbers and variability of 
viruses introduced into rescue shelters, as well as high potential for transmission 
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(Coyne et al., 2007a; Radford et al., 2001). More recently influenza viruses have been 
isolated associated with FIRD, with additional zoonotic spread to people working in 
the shelter (Belser et al., 2017). As in dogs, upper respiratory tract disease in pet cats 
is often relatively easy to manage. However, in shelters, it leads to serious problems 
as infected animals pose a high risk to other cats, decrease in adoption rates and 
increased costs due to treatment and disease management (Bannasch and Foley, 
2005). The specific case of FeHV-1 infection is particularly problematic since the 
stress of being in a shelter environment often leads to reactivation of latent virus 
which can lead to disease outbreaks and severe chronic sequelae in affected animals 
(Pedersen et al., 2004). Furthermore, once adopted, these animals may again 
recrudesce in the first few days at a new home which can lead to frustration by 
adopters and have a negative effect on the public perception of shelters (Bannasch 
and Foley, 2005).  
 
As highlighted above, it is challenging for shelters to manage infectious respiratory 
disease in housed animals. Additionally, each shelter faces different problems when 
faced with disease outbreaks or endemic CIRD or FIRD due to factors unique to each 
organisation (such as staffing, infrastructures, budget, biosecurity measures and 
management strategies). Thus, the goal of this study was to gain a basic 
understanding of the FIRD and CIRD pathogens currently circulating in UK based 
shelters with a focus on both classical and more recently emerged respiratory disease 
associated pathogens. In order to achieve this, a cross-sectional study was conducted 
across four UK based animal shelters housing both cats and dogs, with varied 
population dynamics and management philosophies. Additionally, a longitudinal 
study was conducted in one of the shelters looking at FIRD and CIRD pathogen 
shedding for a period of 10 consecutive weeks.  
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6.3 Materials and Methods 
Sampling 
Four rescue centres were selected to participate in this study based on convenience 
(ease of access, previous participation in similar projects as well as through 
professional contacts). These were designated as R1 (Merseyside), R2 (North Wales), 
R3 (North Wales) and R4 (West Midlands) (Table 6.1).  
 
All centres were visited once with the exception of R1 which was visited once a week 
for 10 consecutive weeks. Oropharyngeal samples were collected by the author and 
University of Liverpool staff members from both cats and dogs as described in 
previous chapters. Gloves, single use overalls and shoe covers were changed 
between sampled animals when housed separately. Samples were transported back 
to the Leahurst Campus, University of Liverpool on the day of collection and handled 
and stored as previously described (Chapter 4 and 5).   
 
Table 6.1 Details of the four rescue centres sampled within this study. All capacities are approximate 
as some animals are sometimes housed in groups.  





R1 Merseyside 180 Dogs and 
cats 
No No 
















Further information about participating shelters 
Shelter R1 is part of a larger, nation-wide organisation and has in-house veterinary 
surgeons and veterinary facilities where consultations, treatment and small 
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procedures are undertaken. No isolation or quarantine facilities were present at the 
time of sampling. Cats and dogs are housed in separate buildings with an 
approximate capacity of up to 60 cats and 120 dogs. All animals were vaccinated 
upon entry to the shelter and, in a significant number of cases, even before this, as 
most were triaged in a larger branch of the organisation. Three weeks prior to 
sampling, a suspected outbreak of FIRD had occurred and the cat wing of the shelter 
was closed to the public. The clinical signs shown by affected animals during the 
outbreak comprised mouth ulcers, nasal discharge and sporadic coughing; During 
this suspected outbreak, nine animals were euthanised.  
 
Shelter R2 is a modern, purpose built, independently run shelter with in-house 
veterinary surgeons and a fully equipped veterinary clinic. Isolation facilities are 
available and used for newly arrived, non-vaccinated animals, as well as animals 
showing clinical disease. At the time of sampling, approximately 85 dogs and 100 cats 
were housed in the shelter. Cats and dogs were housed in separate buildings and all 
animals were vaccinated upon admission.  
 
Shelter R3 is an independent shelter based at the shelter manager’s own residence 
set in farmland. Some animals (both cats and dogs, unknown number) lived with the 
shelter manager and were allowed to roam the premises. Cats and dogs were housed 
in separate buildings, but cats were often housed in groups ranging from 3 to 15 
animals. Vaccination policies were unclear, biosecurity measures were found to be 
poor and records on animal history very unreliable.  
 
Shelter R4 is comprised of modern built housing facilities and a fully equipped 
veterinary hospital and is part of a larger, nation-wide organisation. All animals were 




In each shelter, sample collection was performed on a group of animals selected 
based on convenience by staff members at each of the centres. This was based on 
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ability to handle each animal, behavioural issues as well as concomitant non-
respiratory disease health issues in which animals were deemed to be painful or 
uncomfortable in being handled; such animals were excluded. Table 6.2 shows 
number of animals sampled in each centre. Whenever available, details on age, 
gender, breed, age, vaccination and neutering status, length of stay in the centre and 





Longitudinal study – R1  
Rescue centre R1 was selected for a longitudinal study due to its convenient location. 
Following on from the cross-sectional study, R1 was visited weekly for 9 consecutive 
weeks (10 weeks in total). All animals that were sampled on the previous week were 
then re-sampled if still present at the centre. Otherwise, new animals were selected 
by convenience as previously described. Details on signalment and history of 
respiratory disease were collected as for the cross-sectional study. Throughout the 
10 weeks of study, a total of 100 samples were collected from cats (corresponding to 
a total of 30 animals) and a total of 100 samples were collected from dogs 
(corresponding to a total of 31 animals).  
 
Nucleic acid extraction, reverse transcription and diagnostic testing 
Viral nucleic acid (RNA and DNA) was extracted from oropharyngeal swabs using the 
same method as described in Chapter 2 (Viral RNA mini-kit; Qiagen). Reverse 
transcription was performed using 200 ng random hexamers (Superscript III, Life 
Technologies). Diagnostic tests using PCR and bacterial culture are previously 
described in chapter 4 (feline FIRD pathogens) and chapter 5 (canine CIRD 
pathogens). Canine samples were tested for B. bronchiseptica, S. equi subsp. 
zooepidemicus, M. cynos, CHV, CnPnV, CRCoV, CPiV, CAV-2, CDV and influenza A. 
Feline samples were tested for B. bronchiseptica, M. felis, C. felis, FCV, FeHV-1 and 
influenza A.  
 
Data analysis and result description 
Pathogen prevalence and confidence intervals were calculated for the cross-sectional 
study using EpiTools (Ausvet). Data collection and recording by shelters was found to 
be unreliable and factors such as age and kennel length of stay found to often be 






6.4.1 Cross-sectional kennel sampling 
A total of 163 samples were collected (42 canine samples and 108 feline samples). 
Table 6.2 shows number of animals sampled in each centre. Overall, 7.4% of feline 
samples tested positive for FCV (8/108; 95% CI 3.8, 13.9), 4.6% of feline samples 
tested positive for FeHV-1 (5/108; 95% CI 2.0, 10.4) and 16.8% (18/108; 95% CI 10.8, 
24.8) of samples tested positive for M.felis. Table 6.3 shows the prevalence 
breakdown of these pathogens per rescue centre. 
 
Of the eight animals testing positive for FCV, five were from rescue centre R4: three 
had no recorded history of FIRD, one had unilateral eye discharge at the time of 
sampling and one had history of chronic gingivostomatitis. All of the above were fully 
vaccinated with the exception of one young animal who had only received his first 
vaccinations (primary vaccination; this animal was the one showing unilateral eye 
discharge at the time of sampling; figure 6.1A). Two FCV positive animals were from 
rescue centre R3. These were housed in the same pen with one of them having nasal 
discharge and sneezing at the time of sampling and the other showing no signs of 
FIRD. The remaining FCV positive sample was collected from an animal in R2 who had 
no recorded history of FIRD.  
 
All the animals testing positive for FeHV-1 were housed in R3. Two of these animals 
shared the same pen and both had no history of FIRD, while one was housed with 
four other cats and had signs of FIRD at the time of sampling (sneezing and nasal 
discharge while its co-habitants had no clinical signs, figure 6.1B). The remaining 
animal was housed with a different group of cats and did not show any clinical signs 
of FIRD at the time of sampling. No reliable history was available for these animals.  
 
A total of twenty samples tested positive for M. felis (n=2 in R1, n=12 in R3, n=6 in 
R4). The two positive samples from R1 corresponded to cats with recent (less than 
weeks) recorded history of bilateral eye discharge and conjunctivitis, respectively. In 
R4, one of the animals testing positive for this pathogen had a recent (less than 2 
weeks) history of ocular discharge and one animal suffered from chronic 
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gengivostomatitis. There was no reliable history recorded for any of cats testing 
positive for M. felis from R3. 
 
One cat tested positive for both M.felis and FCV (R4). No cats tested positive for 
Influenza A, B. bronchiseptica or C. felis. All canine samples were negative for all 
pathogens tested.  
 
 
Figure 6.1 A – cat sampled from R1 showing unilateral ocular discharge, tested positive for FCV. B – 
cat from R3 showing signs of purulent nasal discharge, tested positive for FeHV-1. 
 
Table 6.2 Number of animals sampled per rescue centre during cross-sectional sampling (four rescue 
centres, n=163 animals sampled in total, 42 dogs and 108 cats).  
Shelter Number of dogs  
sampled 
Number of cats sampled Total of animals 
sampled 
R1 10 16 26 
R2 21 21 42 
R3 14 29 43 








Table 6.3 Breakdown of positive results for feline samples per shelter during cross-sectional sampling.  
Shelter # cats sampled FCV  
Positive  
FeHV-1 positive M. felis positive 
R1 16 0 (0%) 0 (0%) 2 (12.5%) 
R2 21 1(4.8%) 0(0%) 0(0%) 
R3 29 2(6.9%) 5(17.2%) 12(41.4%) 




6.4.2 Longitudinal kennel sampling 
Results of longitudinal sampling are shown in Table 6.6 (dogs) and 6.7 (cats). Cats and 
dogs were followed for 1 to 10 weeks, being lost to follow-up when rehomed or 
euthanased. Of the 31 dogs sampled in R1, three dogs were followed and sampled 
during the 10 weeks of study and the remainder were sampled between one and 
seven times for the duration of the study. Of the 30 cats sampled, only one was 
sampled 10 times (one per week of the study) while the others were sampled 
between one and eight times.  
 
Over the ten-week period (Table 6.6), three dog samples tested positive for B. 
bronchiseptica (corresponding to two animals: one animal with a positive status on 
week 2 and another on weeks 6 and 7; neither had CIRD related clinical signs at the 
time of sampling or a recorded history of CIRD like disease). 
 
 A total of eight samples tested positive for CnPnV (corresponding to seven animals 
with a positive status with a duration of one to two weeks between weeks 9 and 10; 
during this period volunteer shelter staff reported coughing in some sheltered dogs 
but these observations could not be corroborated as these clinical signs were not 
observed during sampling by University of Liverpool staff). No co-infections were 
detected in sampled dogs.  
 
For feline samples (Table 6.7), nine tested positive for FCV (corresponding to six 
animals with a positive status with a duration of one to three weeks; none of these 
animals had a recorded history of FIRD or signs at time of sampling with the exception 
of C17 who showed signs of bilateral conjunctivitis and lingual mouth ulcers, Figure 
6.2). Interestingly, C21 and C22 which tested positive for FCV in week 8 were housed 
in the same pen. Two samples tested positive for FeHV-1 (corresponding to two 
animals, identified as positive once each, in different weeks; neither of these animals 
had CIRD signs or a recorded history of CIRD like disease and had been in the shelter 
for over one month each). A total of 19 samples tested positive for M. felis 
(corresponding to ten animals and a duration of positive status of one to four weeks). 
Of these, C1 and C2 had a recorded history of chronic gingivostomatitis, C5 and C20 
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had signs of mild conjunctivitis and eye discharge on the day of sampling and C3, C6, 
C9, C12, C13 and C26 had no recorded history of CIRD or signs at time of sampling. 
Finally, one feline sample tested positive for B. bronchiseptica on one single week 
(this animal had no history of respiratory disease). Cat C9 was positive for both FeHV-
1 and M.felis on week 5 and C12 tested positive for both FCV and M. felis in weeks 5 
and 6 (no history of FIRD had been recorded for either animal, nor did they present 
with any signs of respiratory disease at the time of sampling).  
 
Figure 6.2 C17 from R1 showing signs of conjunctivitis and bilateral purulent ocular discharge (left) as 












Table 6.6 Results of cross-sectional (week 1) and longitudinal (week 2 - 9) sampling of dogs at R1. Each column 
represents the week of sampling (all animals sampled on the same day each week), and each row represents an 
individual dog. Cells are colour-coded: grey – animal was sampled, white – animal was not sampled. 
 Week of sampling 
Dog n 1 2 3 4 5 6 7 8 9 10 
D1           
D2           
D3           
D4         CnPnV CnPnV 
D5           
D6           
D7           
D8          CnPnV 
D9           
D10           
D11           
D12  Bb         
D13           
D14           
D15           
D16           
D17      Bb Bb   CnPnV 
D18           
D19           
D20           
D21           
D22         CnPnV  
D23           
D24         CnPnV  
D25           
D26           
D27          CnPnV 
D28          CnPnV 
D29           
D30           
D31           
% (n)  Bb: 10% 
(1/10) 














Table 6.7 Results of cross-sectional (week 1) and longitudinal (week 2 - 9) sampling of cats at R1. Each column 
represents the week of sampling (all animals sampled on the same day each week), and each row represents an 
individual cat. Cells are colour-coded: grey – animal was sampled, white – animal was not sampled. 
 Week of sampling 
Cat n 1 2 3 4 5 6 7 8 9 10 
C1 M.felis M.felis M.felis M.felis       
C2 M.felis          
C3 M.felis M.felis M.felis        
C4           
C5 M.felis          
C6 M.felis          
C7           
C8           




     
C10           
C11           









C13     M.felis      
C14           
C15           
C16           
C17      FCV     
C18      FeHV-1     
C19           
C20       M.felis    
C21        FCV   
C22       FCV FCV FCV  
C23        FCV   
C24          FCV 
C25           
C26          M.felis 
C27           
C28          Bb 
C29           
C30           





















































6.5 Discussion and conclusions 
Infectious upper respiratory tract disease in dogs and cats (i.e. FIRD and CIRD) is 
common in shelter environments worldwide and comprises a serious burden to these 
organisations (Belser et al., 2017; Byun et al., 2009; Möstl et al., 2013; Pereira et al., 
2018; Pesavento and Murphy, 2014; Tanaka et al., 2017; Willi et al., 2016). Despite 
usually leading to low mortality rates, these multifactorial disease complexes cause 
various other issues such as increased shelter running costs and delays in animal 
adoption as well as having a significant impact on animal welfare (Chalker et al., 2004; 
Opperman and Brownlie, 2018; Schulz et al., 2014; Veir et al., 2008). In this study, we 
sought to investigate the presence of known and suspected CIRD and FIRD pathogens 
in UK animal shelters. Since some respiratory pathogens are potentially transmissible 
between dogs and cats, we for the first time focussed these studies on shelters 
housing both species.  
 
The sampling strategy utilised in this study was very selective (convenience based). 
Therefore, generalisation of results is not possible. Aditionally, the lack of data such 
as length of stay and total number of animals present at the shelter (unavailable at 
the time of sampling) led to a limited analysis of results.  
 
In the first and cross-sectional portion of this study, 18.4% (30/163) of the samples 
were positive for at least one of the tested pathogens. All these samples were from 
cats, with all dogs testing negative for the panel of pathogens tested for in this study.  
 
Out of the 30 cats positive for any tested pathogen, only a small proportion of 
animals had a recent history of respiratory disease. Similar observations have been 
made in prior studies, where up to 80% tested animals were positive for FIRD-
associated pathogens but clinical disease was uncommon (Coyne et al., 2007a; 
Tanaka et al., 2017). This partly could be due to the fact that, in the participating 
shelters, most animals were vaccinated at the time of admission, but also highlights 
the importance of asymptomatic carriers, especially for FCV, in the spread of 
infection in high-turnover environments such as these (Coyne et al., 2007a; Radford 
et al., 2009). Unfortunately, our conclusions here are limited due to the unreliable 
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record keeping at some of these shelters as well as the unknown medical history of 
most of these animals prior to arrival at the rescue centre.  
 
The percentage of FCV and FeHV-1 positive samples during the cross-sectional study 
was 7.4% (8/108; ranging between 0 and 11.9% among participating shelters) and 
4.6% (5/108; all samples from same shelter), respectively. These numbers are lower 
than those found in previous studies (Bannasch and Foley, 2005; Helps et al., 2005; 
Radford et al., 2001) and may mirror the good biosecurity and disease prevention 
measures applied in most of the participating shelters. With the exception of R3, all 
participating shelters had well trained members of staff and volunteers. Consistent 
biosecurity measures were seen to be applied, including, but not limited to, hand 
washing or change of gloves between handling different animals, thorough cleaning 
and disinfection of kennels, use of different facilities for vaccinated and unvaccinated 
animals and refraining from keeping animals in groups (apart from where mom and 
litters were present). This was not the case for R3 where often cats would be kept in 
large groups and new animals from unknown provenance were introduced to the 
group.  
 
Previous studies have used the variability of FCV to look at the epidemiology of 
transmission of infection within shelters, suggesting, at least in the populations they 
studied, that infection was maintained by frequent import of new pathogens into the 
shelter with new animals, complemented by rarer examples of transmission within 
the shelter (Coyne et al, 2006). The pattern of infection we observe here, with some 
animals testing positive when first sampled, whilst others becoming positive after 
being in the shelter for some time, perhaps suggests a similar epidemiology here. 
Unfortunately time prevented the sequence analyses of the identified pathogens in 
this study, 
 
M.felis was found in 16.8% of samples (20/108; ranging from 12.5% to 41.4% in 
participating shelters). These numbers are also lower than previous studies where 
the prevalence of M.felis were found to range from 20% to 47% depending on the 
population (Berger et al.; Fernandez et al., 2017). Interestingly, M. felis was, overall, 
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the microorganism most often found in these shelters. A recent systematic review 
and meta-analysis of the association between Mycoplasma spp. and FIRD suggested 
that M. felis may be a primary pathogen of the upper respiratory tract in cats but 
cautioned that this may not happen in all environments, especially not in shelters (Le 
Boedec, 2017). These observations are in line with the results found in this study as 
M. felis was found in a number of animals, but most of these did not present with 
any signs of respiratory disease at the time of sampling and no history of recent 
respiratory disease had been recorded for them (although, it is worth reiterating that 
records were often found to be unreliable). 
 
The fact that, in the cross-sectional portion of the study, no dog tested positive for 
any of the pathogens is curious, especially given the fact that the same methods were 
used in chapter 5 where several samples were positive for the tested pathogens. This 
is particularly interesting given the fact that in this study we were looking at sheltered 
animals where population turnover was considered high with frequent opportunities 
for the introduction of new pathogens (Mochizuki et al., 2008; Schulz et al., 2014). It 
is likely this reflects the sporadic nature of respiratory disease in rescue shelters 
coupled with the relatively short period  over which we were able to sample each 
population. In future studies it may be more fruitful to strategically sample shelters 
at the time of ongoing outbreaks of disease. 
 
In the longitudinal portion of this study, pathogens were found sparingly, especially 
in the case of dogs where B. bronchiseptica was only found in two animals (weeks 2, 
6 and 7). The staff in this shelter was well trained and biosecurity measures were 
constantly being improved under veterinary advice, which could in part explain low 
pathogen numbers. Additionally, animals sampled in the longitudinal study were 
often vaccinated before entry into the shelter (at a different branch of the charity) 
and therefore, live vaccine shedding was potentially no longer occurring. The same 
is possible for introduction of new pathogens into R1 since the animals had been at 
a different branch for a short period of time and could have introduced new 
pathogens at this branch and no longer be shedding them during their stay at R1. It 
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would be, therefore, interesting to compare pathogen and clinical disease prevalence 
between these two branches.  
 
On the other hand, CnPnV was found in seven animals during weeks 9 and 10 (3 
positive samples in week 9, 5 positive samples in week 10 with only one animal out 
of seven testing positive for CnPnV in both weeks 9 and 10). This coincided with staff 
and volunteers reporting coughing in a small number of dogs (data not presented as 
information passed on to author informally). Interestingly, none of the dogs with 
positive samples for CnPnV had clinical signs of respiratory disease at the time of 
sampling. The presence of a growing number of positives from weeks 9 and 10 could 
potentially represent the start of an outbreak. It is interesting to note that an high 
attack rate of 23.3% (7/30) was observed for the population sampled across the 
duration of the study. Although Koch’s postulates are yet to be fulfilled for CnPnV, 
previous studies have found strong associations between presence of the virus and 
CIRD (Mitchell et al., 2013b; Renshaw et al., 2010).  
 
In conclusion, this chapter re-emphasises the importance of kennel environments in 
maintaining infections through silent carriers that may act as reservoirs of disease to 
potentially immunologically naïve animals newly introduced into these 
environments. Similar findings have been reported in previous studies looking at 
pathogen shedding in clinically healthy animals including shedding canine parvovirus 
in cats housed in shelters (Clegg et al., 2012) and canine enteric coronavirus in 









7.1 General discussion 
Despite widespread vaccination, CIRD and FIRD continue to be important issues 
affecting the health and general wellbeing of different feline and canine populations 
worldwide.  
 
For many years, this field received little attention. However, within the last decade, 
a resurgence in interest in infectious respiratory disease in the feline and canine 
species has occurred. This has probably been fueled by the emergence of pathogens 
(such as CIV and CRCoV in dogs and VS-FCV in cats), as well as the perceived lack of 
efficacy of vaccination in the control of outbreaks especially within multi-animal, 
high-turnover populations such as rescue shelters (Priestnall et al., 2014; Radford et 
al., 2009). This project aimed to further the understanding of canine and feline 
infectious respiratory disease with a major focus on pet and unowned shelter 
populations in the UK. This was attempted through re-evaluation of the roles of 
known and suspected pathogens in this syndrome, and identification of risk-factors 
for both pathogen carriage and clinical disease. Despite some frustrations around 
sample sizes, it is hoped the results presented here will contribute to the field in a 
way that will inform the development of future disease reduction strategies.  
 
Initially, a cross-sectional study involving the participation of veterinary practices in 
six European countries (United Kingdom, France, Germany, the Netherlands, Italy 
and Sweden) was used in order to evaluate the diversity and epidemiology of FCV 
(including the identification of risk factors for pathogen carriage) and to assess the 
efficacy of a widely used vaccine strain in neutralising recent field isolates of this virus 
(Chapter 2). To assess seroreactivity of UK cats and dogs to influenza viruses, a 
retrospective serosurvey study was undertaken (Chapter 3). A case-control study 
design was then used in order to further understand the role of known and potential 
FIRD and CIRD pathogens in dogs and cats attending British veterinary practices and 
to attempt the identification of risk factors for clinical disease in veterinary attending 
populations (Chapter 4 and 5). Finally, a cross-sectional and longitudinal study was 
undertaken in UK shelters in order to identify currently circulating CIRD and FIRD 
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associated pathogens (Chapter 6). Despite the variation in objectives and 
methodologies used in these chapters, several re-occurring themes were identified.  
 
In CIRD, it becomes clearer through this body of work that pathogens traditionally 
considered the main culprits of disease (Priestnall, 2017; Wright et al., 1974) are 
perhaps becoming a much lesser threat to upper respiratory health in UK dogs. 
Throughout the studies described in this dissertation, both in pet and shelter 
populations, PCR failed to identify any samples positive to CAV-2, CDV and CHV. 
These findings are further strengthened by previous studies which also failed to 
identify these viruses in healthy CIRD-exposed animals as well as in animals showing 
CIRD clinical signs (Decaro et al., 2016; Erles and Brownlie, 2005) or that found these 
at much lower rates than older studies (Mochizuki et al., 2008; Schulz et al., 2014). 
The absence of these pathogens from collected samples, as well as of CPiV, is 
potentially related to the fact that a high percentage of animals are vaccinated 
against these pathogens in the UK (Sánchez-Vizcaíno et al., 2018). In contrast, 
emerging pathogens such as CnPnV and CRCoV were observed. Even though Koch’s 
postulates are yet to be fulfilled for these viruses, it seems that they consistently 
appear in association with CIRD like disease both in this body of work as well as in 
other studies (Erles and Brownlie, 2008; Mitchell et al., 2013b; Priestnall et al., 2014). 
Proving (or otherwise) Kochs postulates for these viruses seems a sensible way 
forward. 
 
In the work described in this dissertation, FCV is strongly reaffirmed as a common 
infectious agent encountered in feline populations in the UK and other European 
countries. Interestingly the FCV prevalence found in veterinary practice attending 
cats across six European countries (9.2%; chapter 2) was not far from the overall rates 
of infection found in the UK in the case-control study (10.8%; chapter 4). These 
findings are very similar to those of previous studies (Coyne et al., 2007b; Radford et 
al., 2009). While this virus is often identified in clinically healthy animals we have 
found, in the case-control study described in chapter 4, that it was also significantly 
associated with FIRD. This likely reflects the lower rates of cat vaccination in the UK 
(Sánchez-Vizcaíno et al., 2018), as well as the challenges of vaccinating against a 
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variable pathogen like FCV (and a herpesvirus like FeHV-1). For both these pathogens, 
vaccination does not prevent infection and vaccinated animals can be infected and 
become carriers. Perhaps the easiest way to impact on this in the future will be to 
understand the lower rates of vaccination by cat owners in an attempt to increase 
vaccine uptake. 
 
In chapter 3, only 1.5% of canine serum samples were positive for equine H3N8 and 
0.56% of feline samples were positive to human pandemic H1N1 suggesting that UK 
cats and dogs are exposed albeit rarely to influenza viruses. Additionally, the absence 
of Influenza A positives in canine and feline samples tested using PCR (chapters 4, 5 
and 6) further confirms the currently low risk of infection where these viruses are 
concerned. However, there are an increasing number of reports of influenza A viruses 
in dogs and cats in different parts of the world as well as the emergence of several 
new strains that can establish infection and cause disease in these species, such as 
the case of the recent emergence of canine influenza H3N2 in the United States of 
America (Abente et al., 2016; Jeoung et al., 2013; Song et al., 2008). In addition, these 
viruses also pose an additional zoonotic risk (Belser et al., 2017). Together, this 
cautions the veterinary community to remain alert and continue investing their 
efforts in surveillance for these viruses.  
 
It is also important to note that in a high number of animals showing signs of 
respiratory disease and suspected to suffer from upper respiratory infections no 
known or suspected CIRD or FIRD pathogens were detected. This has been previously 
observed and, while it could certainly be due to several human related factors (e.g. 
inappropriate sampling technique, inadequate sample handing or storage, 
misclassification of non-infectious disease as CIRD/FIRD) one must take into account 
the possibility that perhaps, in these animals, disease was caused by currently 
unknown pathogens. This would not be surprising since, for example, CRCoV (Erles 
et al., 2003) was originally described in animals suffering from CIRD like disease 





7.2 Study challenges and limitations 
Challenges with comparing this study’s results with prior studies were clear especially 
during the cross-sectional study of FCV diversity and vaccine cross-reactivity (chapter 
2). Direct comparisons of this study with previous studies looking at FCV vaccine 
cross-reactivity were particularly challenging due to the differences in applied 
methodologies. For the work presented here, an effort was made to apply basic 
epidemiological principles in order to ensure, as far as possible, that the results were 
generalisable to the wider European feline population. Practices were recruited 
based on random selection and all samples were collected prospectively. Although it 
is understood that veterinary practice-attending animals are an inherently biased 
population (Murray and Gruffydd-Jones, 2012), in order to decrease selection bias as 
much as possible, participating vets had clear instructions to sample the next 30 cats 
presented for a consultation once sampling had started. It was postulated that, in 
order to collect field isolates representative of a feline population which is likely to 
be vaccinated, one should not select for diseased animals. FCV is an extremely 
variable virus with numerous circulating strains with different degrees of 
pathogenicity (Coutts et al., 1994; Monné Rodriguez et al., 2014; Radford et al., 2009; 
Rong et al., 2014). Therefore, in order to truly understand the capacity of antisera 
raised to the common FCV-F9 vaccine to neutralise recently circulating field isolates, 
these isolates must also mirror the range of pathogenicity of which FCV is capable 
and the range of isolates to which naïve cats might be exposed – including potentially 
apathogenic strains, isolates collected from carrier animals, isolates collected from 
animals with different FIRD clinical signs, etc. Additionally, since vaccination against 
FCV is known to decrease severity of disease but not infection itself, it was important 
to include isolates collected from both vaccinated (which can still be shedding the 
virus without clinical signs) and unvaccinated animals. In contrast to the methods 
presented here, it seems limiting to try to assess the efficacy of a vaccine strain using 
unstructured population sampling where only isolates collected from animals with 
FIRD clinical signs or retrospective samples from diseased animals submitted for 
diagnostic testing are used. This is the case with various previously published studies 
looking at FCV vaccine in vitro efficacy (Addie et al., 2008; Poulet et al., 2008; 
Wensman et al., 2015). In order to increase comparability of studies in the future it 
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will be necessary to agree an international study protocol as is available for other 
rapidly evolving pathogens such as influenza (e.g. 
https://sites.google.com/site/epiflu/Home). Whilst protocol issues are likely to be 
harmonised through such an approach, it is likely that future veterinary studies 
would largely still be funded by vaccine companies, as opposed to more independent 
funding that is available for human influenza vaccine surveillance. Any agreed 
protocol would need to take this into account and include open publication of all 
results. Although all the work in this thesis was funded by a commercial company, 
publication rights remained with the researchers.    
 
Despite a recent shift towards more evidence-based approaches (Dean et al., 2017; 
Huntley et al., 2017), veterinary medicine still has a strong tradition of using 
anedoctal experiences and word of mouth in order to inform clinical decision-making 
(Stavisky, 2009). As previously mentioned, efforts were made throughout this body 
of work, to apply basic epidemiological principles whenever possible. However, these 
were frustrated on occasion due to various factors. Convenience based recruitment 
of veterinary practices and shelters was used in order to attempt to increase the 
numbers of collected samples. For example, in the case-control studies described in 
chapters 4 and 5, a small number of practices that had been enthusiastic participants 
in the FCV focused study described in chapter 2 were contacted again. This worked 
to an extent, and some of these practices did accept to participate in the case-control 
studies and performed well where sample collection was concerned. However, 
maintaining compliance throughout these studies was extremely challenging and, 
despite a significant number of practices accepting to participate, the number of 
samples collected fell very short of the original sample size calculation. This 
happened even though all practices confirmed that they would be able to provide 
the requested number of cases and controls in a period of three months from the 
start of sampling. Although practices were regularly contacted by phone and/or 
email, this did not seem to make a difference in terms of increased sample collection. 
In fact, it was occasionally mentioned by participating veterinary surgeons that they 
had “forgotten to collect samples” when a FIRD or CIRD suspected case presented to 
the practice. It is likely that the time constraints and pressures in the veterinary 
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profession may have had an impact on the compliance rates observed. In these 
studies, no incentives were offered to participating vets and this would perhaps be a 
way to increase sample numbers in the future.  
 
Reliance on veterinary surgeons to submit samples can also introduce different 
biases. Firstly, we must take into account the fact that respiratory disease or 
respiratory signs may be misclassified as being of infectious origin. Additionally, even 
though practitioners were asked not to select cases or controls, it is not possible to 
discard this possibility and, in fact, it was noticed that in some instances, samples 
from animals belonging to staff members were selected as controls. However, time 
limitations means it is likely that future studies would also have to rely on 
practitioners, and not researchers, choosing cases and controls.  
 
While for the FCV study (chapter 2), questionnaires were filled out by the 
participating veterinary surgeons with the help from cat owners, due to the longer 
nature of the case-control questionnaires, we postulated it would be more likely to 
be able to recruit veterinary surgeries if veterinary surgeons did not have to spend a 
large amount of time involved with the study (since OP swabs are very quick to 
collect) and therefore we decided to administer telephone questionnaires to the 
animal owners. Telephone questionnaires administered to owners in the case-
control studies also proved to be very difficult to complete. Despite several attempts 
to telephone owners (at least three times for each participating animal, during a 
period of time selected by the owner upon agreement to take place in the study), a 
significant proportion of participants did not respond. It is possible that a significant 
proportion of participants did not answer calls from unknown numbers possibly given 
the recent increase in predatory and scam phone calls in the UK. In future studies this 
should be taken into account, and perhaps a shorter, simpler questionnaire should 
be used so that it can be filled out by the owner while waiting for their veterinary 





In chapter 6, shelters were also recruited based on convenience. Personal 
connections, prior participation in University of Liverpool research studies and 
geographical location were some of the factors that influenced choice of sampling 
sites. This would have potentially introduced a bias especially since three of the 
shelters were in a 26 miles radius of the Leahurst campus of the University of 
Liverpool with the fourth shelter being about 100 miles away. Ideally, we would have 
preferred to sample shelters spread throughout the whole of the United Kingdom 
but this was not possible due to time constraints.  
 
The results and conclusions taken from the cross-sectional and longitudinal shelter 
studies (chapter 6) have also been affected by several factors. For once, the 
unreliable record keeping in some of these organisations made it impossible to 
conduct more complex epidemiological analysis. Also, the fact that we were often 
only allowed to sample certain animals or were not allowed full access of the facilities 
proved challenging and, again, led to a biased sampling of the shelter populations. In 
future studies, it would be interesting to be embedded into the shelter environment 
for longer periods of time so that data collection could be made directly by the 
researcher (rather than relying on shelter records) and animals could be followed 
closely for longer periods of time (instead of one weekly sampling, spending a 
consecutive number of days or weeks with daily visits to the shelter would provide 
stronger information and better quality data).  
 
7.3 Further work 
The high proportions of feline and canine cases of suspected infectious respiratory 
disease where no pathogen was identified provides a great opportunity for further 
investigation. Next generation sequencing (NGS) techniques, allowing the analysis of 
viral genomes directly from samples without requiring any previous culture or 
isolation or even knowledge of potentially present microorganisms, has been applied 
to pathogen discovery in veterinary research with great success in recent years 
(Radford et al., 2012). As previously discussed, it is possible that disease in these 
cases where we were unable to identify any pathogen using PCR methods was caused 
by currently unknown pathogens. The application of NGS to these samples would 
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potentially provide further information and answers to this question. During this PhD 
project, a pilot study was undertaken (data not presented), which allowed us to 
attempt NGS in a small subset of samples collected during the FCV study described 
in chapter 2. These samples (n=13) comprised FCV isolates for which, using NGS 
methods, full or nearly full genomes were obtained (corresponding to the already 
sequenced isolates from chapter 2). Other viruses were also identified in these 
samples and further research is currently being undertaken in newly collected feline 
samples. This same approach could be applied to canine samples in future research 
in order to further understand whether currently unknown pathogens may be 
involved in causing disease in these animals where no known viruses or bacteria have 
been detected. Using NGS could also provide useful insight into the role of B. 
bronchiseptica vaccines in the observed high carriage of this organism in controls in 
this study. 
 
In chapter 2, we observed that phylogenetic analysis on collected field strains of FCV, 
which also included the FCV-F9 vaccine strain capsid sequence, produced a radial 
phylogeny where FCV-F9 did not diverge from field strains any more than these did 
from one another. This is an extremely curious finding given that FCV is an RNA virus 
where high rates of evolution are observed (Radford et al., 1999). When compared 
with other RNA viruses such as influenza viruses, FCV seems to show a very different 
evolutionary behaviour. Influenza viruses are under continual immune and vaccine 
selection pressure leading to viral strains being replaced during seasonal outbreaks 
by new or adapted variants which evolve through antigenic drift and shift over time 
(Grenfell et al., 2004). As observed in Figure 2.2, this does not seem to occur with 
FCV where a strain which is approximately 50 years old (FCV-F9) remains clustered 
with the contemporary sequences obtained in this thesis. These findings could 
suggest that FCV is under a strong purifying selection which constrains its evolution. 
It would be therefore interesting to conduct further, more advanced phylogenetic 
analysis (using, for example, Bayesian coalescence frameworks) in order to further 
delve into this mystery. Such an analysis would also benefit from using full genome 
sequences more readily obtainable by NGS, rather than limiting the analyses to the 




Finally, due to time constraints, sequencing and phylogenetic analysis of positive 
samples collected from the case-control and shelter studies were not undertaken. 
Doing so would provide additional information that would potentially allow us to 
infer on the transmission of infection within the studied populations. Such an 
approach would be particularly useful for the more variable pathogens identified 
including FCV.  
 
7.4 Final conclusion 
In conclusion, this thesis took a variety of approaches to review this important 
syndrome in cats and dogs. Although limitations around sampling sometimes 
restricted our interpretation of the results, taken together, this body of work 
provides new and interesting information. In cats, we observed that vaccine 
preventable infections are still common. These findings remind us that vaccination 
against FCV does not prevent infection and highlight the importance of vaccination 
in order to achieve good herd immunity in cats, which are generally less vaccinated 
than their canine cousins. In dogs, findings suggest that classical pathogens involved 
in CIRD seem to be fading away in UK populations, possibly due to success of 
vaccination schedules, although clearly larger sample sizes are needed to confirm 
this. However, other pathogens seem to be arising in the CIRD complex, shifting this 
old paradigm and raising the question of whether new vaccines against pathogens 
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